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Introduction 
Camptothecin, a plant alkaloid isolated from Camptotheca acuminata, was identified in 
the late 1950's. Due to severe and unpredictable toxic side effects in early clinical studies, the 
clinical development of this drug was halted in the 1970's. In the early 1980's several 
important events occurred that resulted in renewed interest in this agent. The molecular target 
of camptothecin, the nuclear enzyme topoisomerase I, was identified. This topoisomerase I 
was described as an enzyme involved in transient scission and relegation of DNA during the 
replication and transcription phases. Binding of carnptothecin to the topoisomerase I-DNA 
complex (cleavable complex) and interference with the relegation step of this process was 
recognized as the primary mechanism of action of camptothecin, finally leading to a double 
stranded DNA break and, ultimately, cell death. At the same time, it was shown that the 
failures encountered in the clinical development of camptothecin were related, at least 
partially, to the drug's poor water solubility, which necessitated pharmaceutical formulation 
in alkaline solutions for i.v. administration. This not only led to chemical modification of the 
original structure into an entity lacking antitumor activity, but also induced profound 
alterations in the toxicological behavior of the agent. 
These two key fmdings then boosted drug-research efforts aimed at identifYing and 
developing new analogues with improved water solubility while maintaining the unique 
mechanism of action. Some of these agents are currently in clinical development, while 
others, among which irinotecan (CPT-11 ), is now registered for use in colorectal cancer. CPT-
11 undenvent extensive clinical evaluation in phase II and III trials and data suggested that 
the drug is also active in various other tumor types in addition to the indication mentioned. 
The main side effects of this drug are bone marrow suppression and late onset diarrhea. 
CPT -II is a prodrug with limited antitumor activity. CPT -II is mainly metabolized by 
two metabolic pathways. One pathway is the hydrolyzation by a carboxylesterase to form the 
active metabolite SN-38, which is 100 to 1000-fold more active than the parent compound. 
SN-38 in its tum can be metabolized further by UDP glucuronosyltransferase !AI to form an 
inactive B-glucuronide derivative (SN-38-G), which in turn is excreted in the bile and 
subsequently the bowel system. The other pathway is the oxidative elimination by the 
cytochrome P-450 system to form the inactive metabolites APC and NPC. The complex 
metabolism in combination with the earlier mentioned clinical toxicity of CPT-11, raises 
questions on probable pharmacological ways to modulate these pathways and toxicity. 
In in vitro studies, topoisomerase I inhibitors showed more pronounced antitumor efficacy 
with protracted exposure to low concentrations. Also in animal models, low dose prolonged 
exposure resulted in less toxicity. Clinical studies have focused on low-dose exposure to 
topoisomerase I inhibitors. Based on this knowledge, considerable effort has recently been put 
in the development of alternative pharmaceutical vehicles that would allow prolonged 
systemic exposure. Among various approaches, liposomal encapsulation of an intravenously 
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administered drug would greatly prolong the exposure. Liposomal encapsulated anticancer 
drugs have been studied extensively both in the laboratory and in the clinic, with reports of 
prolonged plasma exposure, improved tumor delivery, decreased systemic toxicity and 
increased efficacy for a variety of cytotoxic drugs. In addition, the topoisomerase I inhibitor 
lurtotecan, in analogy to other topoisomerase I inhibitors. is significantly influenced by a 
chemical pH-dependent hydrolysis of the active lactone form to the ring-opened biologically 
inactive carboxylate form. Inside liposomes the pH can be modified. So encapsulating 
topoisomerase I inhibitors in liposomes can be beneficial both in the sense of prolonged 
exposure as to maintain the drug in the active lactone form. 
Besides the earlier mentioned important recognition of the workings mechanism of 
topoisomerase I inhibitors, improved understanding of the signal transduction pathways has 
resulted in identification of other potential therapeutic targets, among which farnesyl 
transferase inhibitors. Farnesyl transferase inhibitors were specifically developed to decrease 
Ras processing and subsequently do-wnregulate transduction of proliferative signals. Ras 
mutations have been demonstrated in the majority of colon cancers. Seen the distinctly 
different mode of action of farnesyl transferase inhibitors and topoisomerase I inhibitors, and 
the need of more efficacious treatment for (colon) cancer, a strong rationale exists for 
investigating a CPT -11 based regimen in combination with farnesyl transferase inhibitors. 
This thesis, ··pharmacological modulation of topoisomerase I inhibitors'', includes studies on 
the liposomal encapsulated topoisomerase I inhibitor lurtotecan, studies on pharmacological 
modulation of CPT -ll with common drugs and combination therapy of CPT -ll with the 
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Abstract 
The topoisomerase I inhibitors reviewed in this paper are all semisynthetic analogues of 
camptothecin. Modulation of this intranuclear enzyme translates clinically in antitumor 
activity against a broad spectrum of tumors, and is therefore subject of numerous 
investigations. We present preclinical and clinical data on camptothecin analogues that are 
already being used in clinical practice [i.e., topotecan and irinotecan (CPT-11)] or are 
currently in clinical development (e.g., 9-aminocamptothecin, 9-nitrocamptotecin, lurtotecan, 
DX 895lf and BN 80915), as well as drugs that are still only developed in a preclinical setting 
(Silatecans, polymer-bound derivates). A variety of different strategies is being used to 
modulate the systemic delivery of this class of agents, frequently in order to increase 
antitumor activity and/or reduce experienced side effects. Three principal approaches are 
being discussed, including (i) pharmaceutical modulation of formulation vehicles, structural 
alterations and the search for more water soluble prodrugs, (ii) modulation of routes of 
administration and considerations on infusion duration, and (iii) both pharmacodynamic and 
pharmacokinetic biomodulation. 
Introduction 
Camptothecin (CPT), a plant alkaloid isolated from Camptotheca acuminata. was first 
identified in the late 1950's [!]. Due to severe and unpredictable toxic side effects in early 
clinical studies, including myelosuppression, severe diarrhea and hemorrhagic cystitis, the 
clinical development of CPT was halted in the 1970's [2-5]. In the early 1980's several 
important events occurred that resulted in renewed interest in this agent: (i) the molecular 
target of CPT, viz. the nuclear enzyme topoisomerase I, was identified. This topoisomerase I 
"VVas described as an enzyme involved in transient scission and relegation of DNA during the 
replication and transcription phases. Binding of CPT to the topoisomerase I-DNA complex 
(cleavable complex) and interference 'With the relegation step of this process was recognized 
as the primary mechanism of action of CPT, finally leading to a double stranded DNA break 
and, ultimately, cell death [6-8]. Subsequent investigations indicated overexpression of this 
topoisomerase I enzyme in various types of solid tumors, including ovarian and colon cancer 
[9,10]. (ii) At the same time, it was shown that the failures encountered in the clinical 
development of CPT were related, at least partially, to the drug's poor water solubility, which 
necessitated pharmaceutical formulation in alkaline solutions for i.v. administration. This not 
only led to chemical modification of the original structure into an entity lacking antitumor 
activity, but also induced profound alterations in the toxicological behavior of the agent [11]. 
These n:vo key findings then boosted drug-research efforts aimed at identifying and 
developing new [(semi-)synthetic] analogues with improved aqueous solubility while 
maintaining CPT's unique mechanism of action. Some of these agents are currently in clinical 
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development, whilst irinotecan (CPT-11) and topotecan are now registered for use in 
colorectal cancer [12], and ovarian and lung cancer [13], respectively. Both topotecan and 
CPT -11 underwent extensive clinical evaluation in phase II and III trials and data suggested 
that both drugs are also active in various other tumor types in addition to the indications 
mentioned [14,15]. 
Unlike most other CPT analogues, CPT-!! is a prodrug with very little inherent 
antitumor activity. To form the active metabolite SN-38, which is 100 to 1000-fold more 
active than the parent compound [16], CPT-!! is hydrolyzed by a carboxylesterase [17]. SN-
38 in its tum can be metabolized further by UDP glucuronosyltransferase !Al to form an 
inactive ~-glucuronide derivative (SN-38-G) [18]. In in vitro studies, topoisomerase I 
inhibitors showed more pronounced antitumor efficacy v.rith protracted exposure to low 
concentrations. Also in animal models, low dose prolonged exposure resulted in less toxicity 
[19-23]. It should be noted that for several reasons, including species differences in drug 
disposition and tolerability as well as intrinsic differences in tumor sensitivity, in vitro and 
animal models have been shown to be poor predictors of clinical efficacy and toxicity. 
Nonetheless, most clinical studies have focussed on low dose exposure to topoisomerase I 
inhibitors in cancer patients [24-29]. Meanwhile, numerous researchers are unravelling the 
clinical pharmaco-dynamics and pharmacokinetics of the different analogues. This has lead to 
an explosion in publications on this subject. The present review is focussed on chemical and 
pharmacologic aspects of CPT analogue development, with special emphasis on the choice of 
routes of delivery and on intrinsic differences in toxicity profiles of the various analogues and 
possible ways to modulate these either pharmacodynamically or -kinetically. 
Chemical Properties 
Structure-Activity Relationships 
Most of the currently known CPT analogues share a basic 5-ring structure \\fith a chiral 
center located at C20 in the terminal E-ring. Extensive studies on the synthesis of CPT 
analogues and the development of structure-activity relationships have been carried out over 
the last several years, and some important general relationships have emerged [30]. VVb.ile 
these relationships will clearly be refmed in the years to come, current knowledge is 
potentially adequate for the design of improved analogues of CPT. This current knowledge is 
here summarized in Figure 1 rather than being described exhaustively. Structure-activity 
studies have also shown a close correlation between the ability to inhibit topoisomerase I and 
overall cytotoxic potency [31]. For the purpose of this review, a number of regions in the CPT 
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Figure 1. Structure-activity relationships of camptothecins 
(i) It has been shown that the topoisomerase I inhibitory actmty of these agents is 
stereospecific, with the naturally occurring (S)-isomer being many-fold more potent that the 
(R)-isomer [7-9]. 
(ii) In general, substitutions at C7, C9 and C!O tend to increase topoisomerase I inhibition and 
sometimes increase water solubility, whereas substitutions at Cl2 decrease antitumor activity 
[16]. 
(iii) Similarly, the formation of certaiu additional ring structures, e.g. between C7-C9 or C!O-
Cll increases activity [32-35]. 
(iv) One of the principal chemical features of this class of agents is the presence of a lactone 
functionality in the E-ring, which is not only essential for antitumor activity, but it also 
confers a degree of instability to these agents in aqueous solutions [36]. All known 
camptothecins can undergo a pH-dependent reversible interconversion between this lactone 
form and a ring-opened carboxylate (or hydroxy acid) form (Figure 2), of which only the 
lactone form is able to diffuse across cell membranes, and exert the characteristic 
topoisomerase I inhibitory activity. At neutral or physiologic pH, the equilibrium between the 
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two species favors the carboxylate form for all the camptothecins. As outlined. an 
understanding of this hydrolysis reaction helps to explain several observations in the early 
development of these agents. Because CPT was administered as the more water-soluble 
sodium salt, patients were exposed to high concentrations of the relatively inactive 
carboxylate species, whereas large amounts of drug were excreted in urine, where the low pH 
favored closure of the lactone ring with resulting hemorrhagic cystitis [2,4]. The equilibrium 
betv..reen the lactone moiety ring and the carboxylate form of the camptothecins is not solely 
dependent on the pH, but also on the presence of specific binding proteins in the biological 
matrix, most notably human serum albumin (HSA). Following establishment of equilibration 
at 37°C in phosphate buffered saline (PBS), equal amounts of the various CPT analogues are 
present in the pharmacologically active lactone form, with values of 17, !9, 15, !3 and 15% 
for CPT, 9-aminocarnptothecin (9-AC), topotecan, CPT-11 and SN-38, respectively [37]. 
ddition of 40 mg/mL HSA shifts the equilibrium for CPT and 9-AC towards the carboxylate 
form, with approximately 1% present in the lactone form at equilibrium [37,38]. In contrast to 
HSA, addition of murine serum albumin to 9-AC leads to approximately 35% existing in the 
lactone form at equilibrium [38]. As opposed to CPT and 9-AC, HSA actually stabilizes the 
lactone moiety ofCPT-11 and SN-38, with values of 30 and 39%, respectively, present in the 
lactone form at equilibrium, while ahnost no effect was seen for topotecan [37]. It has been 
proposed that the differences in the percentiles present in the lactone form at equilibrium is 
related to sterical considerations of the various substituents at the R1 and R2 positions (Figure 
2A). For some of the more recently developed CPT analogues, the substituents cause sterical 
hindrance and prevent binding of the carboxylate forms to HSA, and so drive the equilibrium 
towards the lactone species. 
Conventional Drug Formulations 
The inherent instability of the lactone form and the inactivity of the carboxylate form 
have posed a specific challenge to the development of a suitable dosage form of CPT 
analogues. Since the lactone form is strongly favored by an acidic pH, as outlined above, the 
currently registered agents topotecan and CPT-11 have both been formulated in buffered 
dosage forms. Topotecan is available as a powder containing topotecan hydrochloride and 
tartaric acid, yielding an aqueous solution for infusion of pH 2.5-3.5 after reconstitution. This 
solution is stable for at least 12 hours at room temperature, whereas the dry powder is stable 
for at least 2 years at room temperature. The pharmaceutical dosage form of CPT -11 is 
similarly based on formulation of the hydrochloride form of the drug in an aqueous solution, 
containing a lactic acid-sodium hydroxide buffer system of pH 3.5-4.5. Current shelf-life 
studies have shown that the injection concentrate is stable for at least 3 years at room 
temperature when protected from light. 
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In recent years, a variety of alternative pharmaceutical formulations have been or are 
currently being evaluated. Important properties of these alternatives will be that they allow 
drug doses to be delivered at levels (at least) similar to those achieved with the conventional 
formulations, and that the drugs should be stable for several hours in order to be handled in a 
clinical setting. Despite the tremendous efforts invested so far, only very few of the 
alternative have fulfilled the requirements to justify clinical testing. The rationale for re-
formulation of CPT or its analogues has been either to stabilize the lactone moieties or to 
induce sustained release combined with specific tumor targeting of these agents. An example 
of the first approach has been the formulation of CPT, CPT-!! or 10-hydroxy-CPT in 
nticrospheres composed of poly-D,L-lactic acid or poly(D,L-lactic-co-glycolic acid) [39-42]. 
The influence of various encapsulation procedures on the release of these agents has been 
extensively examined, and has shov.rn stabilization of the lactone form due to an acidic 
microclimate of the microspheres combined with enhanced pharmacokinetic characteristics in 
animal models [43]. Although from a theoretical perspective the modulation of CPT in this 
prolonged release system could be attractive in the way of reducing local toxicity and 
improving therapeutic efficacy, no phase I studies have been performed so far. 
Alternatively, substantial progress has been made recently toward liposomal formulation 
of a number of important CPT analogues. Liposomes are microparticulate carriers that consist 
of one or more lipid bilayer membranes enclosing an internal aqueous phase. The most 
common constituents are synthetic or naturally occurring phospholipids and cholesterol. 
Although several reports address the considerations in choosing the specific liposome 
constituents and their physical properties (e.g. for CPT [21], topotecan [ 44,45] and CPT -ll 
[46,47]), relatively little information has been presented on toxicity profiles and antitumor 
activity. A recent study reported, however, that liposomal topotecan, encapsulated in 
sphingomyelin/cholesterol liposomes using an ionophore-generated proton gradient, was 
eliminated from the plasma much more slowly than the free drug, resulting in a 400-fold 
increase in systemic exposure [48]. The liposomal preparation also protected topotecan from 
lactonolysis and increased antitumor activity in both murine and human tumor models. 
Likewise, data have been generated demonstrating that unilamellar liposomal formulations of 
lurtotecan (NX 2!1 [49] and SPI-355 [50]) have significant therapeutic advantage over free 
drug and that the increased activity is consistent with increased systemic exposure and 
enhanced tumor-specific delivery of the drug. Based on these exciting data. several phase I 
clinical trials have been initiated with NX 211 given to cancer patients in either weekly or 3-
weekly regimens, and preliminary findings corroborate the preclinical pharmacological 
profile of this agent [51]. 
17 
Chapter I 
CPT and a number of analogues, notably topotecan, have also been formulated in solid-
lipid nanoparticles [composed of stearic acid, soybean lecithin and polyoxyethylene-
polypropylene copolymer (Poloxamer 188)] [52] and dimethyl-beta-cyclodextrin to stabilize 
the lactone form [53]. Although these systems are promising sustained release and drug-
targeting systems in various preclinical models, their clinical merit has not yet been evaluated. 
Synthetic Derivatives 
9-Aminocamptothecin 
9-AC is a semisynthetic CPT derivative which showed outstanding preclinical activity 
against a wide spectrum of tumor types, including those of breast, colon, lung and prostate 
and melanoma [54]. In clinical trials, the drug has been very extensively studied using two 
different formulations based on the use of dimethylacetamide/polyethylene glycol 400 or a 
colloidal dispersion preparation, which enhances solubility and stability. Clinical phase I 
investigations have been conducted using a variety of i.v. administration schedules, including 
a 30-min infusion given daily for 5 days every 3 weeks, and more prolonged infusion 
schedules using 24-hour, 72-hour, 96-hour and 7-day or 21-day continuous dosing repeated 
every 4 weeks [55-61]. All of the studies report neutropenia as the dose-limiting toxicity, 
while thrombocytopenia is also frequent and sometimes severe. Gastrointestinal toxicity is the 
second most reported though not dose limiting. Other toxicities are considered mild to 
moderate. Numerous multi-institutional phase II studies have been conducted in several 
disease types, and overalL 9-AC shows only very modest single-agent activity and its further 
evaluation does not seem indicated [59,62-64]. It has been suggested that the lack of clinically 
relevant antitumor efficacy relates to substantial inactivation of the agent due to the 
unfavorable lactone/carboxylate ratio in patients [38]. 
Homocamptothecins 
In the search for more stabile CPT analogues, the synthetic preparation of derivatives 
bearing a 7-membered E-ring, the so-called homocamptothecins has been described (Figuur 
2) [65]. The lactone ring is stabilized by modification of the naturally occurring 6-membered 
a-hydroxylactone ring into a 7-membered ~-hydroxy lactone ring by insertion of a methylene 
spacer betv.reen the alcohol and the carboxyl moiety. The lead compound in this series, i.e. 
homocamptothecin (hCPT), has been shown to be more stable than CPT, remains a highly 
potent inhibitor of both cell grov.rth "With superior topoisomerase I inhibitory activity as 
compared to CPT [66-68] and, most interestingly, changes the sequence-specificity of the 
drug-induced DNA cleavage by topoisomerase I [69]. Indeed, in contrast to CPT which shows 
a rapid hydrolysis of the lactone moiety until a pH and protein dependent equilibrium has 
been reached, hCPT displays a slow and irreversible hydrolytic lactone ring-opening [70]. 
After a 3 h incubation of CPT and hCPT in human whole blood at 3TC, the fraction present 
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in the lactone form was 6% in the case of CPT and 80% in the case ofhCPT. This remarkable 
difference is not only due to the slower ring opening ofhCPT, but also to a higher affinity of 
hCPT for red blood cells [71]. Based upon this promising feature of hCPT, a series of 
derivatives of this agent was developed that combine enhanced plasma stability and potent 
topoisomerase !-mediated cytotoxicity. Various fluorinated analogues were subsequently 
found to have potent cytotoxic activity against several cell lines, including those 
overexpressing a functionally active P-glycoprotein [72]. Figure 2 shows the chemical 
structure of BN 80915, one of the most promising fluorinated hCPT analogues, which 
recently has entered clinical phase I testing. 
Silatecans 
Using a cascade radical annulation route to the CPT family, a novel series of CPT 
analogues, viz. 7-silylcamptothecins or silatecans, have been synthesized that exhibited potent 
inhibition of topoisomerase I, dramatically improved blood stability and sufficient 
lipophilicity to favor blood-brain barrier transit [73]. Preliminary evaluation in preclinical 
mouse models indicate that silatecans may hold significant promise for the treatment of high-
grade gliomas and provide a rationale for proceeding with further (pre)clinical evaluation of 
their efficacy and safety versus commercially available CPT derivatives, including topotecan 
and CPT-11. 
Hexacyclic Camptothecins 
Two representative agents of the hexacyclic CPT analogues are currently under 
investigation. The first of these, lurtotecan (also known as GI147211 or GG211), is a water-
soluble, totally synthetic derivative with a dioxalane moiety between ClO and Cll [74]. This 
agent has been evaluated clinically in various phase I and phase II trials using a 30-min i.v. 
infusion given daily for 5 consecutive days or as a 72-hour continuous i.v. infusion. [75-77]. 
The dose-limiting toxicity in both schedules was myelosuppression, including severe 
neutropenia and thrombocytopenia. Non-hematological toxicities were various and only mild 
to moderate. Because the oral bioavailability was highly variable and as low as 10% [78], 
alternative ways of drug administration are currently being developed, including a new 
liposomal formulation (NX 211; see above). 
The second agent, DX-8951f or exatecan mesylate, is a new water-soluble, CPT analogue 
with an amino group at Cl and a fluorine at C5 [79]. DX-895lf showed superior and a 
broader spectrum of antitumor activity in vitro and in vivo in comparison with the other CPT 
analogues tested [80,81]. Recently, the results of a phase I evaluation of DX-8951f have 
become available, with the drug administered as a 30-min i.v. infusion given daily for 5 days 
every 3 weeks [82,83]. Brief, noncumulative neutropenia was the most common toxicity, and 
was seen consistently at doses greater than 0.5 mg/m2/day. Other nonhematologic toxicities 
were mild to moderate in severity. Various other schedules, including a once every 3 weeks 
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regimen with 30-min i.v. infusions [84,85] and one based on continuous i.v. infusions of 5 to 
21 days are presently under investigation [86]. The 30-min infusion regimen with daily 
administration for 5 consecutive days is now being tested in clinical phase II trials in various 
disease types. including non-small cell lung cancer [87], pancreatic cancer [88], ovarian 
cancer [89], and colorectal cancer [90]. 
Pro drugs 
Because of the poor aqueous solubility of some CPT analogues, some major efforts have 
been put into the design and synthesis of more water-soluble prodrugs that could be more 
readily formulated than the parent drug. Many of the synthesized compounds have shown 
only marginal improvements in solubility or are too unstable to allow administration in a 
clinical setting. The instability of prodrug forms of, for example, CPT is particularly 
problematic, since the product of degradation (generally the parent drug) is insoluble and 
precipitates in aqueous solutions. Other synthetic approaches have produced fairly stable 
prodrugs, but the rate of active drug liberation proceeds at a too slow and variable rate. To 
date, two approaches in prodrug design have yielded agents that have progressed to clinical 
evaluation, viz. the 9-nitro derivative of CPT and polymer-coupled derivatives of CPT and 
DX-895!f. 
C9-Substituted Derivatives 
One of the most extensively studied agents of this class is 9-nitrocam.ptothecin (9-NC), 
which acts as a partial prodrug of 9-AC [91,92]. 9-NC has a nitro radical in the C9-position 
and is highly insoluble in water, and was initially identified as a precursor in the semi-
synthetic production of9-AC. Since nearly all human cells are able to convert 9-NC to 9-AC, 
including tumor cells. it has been proven difficult to identifY whether 9-NC-mediated 
antitumor activity is directly associated with the parent drug alone or -with 9-AC alone or the 
combination of both [93]. Preliminary evidence generated in clinical phase II trials suggest 
that 9-NC may be potentially be useful in the treatment of advanced pancreatic cancer and 
refractory ovarian cancer using a daily times 4 or 5 per week schedule with the drug given 
orally [94]. An extensive clinical phase II program is currently being conducted to test the 
efficacy of this agent against various malignant diseases [95,96]. 
Polymer-bound Derivatives 
One of the possible ways to modulate anticancer agents is the use of its attachment to 
macromolecules because these high molecular weight prodrug carriers can lead to reductions 
in systemic toxicity, longer retention time within the body, alterations in biological 
distributions and possible improvements in therapeutic efficacy [97 ,98]. Its use is dependent 
on the concept of the enhanced permeability and retention (EPR) effect in solid tumors [99]. 
Tbis EPR effect is based on four general characteristics of tumor tissues in comparison with 
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normal tissues: (i) hyper-vascularity, (ii) hyperpermeability, (iii) defective vascular 
architecture, and (iv) less efficacious drainage due to hypoplastic or minimally effective 
lymphatic system [99]. The pharmacokinetic characteristics of CPT were the starting-point to 
modulate its structure in this way. As indicated, CPT is highly insoluble in water, and by 
converting the C20-0H moiety into an ester coupled to an amino-acid spacer to allow better 
solubilization in aqueous environments, several macromolecular prodrugs of CPT have been 
generated in recent years [100]. Two of these, MAG-CPT ar1d PEG-CPT have progressed to 
clinical evaluation [97.101]. The former consists of CPT covalently bound to a soluble 
polymer [N-(2-hydroxypropyl) methacrylamide (HPMA)] through a glycyl-arninohexanoyl-
glycyl spacer, whereas the latter is a macromolecule derived through conjugation of 
chemically modified polyethyleneglycol with CPT at the C20-0H position. A variety of 
preclinical studies with MAG-CPT and PEG-CPT have shown stabilization and sustained 
release of CPT and also prolonged drug retention within experimental tumors [97,101]. 
Recently, the preliminary results of clinical phase I studies of PEG-CPT [102] and MAG-CPT 
(also referred to as PNU 166148) [103] have been reported, and indicate substantially 
prolonged exposure times to the active species as compared to administration schedules of the 
free drugs. 
In an effort to prolong exposure times ofDX-895lfto tumor tissues that might increase 
cytotoxic properties and antitumor efficacy, a prodrug has recently been generated by linking 
the agent to a biodegradable carrier via a peptide spacer (DE-310). Clinical evaluation of this 
prodrug to examine this hypothesis is currently being conducted. 
Routes of Delivery 
Intravenous Dosing and Considerations of Infusion Duration 
I.v. administration of CPT analogues is currently the most commonly used route of 
delivery. The advantages of this route are many, including the fact that the total amount and 
duration of the administered drug can be controlled. As mentioned earlier, this has the 
advantage of controlled prolonged delivery of the drug. In this regard, most of the studies 
have been done with topotecan,5 and several of the most promising regimens have been 
selected to enter phase II testing, viz. a daily times 5 every 3 weeks 30-min schedule 
[104,105], weekly or 3-weekly 24-hour infusion [106,107] and a 21-day continuous low dose 
infusion administered every 4 weeks [13,25,27,29,!08]. Besides proposed schedule 
dependency on antitumor activity, toxicity also appears to va...--y considerably. Overall, the 
dose-limiting toxicity is myelosuppression. consisting primarily of neutropenia, whereas in 
some continuous infusion schedules thrombocytopenia was more pronounced [25,104]. 
Anemia and nonhematological side effects, including nausea, vomiting. diarrhea, fatigue, 
asthenia, alopecia and mucositis are common but usually mild, and do not seem to be 
schedule dependent. Most of the studies showed that prolonged exposure to i.v. administered 
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topotecan is feasible. Randomized comparison of the daily times 5 schedule every 3 weeks 
and 24-h infusion once a week for 4 weeks repeated every 6 weeks in patients with ovarian 
cancer suggests that the daily times five topotecan regimen was significantly superior with 
respect to response rate [1 00,11 0]. Randomized studies between the 5-day schedule and the 
21-day continuous infusion schedule are not yet available [Ill]. 
Regarding the administration of CPT -11, different schedules are currently being used in 
Europe (350 mg/m2 as a 90-min infusion once every 3 weeks) [112], the USA (125 mg/m2 
given weekly as a 90-min infusion for 4 or 6 weeks) [113] and Japan (100 mg/m2 given 
weekly as a 30-min infusion) [114]. In all these dosing schedules, the total amonnt of CPT-!! 
that can be tolerated in any time period is similar [115]. Schedules with protracted infusions 
that have been investigated vary between 96 hours weekly to 14~days continuous infusion 
[!16]. [26,117] The maximum tolerated dose in these studies (10-30 mg/m2/day) is much 
lower then for the short duration schedules. Surprisingly, the AUC of the active metabolite 
SN-38 reaches comparable levels as reported for the short duration regimens, which is not 
completely understood. One possible explanation would be that the enhanced metabolism of 
CPT-!! relates to saturation of carboxylesterase-mediated conversion of CPT-!! with (high-
dose) short infusion schedules. As for toxicity, myelosuppression and diarrhea are the dose-
limiting events in all tested regimens. Like -with topotecan, protracted low-dose schedules 
give more rise to thrombocytopenia [116] while in shorter schedules neutropenia is more 
prominent. The influence of infusion duration of antitumor activity has not yet been evaluated 
in a randomized setting. 
Ora/Dosing 
As indicated, the high specificity in the mechanism of action of CPT analogues for the S-
phase in the cell cycle has led to the recognition that the compounds may require prolonged 
exposure to maximize the fractional cell kill. In this regard, the availability of clinically useful 
oral formulations of currently available CPT analogues would provide increased convenience 
for the administration of chronic dosing regimens and the opportunity for cost-effective 
outpatient therapy [94]. Since most of the CPT analogues have relatively short terminal 
disposition half-lives, the use of protracted oral dosing is not necessarily the same as 
continuous i.v. infusion, although if the postulated concept of time over threshold 
concentration is a valid indication of both toxicity and efficacy, oral dosing can mimic 
continuous infusion regimens. Formal oral bioavailability studies have been conducted for 
several agents, and have yielded bioavailability values for topotecan of 30 to 44% [118-120], 
for 9-AC of -50% depending on the formulation applied [121,122], and for lurtotecan of 11% 
[78]. Clinical data are not yet available for CPT-!!, although murine data show an oral 
bioavailability of between 10 and 20%, depending on the dose administered [123]. 
The development toward suitable oral regimens for CPT analogues have to date been 
most extensively studied for topotecan using daily or bi-daily administration of 5-day [124], 
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10-day [125], or 21-day schedules [126]. A variety of clinical studies have shown that with an 
increase in prolonged topotecan administration by this route, a shift occurs in dose-limiting 
toxicity from hematological toxicity (mainly granulocytopenia) toward severe gastrointestinal 
side effects, most notably diarrhea [127]. These investigations further indicated that the 
schedule applied. rather than the applied systemic exposure per course seemed to be related to 
the type of experienced toxicity [127]. Based on these considerations, the daily time 5 
schedule has been recommended for future studies. The need for further clinical development 
of the oral topotecan formulation became even more important in view of recent findings that 
the oral formulation has similar efficacy in the treatment of advanced ovarian and small-cell 
lung cancers as compared to the i.v. formulation, while less hematological toxicity was 
observed [128,129]. 
Based on theoretical considerations, including the fact that carboxylesterases are highly 
expressed in human liver and the gastrointestinal tract that could result in presystemic 
metabolism to SN-38 [130], it appears particularly attractive to deliver CPT-11 by the oral 
route. Indeed, the preliminary findings of substantially increased SN-38 to CPT-11 
concentration ratios with oral CPT -11 administration as compared to i.v. administration seems 
to sustain this notion. [131,132] In addition, oral drug administration was associated with 
increased persistence of circulating levels of the lactone form of SN-38, which might be an 
additional advantage with potential pharmacodynamic importance [133]. The clinical utility 
of oral CPT -11 administration is currently under further investigation. 
Local Drug Administration 
Hepatic Arterial Dosing 
The narrow therapeutic window of systemic administration of CPT and its analogues has 
prompted a search toward local drug administration, with the rationale to obtain selectively 
higher activity against locally confined tumors and/or lower systemic toxicity without loss of 
antitumor activity. The pharmacokinetic behavior of CPT -11 was recently compared during 5-
day hepatic arterial and i.v. infusion in a group a cancer patients [134]. These fmdings 
indicated that arterial drug administration is leading to significantly higher conversion of 
CPT-11 into the active metabolite as compared to the i.v. administration, although the clinical 
relevance of this observation is, as yet, unknown [135]. In recent years, various agents have 
also been used for arterial embolization in an attempt to encapsulate the concomitantly 
administered chemotherapeutic agent, and, thereby, further enhance the local drug 
concentration. This concept has been tested with CPT -11 administered with hepatic arterial 
chemoembolization to patients with primary and metastatic hepatic malignancies [134]. 
Further studies are clearly required to confirm efficacy of this treatment and should aim at 




Liposomal aerosol formulations of CPT and 9-NC have recently been developed for nasal 
inhalation treatment of experimental hmg tumors xenografted in nude mice. It was found that 
this preparation was strikingly effective in the treatment of these xenografts growing 
subcutaneously over the thorax at doses much lower than those traditionally used in 
preclinical models administered by other routes [136]. Interestingly, 9-NC aerosol therapy 
was also effective against established melanoma and osteosarcoma lung metastases [137]. 
Concurrent pharmacokinetic studies showed that this type of treatment results in a prompt 
pulmonary distribution at substantial levels that could not be achieved with conventional 
routes of delivery, including oral and intramuscular [138,139]. Overall, these data suggest that 
local delivery of CPT analogues to the respiratory tract by liposome aerosol treatment might 
offer advantages over existing methods in the treatment of some diseases. 
Intraperitoneal Dosing 
Intraperitoneal (i.p.) administration has been used as a strategy for increasing total drug 
delivery to ovarian cancers confmed to the peritoneal cavity. The phannacokinetic behavior of 
topotecan suggests that a substantial phannacokinetic advantage might be obtained following 
i.p. injection. Indeed, recent clinical evidence suggests very slow peritoneal clearance of 
topotecan and high peritoneal:plasma concentration ratios of> 10 after i.p. drug administration 
[140]. I.p. administration of CPT-11 has also been studied recently in animal models and 
showed some potential advantages over the i.v. route. It appeared that the therapy was more 
efficient with an increase in life span and was less toxic as compared to the i.v. route in mice 
bearing C26 colon tumors. In addition, substantially elevated AUCs of CPT-1! and SN-38 
were fouod in the peritoneum, although plasma levels were comparable to i.v. dosing [140]. 
The clinical implications of these observations have not yet been evaluated. 
Biomodulation 
Pharmacodynamic Alterations 
The use ofbiomodulators to increase the therapeutic index of chemotherapeutic treatment 
has made a significant impact on certain diseases [141]. A number of cancer chemotherapy 
biomodulators has been approved for clinical use in humans, and these agents can modulate 
anticancer drugs through either phannacodynanllc or -kinetic modulations. Among 
extensively studied biomodulating agents are the class of hematopoietic growth factors to 
decrease chemotherapy-induced neutropenia and anemia. Initial attempts to increase 
topotecan dose intensity with the use of granulocyte colony-stimulating factor (G-CSF) failed, 
since thrombocytopenia and fatigue rapidly emerged as dose-limiting effects with the daily 
time 5 schedule [142,143]. On the other hand, G-CSF administered after 5 daily infusions of 
topotecan pernritted a 2.3-fold dose escalation above the maximum-tolerated dose [144,145], 
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although it was concluded that the substantial toxicity, inconvenience and costs associated 
with this high dose topotecanJG-CSF regimen does not warrant further development. 
Similarly disappointing results have been obtained with topotecan or 9-AC administered by 
prolonged continuous infusions [146,147]. The addition of G-CSF with CPT-ll 
administration has also been advocated by some investigators [148,149], evidence for 
increased dose intensity or clearly improved chemotherapy based on G-CSF support is still 
lacking. Therefore, the use of G-CSF outside clinical trials to support chemotherapeutic 
treatment is not recommended. 
The principal non-hematologic toxicity for all topoisomerase I inhibitors is gastro-
intestinal. Nausea and vomiting are frequent [56,75,104,112] but, with the introduction of 
selective serotonine antagonist of the 5HT 3 -receptor, this side effect is adequately 
manageable. Diarrhea is also frequent, and mild to moderate in severity with i.v. 
administration schedules. It appears to be unrelated to the schedule used [56,75,104,112], 
except in case of CPT -11, where with the oral administration diarrhea becomes the prime dose 
limiting toxicity especially when using the prolonged schedules [24,122,125,126,150]. 
In the treatment with CPT -11 two types of diarrhea can be distinguished, viz. an early and 
a late onset form. The early onset diarrhea is part of a cholinergic-like syndrome and 
manifests in sweating, salivation, abdominal cramping and diarrhea [151]. Interestingly, this 
cholinergic syndrome has not been described for other CPT analogues. It has been argued that 
the unique structural features ofCPT-ll, including a bipiperidino group that shows similarity 
with a knovvn stimulant of nicotine receptors of autonomic ganglia, 
dimethylphenylpiperazinium iodide, is responsible for this phenomenon [152]. More recently, 
it has been found that the mechanism behind the transient cholinerigic reaction observed 
clinically is more likely mediated through a rapid reversible inhibition of acetylcholinesterase 
by the lactone form of CPT-!! [153]. Clinical evidence indicates that this side effect can be 
adequately treated in the acute phase as well as prophylactically with the use ofi.v. atropine. 
CPT -!!-induced delayed type diarrhea has been reported to be severe (NCI-CTC grade 3-
4) in 11-23% of the patients [113,154], but even the less severe diarrhea still might influence 
continuation of therapy. Moreover, diarrhea related to drug-induced colon-mucosal damage, 
as observed in both rodents [155] and humans [156], can cause severe and potentially lethal 
illness especially during concomitant occurrence of neutropenia. Once delayed type diarrhea 
has occurred.. a high dose regimen loperamide renders the diarrhea manageable [157]. 
Prophylactic treatment of this frequently observed side effect has been investigated in 
numerous studies. Potential modulation of delayed-type diarrhea has been examined clinically 
with several agents, including an enkephalinase inhibitor [158] and glutamine [159], and in 
animal models with a lipopeptide [160] and interleukin 15 [161], with different results. A 
recent preliminary report on co-treatment with thalidomide claims a good protection against 
diarrhea, but we still have to await phannacokinetic results to weigh this study on its proper 
value [162]. To explain the mechanism by which CPT-11-mediated delayed-type diarrhea is 
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triggered, many pharmacokinetic analyses in humans have been performed in order to predict 
the incidence of this diarrhea, with conflicting results. Some studies described a correlation 
benveen late-onset diarrhea and the systemic glucuronidation rates of SN-38 (i.e., the biliary 
index) [163]. Recently it was suggested from animal models, that ~-glucuronidase activity 
from the micro flora in the large intestines may play a major role in the development of CPT-
!!-induced diarrhea, by mediating the hydrolysis of biliary secreted SN-380, thereby causing 
local accumulation of SN-38, which subsequently causes damage to the intestinal epithelium 
[164]. This observation has led to experiments in which antibiotic treatment inhibited the~­
glucuronidase activity from the intestinal microflora, thereby decreasing the luminal SN-38 
concentration and subsequently reducing intestinal damage and ameliorating diarrhea [155]. A 
recent study in humans showed that antibiotic treatment with neomycin did not alter SN-38 
phannacokinetics in plasma, and gave protection to recurrent diarrhea in over 85% of the 
patients experiencing diarrhea in the first course (unpublished data, DK and AS). The 
expected mechanism of blocking bacterial ~-glucuronidase activity causing a subsequent rise 
in SN-38/SN-380 concentration ratio has recently been confirmed. It would be even more 
attractive to use an agent that specifically inhibits the microbial ~-glucuronidase activity. 
Hange-shasin-to (also referred to as TJ14), a herbal medicine that contains the ~­
glucuronidase inhibitor baicalin, has recently been described to be a potent inhibitor of 
delayed-type diarrhea caused by CPT -11 in a rat model [165] as well as in humans [166]. 
Unfortunately there is no information yet on possible changes in the systemic disposition of 
CPT -11 and its metabolites which are likely to occur due to inhibition of plasma ~­
glucuronidase activity by this agent, information of vital importance in view of antitumor 
activity. 
It has also been speculated based on in vitro studies, that raising pH-values in the 
intestines by intestinal alkalization might decrease reabsorption of biliary secreted SN-38 after 
i.v. CPT-11 administration and, as a result, lowers intestinal side effects [167]. Again, 
demonstration of unaltered phannacok:inetics of SN-38 in the presence of intestinal 
alkalization is of crucial importance. Thus, although this approach might show reduced CPT-
11-mediated intestinal toxicity, this may be a phyrric victory if a simultaneously altered 
metabolic clearance (by way of a decreased enterohepatic recirculation of SN-38) results in 
reduced antitumor activity. 
Pharmaco/..:inetic Alterations 
Intestinal metabolic systems and drug efflux pumps, located in the intestinal mucosa 
represent a major limitation in the bioavailability of orally delivered drugs [168]. Several 
enzymes located in the enterocyte, like the cytochrome P450-3A4 isozyme (CYP3A4), are 
involved in the presystemic metabolism of many anticancer agents, including etoposide and 
paclitaxel, thereby limiting the oral absorption of these drugs. Since CYP3A4 is involved in 
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the metabolism of CPT-11, it has been proposed that the bioavailability of this agent might be 
substantially enhanced by phannacokinetic modulation of enteric CYP3A4 activity, e.g. by 
concomitant adntinistration of ketoconazole, erythromycin or quinidine [169]. Similarly, P-
glycoprotein and the Breast Cancer Resistance Protein (BCRP), which are abundantly present 
in the gastrointestinal tract, have been shown recently to limit the intestinal absorption of 
various agents, including topotecan [170]. Combined inhibition of intestinal P-glycoprotein 
and BCRP by the investigational agent GF120918 was shown recently to increase the 
systemic exposure to topotecan in both animals and patients with the bioavailability 
increasing from a mere 30-44% to >90%, suggesting that modulation of these transporters 
simultaneously could be considered in the development of substrate anticancer agents given 
by the oral route [171]. 
As indicated, several preclinical studies have identified CYP3A4, to form two 
pharmacologically inactive oxidation products known as APC and NPC, as one of the 
principal enzymes involved in CPT-ll. In addition, it was shown that ketoconazole, a 
synthetic imidazole-type broad-spectrum antifungal agent as well as a potent inhibitor of 
CYP3A4, inhibited APC and NPC formation by 98 and 99%, respectively, at tested 
concentrations as low as 1 J..lM [ 172, 183]. Previous investigations indicated that with standard 
oral doses of ketoconazole (200 to 400 mg/day), peak plasma concentrations are in the range 
of 4 to 20 J..lM, suggesting that concomitant treatment ofketoconazole is likely to substantially 
alter the disposition of CPT-11 administered i.v. to cancer patients. Indeed, a recent pilot 
pharmacokinetic study in a cancer patient receiving CPT -11 with or without ketoconazole 
indicated a substantial phannacokinetic interaction between the two drugs at the level of drug 
metabolis~ and indicated that these agents can not be administered together without dose 
adjustments (unpublished data, AS and JV). If confirmed in a larger group of patients, the 
concomitant administration of ketoconazole might enable CPT -11 dose reductions without 
affecting systemic exposure to the active metabolite, SN-38, and potentially eliminates 
interpatient variability in CPT -11 pharmacokinetics that arise as a result of (genetically-
defined) patient differences in CYP3A4 expression levels [174]. 
There are many other potential approaches to improve the therapeutic index of CPT-11 
through pharmacokinetic biomodulation, including modulation with inhibitors of biliary 
secretion processes mediated by P-glycoprotein and/or cMOAT (e.g., cyclosporin A) and with 
inducers of UDP glucuronosyltransferase isofonns involved in SN-38 glucuronidation (e.g., 
phenobarbital) [175,!76]. A clinical trial to evaluate the phannacological and toxicological 
implications of a combination regimen of CPT-11, cyclosporin A and phenobarbital is 
currently in progress, and preliminary findings indicate substantial antitumor activity with this 
combination without the occurrence of significant diarrhea despite a very low systemic 
exposure to SN-38 [177]. This finding is supportive of the conjecture that activation ofCPT-




Conclusions and Future Perspectives 
Camptothecins are among the most promising new anticancer drugs that have been 
developed in recent years. Topotecan and CPT-11 are now registered for the treatment of 
ovarian and colon cancer, respectively. The unique mechanism of action on topoisomerase I 
and activity against a broad spectrum of other malignancies are an ongoing stimulus for 
further clinical development. With the growing knowledge on pharmacodynamics and 
pharmacokinetics of the different campotothecin analogues, the poor water solubility and pH-
dependent reversible interconvention between the active lactone and inactive carboxylate 
for:m, as well as increase in activity or stability by substitutions to specific sites on the 
molecule, much effort has and will be done to increase antitumor activity of this group of 
drugs. Meanwhile pharmacological modulation, particularly of CPT -11, can be of interest to 
reduce toxicity and to influence metabolic pathways. Although much effort is being put into 
development of new analogues, the question to answer remains if drugs under development 
will ultimately lead to the theoretically expected higher activity and/or reduced toxicity. Last 
but not least optimization of schedules, routes of administration and combination therapies 
"\."Vill lead to numerous new studies in different tumor types. It is to be expected that in the 
future many new formulations and/or combinations will be developed. In contrast to other 
previously registered anticancer drugs, the pharmacological knowledge on how camptothecin 
analogues behave in humans "\."Vill lead to a more logic and quicker development of these 
agents. 
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Abstract 
Lurtotecan (Gll472ll; LRT) is a semisynthetic and water-soluble analogue of the 
topoisomerase I inhibitor camptothecin. To determine whether the therapeutic efficacy of 
LRT in patients could be improved, the drug was encapsulated in liposomes (NX 211; Gilead 
Sciences). In order to allow accurate description of the pharmacokinetic behavior ofNX 2!1 
in cancer patients, we have developed sensitive RP-HPLC assays with fluorescence detection 
(A.a=378 mn; A.,m=420 mn) for the determination of total LRT levels in human plasma and 
urine. Sample pretreatment involved deproteinization with I 0% (w/v) aqueous perchloric 
acid-acetonitrile (2:1, v/v), and chromatographic separations were achieved on an Inertsil-
ODS 80A analytical column. The lower limit of quantitation (LLQ) was established at 1.00 
ng!ml in plasma (200-)ll sample) and at 100 ng!ml in urine (200 j.tl of 40-fold diluted sample). 
The within-run and between-run precisions were <7.5%. LRT concentrations in urine <100 
ng/ml were determined by a modified procedure comprising a single solvent extraction with 
n-butanol-diethyl ether (3:4, v/v). In this assay, the fluorescence sigual ofLRT was increased 
14-fold prior to detection by post-column exposure to UV light (254 mn) in a photochemical 
reaction unit. The LLQ of this assay was 0.500 ng!ml (150-j.tl sample) and the within-run and 
betvveen-run precisions were <10%. 
Introduction 
Lurtotecan (7 -( 4-methylpiperazinomethylene )-I 0, 11-ethylenedioxy-20(S)-camptothecin; 
also known as Gll47211; LRT) (Fig. I) is a novel semisynthetic analogue of camptothecin, a 
cytotoxic plant alkaloid that was first extracted from the wood and bark of the oriental tree, 
Camptotheca acuminata [l]. The mechanism of action of camptothecin derivatives is based 
on stabilization of the cleavable complex formed by the intranuclear enzyme topoisomerase I 
and DNA, and on induction of single-stranded DNA breaks [2]. LRT has previously been 
sho'WD to have significant activity in both in vitro cytotoxicity assays and in vivo tumor model 
systems [3-5], and was recently introduced into clinical trials [6-8]. 
Clinical pharmacokinetic studies of camptothecin derivatives, including LRT, are 
complicated by a chemical, pH-dependent instability of the a-hydroxy-3-lactone moiety in the 
core structure of the compounds, generating a ring-opened carboxylate form. This lactone 
functionality undergoes rapid hydrolysis in aqueous solution under physiological conditions, 
i.e. at pH 7 or above, and results in a virtually complete loss of biological activity [9]. In 
recent years, considerable effort has been put in the development of alternative formulations 
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Figure 1. Chemical structure oflurtotecan (LRT). 
One of these approaches is the incorporation of the lactone forms of camptothecins in 
liposomal particles. Indeed, recent preclinical studies indicated that liposomal encapsulation 
of the topoisomerase I inhibitors topotecan [10,11], camptothecin [12,13] and irinotecan 
[14,15] proved to be very efficient against lactone ring opening, increased antitumor activity 
in experimental tumor models and dramatically enhanced tissue distribution and the systemic 
availability. Efficacy studies performed in nude mice bearing human colon and head and neck 
tumor xenografts have also indicated improved therapeutic efficacy for a new liposomal 
formulation ofLRT (NX 211; Gilead Sciences) as compared to nonliposomal LRT [16]. 
Based on these favorable results, we recently started a project to study the safety profile and 
clinical pharmacokinetics ofNX 211 in patients with advanced solid tumors. In the context of 
this study, we have now developed sensitive RP-HPLC methods with fluorescence detection 
using a sample clean-up procedure that disrupts the liposomes, thus enabling determination of 
total drug levels in plasma and urine samples following NX 211 administration. The methods 
have been validated in terms of sensitivity, accuracy and precision [17], and have been used in 
a pharmacokinetic experiment in a patient to investigate their applicability in vivo. 
Experimental 
Chemicals and Reagents 
LRT dihydrochloride monohydrate (lot: U2044/164/l, containing 78.11% of the free 
base) and NX 211 (liposomal LRT, lot: 181801F, containing 0.49 mg LRT as free base/ml) 
were delivered by Gilead Sciences (San Dimas, CA, USA). The internal standard (IS) 6,7-
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dimethoxy-4-methylcoumarin (lot 79F3652) was obtained from Sigma (St. Louis, MO, USA). 
Dimethyl sulfoxide (DMSO), diethyl ether, n-butanol, methanol and acetonitrile were 
purchased from Rathburn (Walkerburn, UK). Perchloric acid (70-72%, v/v, in water), neat 
acetic acid and sodium hydroxide were supplied by Baker (Deventer, The Netherlands). 
Ammonium acetate was delivered by Roth (Karlsruhe, Germany) and sodium chloride by 
Merck (Darmstadt, Germany). All water used in the study was filtered and deionized with a 
Milli-Q-UF system (Millipore, Milford, MA, USA). Drug-free human plasma for the 
construction of calibration curves and quality control (QC) samples originated from the 
Central Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). 
Stock Solutions 
Stock solutions ofLRT were made in triplicate by dissolving X mg LRT in (X x 0. 7811) 
ml DMSO, resulting in a solution containing 1.00 mg/ml LRT (free base). The working stock 
solution ofLRT, containing 0.100 mg/ml free base, was prepared by a 10-fold dilution of the 
stock solution in DMSO. A stock solution of the IS at a concentration of 1 mg/ml was 
prepared by dissolving 50 mg IS in 50 ml DMSO. 
Standards for Total LRT in Plasma and Urine 
Spiked plasma samples used as calibration standards were prepared daily in duplicate by 
addition of 10 ~1 of serial dilutions in methanol-water (l:l,v/v) from the working solution of 
LRT to 240 ~1 of drug-free human plasma. This resulted in calibration standards of 1.00, 2.50, 
5.00. 10.0, 25.0, 50.0 and 100 ng/ml LRT (free base) in plasma. Four pools ofQC samples for 
LRT were prepared in human plasma at concentrations of 4.00, 20.0, 75.0 and 750 ng/ml, by 
addition of the appropriate volume of the LRT working solution or dilutions in 10 mM 
aqueous sodium hydroxide-methanol (1:1, v/v) (to shift the equilibrium to the carboxylate 
form) to human plasma. The QC containing 750 ng/ml LRT was used to investigate the 
suitability of small-volume (20 ~1) injections. Lower limit of quantitation (LLQ) samples in 
plasma were prepared daily in separate blank plasma samples obtained from 5 healthy 
volunteers at a concentration of 1.00 ng/ml. To minimize a potential difference with clinical 
samples, 2 pools of recovery control (RC) samples containing 20.0 and 750 ng/ml NX 211 
were also prepared by addition of an aliquot of the NX 211 stock solution (in phosphate-
buffered saline) to human plasma. Two pools ofQC samples were prepared in human urine at 
concentrations of 250 and 2500 ng/ml, which were diluted 40-fold in blank human plasma 
prior to extraction. The LLQ samples for urine were prepared daily at a spiked concentration 
of 100 ng/ml in quintuplicate using 5 different drug-free urine samples. 
Standards of LRT in the Sensitive Urine Assay 
Calibration standards in urine were also prepared daily in duplicate by addition of 10 ~1 
of serial dilutions ofLRT in methanol-water (1:1, v/v) to 240 ~1 blank human urine, at final 
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concentrations of the free base of0.500, 1.00, 2.50, 5.00 and 10.0 ng/rnl. Three pools ofQC 
samples were prepared at concentrations of 1.25, 7.50 and 250 ng/rnl by addition of 
appropriate volumes of a dilution of the LRT working stock solution [in 10 mM aqueous 
sodium hydroxide-methanol (1:1, v/v)]. The QC sample containing 250 ng/rnl, identical to 
that used for the assay of total LRT in plasma and urine, was diluted 10-fold in blank urine 
before extraction, and was further used to show the applicability of low volume injections (! 0 
f!l). The LLQ samples were prepared daily at a concentration of 0.500 ng/rnl, again in 
quintuplicate using 5 different drug-free urine samples. 
HPLC Instrumentation and Conditions 
The HPLC systems consisted of consta.L'v!etric 3200 and 4100 solvent delivery systems 
(LDC Analytical, Riviera Beach, FL, USA), Waters 717plus autosampling devices (Milford, 
MA, USA), a Beam Boost photochemical reaction unit supplied with a coil of 25 m and an 
internal diameter of 0.3 = (ICT-ASS-Chem, Bad Homburg, Germany), and Jasco 821-FP 
and FP-920 fluorescence detectors (Jasco Benelux B.V., Maarssen, The Netherlands). 
Separations were achieved on a stainless-steel analytical column (150x4.6 mm internal 
diameter) packed with lnertsil ODS-80A material (5 flill particle size), delivered by Alltech 
Applied Science (Breda, The Netherlands). The mobile phase was identical in both assays and 
was composed of 1.0 M aqueous anunonium acetate (pH 5.5)-water-acetonitrile 
(10:72.5:17.5, v/v/v) with the pH adjusted to 5.5 (acetic acid). The analytical coluruns were 
maintained at 60°C using a model SpH99 colurun oven (Spark Holland, MeppeL The 
Netherlands). A detailed composition of the various HPLC systems used for the two assays is 
provided in Table 1. Peak: recording and integration were performed with the Chrom-Card 
data analysis system (Fisons, Milan, Italy). All calibration curves were fitted by weighted 
(1/x) least-squares linear regression analysis using the peak height ratios of LRT and the IS 
versus the nominal concentrations of the standards. 
SampleTreatmentfor TotalLRTin Plasma and Urine 
Samples were prepared by addition of 100 flliS solution [100 ng/rnl in 10% perchloric 
acid-acetonitrile (2:1, v/v)] to 200 fll human plasma, or 40-fold diluted urine in plasma, in a 
1.5-rnl polypropylene vial (Eppendorf, Hamburg. Germany). Samples were mixed vigorously 
for 30 min on a multi-tube vortex mixer, followed by centrifugation at 23,000xg (5 min) at 
ambient temperature. A 250-~1 volume of the clear supernatant was transferred to a low 
volume glass insert, from which 200 fll (or 20 fll in case of QC and RC samples containing 



















Lamp: A-~254 nm 
Coil: 25 m: ID: 0.3 mm 
Acx=378 nm 
A.em~20nm 
Em band: 40 nm 
Sample Treatment for LRT in the Sensitive Urine Assay 
Total plasma/urine 
Flow-rate: 1.25 ml/min 
Aex=378 nm 
A0m~20nm 
Em band: 30 nm 
A 100-).ll volume of IS solution (50 ng/ml in 25 mM aqueous ammonium acetate, pH 3.0) 
was added to a 12-ml glass tube supplied with a PTFE-covered screw cap containing 150 ).ll 
urine. After incubation for 30 min at room temperature~ 0.8 g solid sodium chloride was 
added, followed by extraction with 2 ml n-butanol-diethyl ether (3 :4, v/v) by vigorous vortex 
mixing for 5 min. Subsequently, the sample was centrifuged at 4000xg (5 min), followed by 
collection of 1 ml upper organic layer, which was evaporated to dryness under a gentle stream 
of nitrogen at 70°C for a period of 45 min. The dried residue was redissolved in 150 ).ll 25 
mM aqueous ammonium acetate (pH 3.0) and transferred to a glass insert. A volume of 50 ).ll 
(or 10 ).ll for the QC sample containing 250 ng/ml LRT) was injected into the HPLC system. 
Validation 
Validation runs of LRT in plasma and urine and of LRT in the sensitive urine assay 
included a set of calibration samples assayed in duplicate, and LLQ and QC samples in 
quintuplicate, and was performed on 4 separate occasions. Precisions were calculated by one-
way analysis of variance (ANOVA) for each test concentration, using the run-day as the 
classification variable. The accuracy of at least 80% of the samples assayed at each 
concentration should be in the range of 80 to 120%. The within-run (WRP) and between-run 
precisions (BRP) should be <20% at the concentration of the LLQ and <15% at the 
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concentrations of the QC samples and the average accuracy (ACC) should be within 85-115% 
for each concentration, including the LLQ. 
The extraction recoveries of LRT and the IS in the assay for total LRT in plasma and 
urine were calculated by comparing peak heights obtained from a sample containing 25.0 
ng/ml LRT in phosphate-buffered saline that was extracted (as described for plasma), to those 
obtained in extracted QC samples prepared in the biological matrix. The extraction recoveries 
in the sensitive urine assay were calculated by comparing observed peak heights of the 
processed urine samples of the calibration curves to peak heights obtained from spiked 
samples containing 1.00 ng/ml LRT and 10.0 ng/mliS in 25 mM aqueous anunonium acetate 
(pH 3.0). 
The stability of LRT and the IS in plasma and urine was established (i) during 3 
consecutive freeze-thaw cycles, in which the samples were put at room temperature for 30 
min after thawing, and (ii) during an overnight incubation at 37°C. The concentrations used 
were 20.0 and 75.0 ng/ml for plasma and 250 and 2500 ng/ml for urine, and were analyzed 
using the assay for the determination of total LR T in plasma and urine. 
The selectivity of the assays was tested by the degree of separation of the compounds of 
interest and possible other chromatographic peaks caused by endogenous components and/or 
potentially co-administered drugs. The interference from endogenous material for LRT and 
the IS in human plasma and urine was determined by visual inspection of HPLC profiles of 5 
processed blank plasma and urine samples obtained from 5 healthy volunteers. Interference 
from potentially co-administered drugs was tested at a spiked concentration of 10 ~g/ml in a 
blank plasma extract for the assay of total LRT in plasma and urine, and at 10 !!g/ml in 25 
niM aqueous ammonium acetate (pH 3.0) for LRT in the sensitive urine assay. The tested 
compounds included acetaminophen, alizapride, codeine, dexamethasone, domperidon, 
metoclopramide, morphine, leucovorin, lorazepam, paroxetine, and ranitidine. 
Results and Discussion 
In approaching the present analytical procedures, we used our own previous RP-HPLC 
procedure for the quantitative determination of total nonliposomal LRT (lactone plus 
carboxylate forms) in human whole blood as a starting point [18]. Because of the pH-
dependent instability of the o:-hydroxy-8-lactone moiety in the core structure of LRT, 
resulting in the ring-opened carboxylate from at hight pH and the ring-closed lactone form at 
low pH, we decided to focuss only on measurement of total concentrations in the present 
study, since disruption of liposomes while maintaining the physiologic lactone to carboxylate 
ratio may not be feasible. The choice of the IS, 6,7-dimethoxy-4-methylcoumarin, and the 
optimal fluorescence wavelength couple of LRT (378/420 nm) was based on earlier work 
descibed for determination ofLRT in human blood and dog plasma by Selinger et al. [19] and 
Stafford and St. Claire [20], respectively. 
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For the purpose of assay validation, all QC samples were prepared with the carboxylate 
form ofLRT~ to ensure a quantitative conversion to the lactone species of the total amount of 
LRT, prior to measurement, present in plasma and urine of clinical samples. 
Assay of Total LRT in Plasma and Urine 
Initially, the assay of total LRT in plasma and mine was validated with only LLQ and QC 
samples ofnonliposomal LRT (free base) in plasma and urine, using an extraction time of 15 
min. The calibration curves were linear in the range of 1.00 to 100 ng/ml with Pearson's 
regression correlation coefficients ranging from 0.9986 to 0.9997, by using weighted (1/x) 
linear least-squares regression analysis. The retention times ofLRT and the IS were 11 and 15 
min respectively, with an overall run time of20 min. 
One of the tested blank plasma sample specimens showed a minor (unknown) interfering 
peak in the chromatogram for LRT, and was replaced by a new blank plasma obtained from a 
healthy volunteer to enable accurate determination of the LLQ. No interfering peaks with 
retention times around the IS were found in the tested blank plasma samples. In the 5 ( 40-fold 
diluted) blank human mine samples, no interfering peaks were found for LRT; however, all 
tested urine samples showed a small peak with the same retention time as the IS, but this 
interference did not significantly alter the observed data. The tested drugs potentially co-
administered with NX 211 did not interfere with the analytes of interest. Some minor peaks 
were found with retention times of 1 to 3 minutes, causing no problem for the determination 
ofLRT in plasma and urine. 
The LLQ was established in plasma at 1.00 ng/ml and in urine at 100 ng/ml, with 95% of 
the LLQ samples falling within the acceptable accuracy range of 80 to 120% [17]. The 
within-run and betv.reen-run precisions at the 5 tested concentrations in plasma, including the 
LLQ, were <7.5% and <4.1%, respectively, with the accuracy ranging from 96 to 110% 
(Table 2). The within-run and betv.reen-run precisions in urine at the 3 tested concentrations 
were <6.7% and <4.4%, respectively, with an accuracy range of97 to 108% (Table 2). The 
extraction recoveries, estimated by comparing peak heights obtained by direct injection of 
standard solutions containing 25.0 ng/ml LRT and IS in blank plasma extracts to those 
obtained in extracted plasma samples of the calibration curves, were 89±8.2% (mean ± 
standard deviation) and 67±4.8% for LRT and the IS, respectively. No loss of LRT was 
estimated at the tested concentrations after 3 freeze-thaw cycles or during overnight 




Validation characteristics of total LRT in plasma and urine. 
Matrix Nom.conc. Mean WRP' BRP' ACC' 
(ng/ml) (ng/ml) (%) (%) (%) 
Plasma 1.00 b 0.959 7.5 4.1 96 
4.00 3.84 7.4 c 96 
20.0 22.0 2.7 1.0 llO 
75.0 81.4 2.3 2.1 109 
750 789 2.8 2.4 105 
Urine 100 b 96.8 6.7 4.4 97 
250 269 3.0 0.12 108 
2500 2525 4.3 2.1 101 
a: Abbreviations: WRP, 'Nithin-run precision: BRP. between-run precision: ACC, average accuracy 
b: Lower limit of quantitation sample 
c: No additional variation was observed as :1 result of performing the assay in different runs 
Using an extraction time of 15 min. we noted that the extraction recovery of plasma 
samples containing NX 2ll (liposomal LRT) was approximately 10% lower for LRT as 
compared to plasma samples spiked with nonliposomal LRT (free base). The extraction 
efficiency of the samples containing NX 211 was eventually increased by extending the 
vortex-mixing time to 30 min, at which maximum recovery was reached (data not shovvn). 
The assays of total LRT in plasma and urine were re-validated during 3 analytical runs (with a 
30-m.in mixing time during sample extraction), and the calibration cruves were assayed in 
duplicate with the 4 QC samples of LRT and 2 RC samples containing NX 211 spiked at 
concentrations of 20.0 and 750 ng/ml, both in plasma, in triplicate. The Pearson's regression 
correlation coefficients in the re-validation runs ranged from 0.9995 to 0.9998, and the range 
of the within-run and between-run precisions of the QC samples containing LRT were 1.8 to 
3.6% and 0.73 to 2.5% respectively, with an overall accuracy between 99 and 104%. The 
within-run precisions of the RC samples were 1.9 and 2.5%, respectively, for the samples 
containing 20.0 and 750 ng/ml, whereas the respective between-run precisions were 2.3 and 
7.3%. The extraction recoveries of LRT in the QC and RC samples containing 20.0 ng/ml 
LRT and NX 2ll were 90±2.1% and 85±3.9%, respectively, and 83±3.0% (LRT) and 
82±3.0% (NX 211) for the samples containing 750 ng/ml. 
Representative RP-HPLC chromatograms derived from a blank human plasma pool and a 
plasma sample spiked to contain 10.0 ng/ml LRT (free base) are shown in figs. 2A and 2B. 
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Chromatograms of a blank human plasma sample (A), a plasma sample spiked 
with 10.0 ng!ml LRTfree base (B) and a plasma sample obtained/rom a patient 
8 h after the administration of NX 211 at a dose level of 0.8 mg (C). Peaks 
labeled I and II correspond to LRT and the IS. respectively. 
An additional chromatographic peak was found in the RC samples containing NX 211 with a 
retention time of approximately 48 min. This peak was later identified as a photochemical 
degradation product ofNX 211 by comparison of the compound's chromatographic behavior 
on the RP-HPLC colunm and spectroscopic properties with a pure reference standard. 
Isolation, purification and structural identification, in addition to the role of this compound in 
the overall drug disposition will be described separately. 
Assay for the Sensitive Determination of LRT in Urine 
Previous studies have shown that renal clearance of LR T in patients treated 'With 
nonliposomal drug was low, with approximately 10-14% of the delivered dose excreted as 
unchanged parent drug in urine [6]. In order to allow determination of low concentrations of 
LRT in urine, which can be anticipated following treatment with NX 211 at low dosages, an 
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assay was also required with increased sensitivity as compared to the assay described for total 
LRT concentrations in plasma and urine with an LLQ (for urine) of 100 ng/ml (see above). 
The sensitivity of this assay could theoretically be improved by decreasing the dilution factor 
used for urine samples prior to extraction. However, this will likely result in substantially 
prolonged run times in order to get sufficient separation between the peaks of interest (i.e. 
LRT and the IS) and those resulting from the presence of endogenous materiaL which would 
in turn compromise assay sensitivity. 
Eventually, the assay sensitivity could be significantly improved, in part, by increasing 
the fluorescence intensity of LRT through a modification of the detection procedure. LRT is 
knovm to be slightly light sensitive [19] and since photochemical reactor units in combination 
with HPLC has been described for a wide variety of other compounds [21-25], where 
increased detector signal outputs have been described from 2 to 80 folds, we have evaluated 
the impact of post-column photodegradation on the fluorescence activity of LRT. Post-
column exposure of LRT to UV light (254 mn) results in a loss of the piperazinomethylene 
moiety on C7 of the LRT molecule, as determined by electro-spray ion-trap mass 
spectrometry [m/"=409 (LRT-C7 side chain)]. The influence of the photochemical reaction 
unit on the fluorescence of LRT was estimated by injections of 50 J.Ll of 5 ng/ml LRT in 25 
mM ammonium acetate (pH 3.0) onto the HPLC system as described for this assay. The flow 
rate was varied from 0.50 to 2.00 mJJmin, resulting in irradiation times of 300 to 75 s. At each 
flow rate, 2 injections were performed, one with the lamp of the photochemical reaction unit 
on and another one with the lamp switched off. The ratios of the peak heights obtained with 
the lamp on and off were calculated. As displayed in fig. 3, the fluorescence intensity ofLRT 
increased 9 to 15-fold depending on the flow rate used (0.50 to 2.00 ml/min). The use of a 
flow rate set at 0.75 ml/min (i.e. and irradiation time of200 s) resulted in a 14-fold increased 
fluorescence signal of LRT, and was associated with an acceptable total run time (35 min) 
with retention times of 19 and 24 min for LRT and the IS, respectively. 
Fig. 4 shows representative chromatograms of a blank human urine sample and a sample 
spiked with 2.50 ng/ml LRT (free base). The calibration curves of LRT were linear in the 
range of 0.500 to 10.0 ng/rnl, with Pearson's correlation coefficients ranging from 0.9954 to 
0.9994, also using weighted (1/x) least-squares linear regression analysis. No analytical 
interference was found between LRT or the IS and of the tested drugs potentially co-
administered with NX 211. However, a number of three additional peaks were found with 
retention times of 6, 7 and 10 minutes. Since these elute in the big front of the chromatograms 
of urine and high concentrations of the drugs were spiked these peaks have no impact on the 
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Influence of the photochemical reaction unit on the fluorescence intensit}' of 
LRT. 
Small peaks with the same retention time as LRT and the IS were found in all of the tested 
blank urine samples, so the LLQ could not be established below a concentration of 0.500 
ng/rnl, v.rith 80% of all samples in the acceptable range of accuracy. The within-run and 
between-run precisions at the 4 tested concentrations were <5.5 and <10%, respectively, with 
the accuracy ranging from 97 to 108% (Table 3). Taking into consideration that only 
approximately half of the added volume of the organic layer was evaporated, the extraction 
recoveries were around SO and 92% for LRT and IS respectively. 
Assay Application 
The suitability of the developed methods for clinical use was demonstrated by the 
determination ofLRT in biological specimens obtamed from a patient treated with NX 211 at 
a dose of 0.8 mg. Examples of the patient's sample trace are shown in Fig. 2C (plasma) and 
Fig. 4C (urine). Distinct peaks were obtained for LRT in both matrices that were well 




Validation characteristics of total LRT urine (sensitive assay). 
Nom. cone. Mean WRP' BRP" ACC' 
(ng/ml) (ng/ml) (%) (%) (%) 
0.500 b 0.539 5.5 c 108 
1.25 !.31 3.0 3.1 105 
7.50 7.27 2.8 6.7 97 
250 243 4.2 10 97 
a: Abbreviations: VVRP. within-run precision: BRP. between-run precision: ACC, average accuracy 
b: Lower limit of quantitation sample 
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Chromatograms of a blank human urine sample (A), a urine sample spiked with 
2.50 nglml LRT free base (B) and a urine sample obtained from a patient, 
collected 12-24 h after the administration of NX 211 at a dose level of 0.8 mg 




In conclusion, we have developed and evaluated new liquid chromatographic methods for 
measuring total LRT levels in human plasma and urine. The primary elements of novelty 
described in this work are the use of human plasma as biological matrix containing liposomal 
LRT (NX 211) and the utilization of a photochemical reaction unit to increase the native 
fluorescence intensity ofLRT in order to achieve sub-nanogram per milliliter determinations. 
The methods were shov.rn to meet the current requirements as to validation of bioanalytical 
methodologies [17], providing excellent precision and accuracy. The described methods 
permit the analysis of patient samples, and will be implemented in an ongoing clinical trial to 
investigate the disposition ofLRT in cancer patients receiving NX 211. 
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Purpose: To determine the maximum-tolerated and recommended dose, toxicity profile 
and pharmacokinetics of the liposomal topoisomerase I inhibitor, lurtotecan (NX 211) 
administered as a 30-minute IV infusion once every 3 weeks in cancer patients. 
Patients and Methods: NX211 was given by peripheral infusion. Dose escalation 
decisions were based upon all toxicities during the firSt cycle as well as phannacokinetic 
parameters. Serial plasma, whole blood, and nrine samples were collected for up to 96 hours 
follo....ving the end of infusion and drug levels were determined by high-performance liquid 
chromatography. 
Results: Twenty-nine patients (13 males116 females; median age, 56 years; range, 39-74) 
received 77 courses ofNX 211 at dose levels of0.4 (n~3 patients), 0.8 (6), 1.6 (3), 3.2 (6), 3.8 
(6) and 4.3 mg/m2 (5). Neutropenia and thrombocytoperua were the dose-limiting toxicities, 
and were not cumulative. Other toxicities, including nausea, vomiting and fatigue, were mild 
to moderate. Nine patients bad stable disease (some of which prolonged) while on treatment, 
whereas one of these with an adenocarcinoma of unknovm origin (ACUP) had a significant 
regression just not reaching the criteria of partial response (PR). The systemic clearance of 
lurtotecan in plasma and whole blood was 0.82±0.78 and 1.15±0.96 L/b/m', respectively. 
Urinary recovery (Fu) of lurtotecan was I 0.1±4.05% (range, 4.9 to 18.9). In contrast to 
systemic exposure measures, the dose excreted in urine (i.e., dosexFu) was significantly 
related to the percent decrease in neutrophil and platelet count at nadir (P<.OOOO I). 
Conclusion: The dose-limiting toxicities of NX 211 are neutropenia and 
thrombocytopenia. The reconunended dose for phase II studies is 3.8 mglm2 once every three 
weeks. Phannacologic data suggest a relationship betvveen exposure to lurtotecan and NX 
211-induced clinical effects. 
Introduction 
Lurtotecan (7 -( 4-methylpiperazinomethylene )-1 0, ll-ethylenedioxy-20(S)-carnptothecin, 
also known as Gll47211 (Fig. 1), is a semisynthetic analogue of carnptothecin, a cytotoxic 
plant alkaloid that was first extracted from Camptotheca acurninata [I]. Structurally, 
lurtotecan is unique among camptothecin drugs, because of a dioxalane moiety on the A-ring 
and a bulky 4-methyl-piperazinomethylene group on the C-7 position. These molecular 
modifications have resulted in enhanced aqueous solubility as compared to the original agent 
and increased affinity of the drug for DNA topoisomerase I, the cellular locus through which 
camptothecin analogues produce their antitwnor activity. Its mechanism of action is based on 
stabilization of the cleavable complex formed by the intranuclear enzyme topoisomerase I and 
DNA, and on induction of the single-stranded DNA-breaks [2]. The cytotoxicity of the 
topoisomerase I inhibitors is distinctly S-phase specific, and various preclinical studies with 
56 
Phase I NX211 
lurtotecan and other camptothecin drugs have suggested that prolonged exposure, achieved 
either by repeated doses or prolonged infusion, might be beneficial for efficacy profiles.3 
Preclinical in vivo studies 'With lurtotecan as a single agent demonstrated that it is an effective 
inhibitor of mammalian DNA topoisomerase I, with at least similar potency as the related 
agent, topotecan [1,4]. 
"-'::: "-'::: 0 
N lj 
/ /-N ;; 
0 
HzC OH~O I H3C 
Figure L Chemical structure of lurtotecan. 
Several clinical trials with lurtotecan have been performed to exploit the possible 
schedule dependence, focussing on intermittent (daily for 5 days every 3 weeks) [5-8] or 
prolonged IV administration (72-hour infusion every 4 weeks, and 7, 14 or 21-day infusion 
schedules) [9-10]. These studies have shown that the pharmacokinetic behavior oflurtotecan, 
in analogy to other topoisomerase I inhibitors, is significantly influenced by a chemical pH-
dependent hydrolysis of the active lactone form to the ring-opened carboxylate form, which is 
devoid of biological activity [11 ]. Based on this knowledge, considerable effort has recently 
been put in the development of alternative pharmaceutical vehicles that would allow 
prolonged systemic exposure to the biologically active lactone form. Among various 
approaches, liposomal encapsulation of camptothecin analogues was shovro to effectively 
diminish lactone hydrolysis [12-18]. Besides this, liposomal encapsulated anticancer drugs 
have been studied extensively both in the laboratory and in the clinic, with reports of 
prolonged plasma exposure, improved tumor delivery, decreased systemic toxicity and 
increased efficacy for a variety of cytotoxic drugs [19]. Increased antitumor activity by 
enhancement of tissue distribution and systemic drug availability of liposome-encapsulated 
topoisomerase I inhibitors has been found in rodent models, including improved therapeutic 
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efficacy for a new stable unilamellar liposomal formulation of lurtotecan (NX 211) as 
compared to non-liposomallurtotecan [20]. 
In view of the above, a phase I open-label. dose-escalating trial was initiated to 
investigate the clinical utility ofNX 211 administration. The objectives of this study were i) 
to assess the safety and toxicity profile of this lurtotecan formulation; ii) to determine the 
Dose Limiting Toxicities (DLT), the Maximum-Tolerated Dose (MTD) as well as the 
recommended dose for phase II studies with the drug given by N administration once every 3 
weeks; and iii) to examine the disposition of this drug. 
Patients and Methods 
Eligibility Criteria 
Patients were eligible if they had a histologically confirmed diagnosis of advanced solid 
tumor refractory to standard chemotherapy or a malignancy for which there was no effective 
standard chemotherapeutic regimen. Additional criteria included: age ?=: 18 years; Eastern 
Cooperative Oncology Group (ECOG) status of 0-2~ no previous treatment with antineoplastic 
agents for at least 3 weeks ( 4 weeks in case of carboplatin or an investigational drug, 6 weeks 
in case of nitrosoureas or mitomycin C), or radiotherapy exceeding 25% of the bone marrow 
volume; adequate bone marrow function defined as absolute neutrophil count (ANC) ;;::: 
1.5xl09/L and platelets ;oo 100xl09/L. adequate renal function as defmed by a serum 
creatinine within normal limits; adequate liver function as defined by bilirubin within normal 
limits, and aspartate aminotransferase (AST) and alanine aminotransferase (AL T) :> 2.5 times 
upper limit of normal in the absence of liver metastasis and :S: 5 with documented liver 
metastasis; and no knmvn hypersensitivity to systemic liposomal formulations or any drug 
chemically related to lurtotecan. The current clinical protocol was approved by the Rotterdam 
Cancer Institute Ethics Board, and the Ethics Board of the University Hospital Groningen and 
all patients signed a written informed consent before study entry. 
On-Study and follow-up Investigations 
Patients underwent a complete physical examination at enrollment and at the start of every 
new NX 211 course. At these visits, ECOG performance status and weight were recorded. 
Determination of hematologic parameters (i.e., full blood count with white blood cell 
differential) was performed twice weekly at least during the first t\v"o cycles, then weekly for 
following cycles. Clinical chemistry analyses (i.e., electrolytes, creatinine, calcium, random 
glucose, albumin, phosphate, urea, uric acid, total protein, ttiglycerides, total cholesterol, 
bilirubin, alkaline phosphatase, ALAT, ASAT and lactate dehydrogenase) were performed 
weekly. ECG was performed before study entry, on completion of the study and during 
treatment only if clinically indicated. Tumors were assessed radiologically before patients 
were enrolled on the study, and after every even-numbered course. 
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Pharmaceutical Preparation and Drug Administration 
NX 211 was formulated as a sterile liposomal dispersion in a buffer composed of 10-rnM 
ammonium chloride and 9% sucrose, and was obtained from Gilead Sciences Inc. (San 
Dimas, CA). Detailed description on the liposomal preparation of the unilarnellar small 
liposomes composed from hydrogenated soy phosphatidylcholine and cholesterol has recently 
been published [20]. The drug product was supplied in 50-mL vials containing 5 mg of 
lurtotecan. Each vial contained 80 mg of hydrogenated-soy phosphatidylcholine, 20 mg of 
cholesterol, 0.9 g of sucrose, 2 mg of citric acid and 5 mg of ammonium chloride to a total 
volume of 10 mL. Dose solutions for administration were prepared under aseptic conditions 
by dilution of the pharmaceutical product with sterile 5% dextrose to a volume of 25 mL for 
administration by a controlled-rate pump. The whole process described above was performed 
under strict light protection. 
NX 211 was administered on day 1 of each 21-day course as a 30-minute IV infusion 
under complete light protection, where both the syringe and infusion line were totally 
wrapped in alwninwn foil. All patients were admitted to the hospital for the first dose of the 
drug to facilitate pharmacokinetic sampling (see below). Subsequent doses were given in an 
outpatient setting. Chemotherapy was repeated every 3 weeks for at least 2 courses. No 
standard premedication was given in any course. 
Study Design 
The starting dose ofNX 211 (0.4 mg/m2) was the equivalent of 1/50 of the acute LDIO in 
mice. This safety margin~ as compared to the classical starting dose of 1/10 of the LDlO in 
mice, is implemented based on data from the parent compound and topotecan. Dose escalation 
was performed based on toxicity and pharmacokinetics. For safety, the next dose level was 
not opened until at least 3 patients were assessable in the first course. In case only one patient 
developed dose-limiting toxicity (DLT), the dose level was expanded with another 3 patients 
to a total of 6. In case less than 2 of 6 patients experienced DLT, or no DLT was observed, the 
dose level for the next patient cohort was established based on both clinical toxicity and 
pharmacokinetic data observed at the previous dose level. In addition information gathered 
from two other parallel phase I studies with NX 211 (day I ,2 ,3 q 3 weeks and day I and 8 q 
3 weeks) was also taken into account. 
Toxicity Evaluation 
Toxicity was evaluated and graded according to the NCI Common Toxicity Criteria 
version 2.0 (CTC). Hematologic DLT was defmed as ANC < 0.5 x 109/L for<: 7 days and/or 
associated with fever, and/or platelets $. 25 x 1 09/L or bleeding episodes requiring platelet 
transfusion. Non-hematologic DLT was defined as any toxicity CTC grade ~ 3, with the 
exception of vomiting in the absence of appropriate antiemetic therapy, as well as CTC grade 
;:: 2 neurotoxicity or cardiac toxicity. In case DLT was reached in;?: 2 of 3 or;?: 2 of 6 patients, 
59 
Chapter 3 
dose escalation was ceased, and the dose level defined as maximum tolerable dose (MTD). 
Once the MTD had been determined, intermediate dose levels could be studied. The 
recommended dose was defined as one dose level below the MTD. 
Response Evaluation 
Tumor response definitions were based on the WHO criteria (WHO handbook for 
reporting results of cancer treatment, WHO, Geneva, 1979). 
Pharmacokinetic Sample Collection and Preparation 
Blood samples for pharmacokinetic analysis were drawn from a vein in the ann opposite 
to that used for drug infusion, and collected in 7-mL glass tubes containing lithium heparin as 
anticoagulant. Duplicate samples were obtained before drug administration and at 0.5 (end of 
infusion), I, 1.5, 2.5, 4, 6, 8, 24, 48, 72 and 96 hours after start of infusion. At each sampling 
time point, one aliquot of whole blood was immediately transferred to a polypropylene vial 
and stored at -80°C, while another was processed to plasma by centrifugation for 5 minutes at 
3000xg ( 4°C), which was then also stored at -80°C until the time of analysis. Complete urine 
collections were obtained for the duration of the study in 12-hour or 24-hour portions, and 
aliquots were stored frozen in polypropylene vials. In addition to the protocol, in those 
patients who consented, complete collections of feces up to 96 hours were also obtained in 
polystyrene containers, and stored immediately at -80°C. After thawing~ these samples were 
homogenized individually in 4 volumes of phosphate-buffered saline using an U1tra-Turrax 
T25 homogenizer (IKA..-Labortechnik, Dottingen~ Germany). 
Analytical Methods 
Lurtotecan dihydrochloride monohydrate (lot: U2044/164/I, containing 78.11% of the 
free base) was supplied by Gilead Sciences Inc. (San Dimas, CA) and was used as a reference 
standard for all reversed-phase high-performance liquid chromatographic (HPLC) assays. 
Plasma and urine concentrations of lurtotecan were determined using validated HPLC assays 
as described previously [21]. 
For the determination of lurtotecan in whole blood and feces, the assay for total plasma 
concentrations was modified as outlined below. The HPLC systems consisted of a 
constaMetric 3200 solvent delivery system (LDC Analytical, Riviera Beach, FL), a Waters 
717plus autosampler (Milford, MA), an Inertsil-ODS 80A analytical column (150x4.6 mm 
J.D., 5 ~m particle size; Alltech Applied Sciences, Breda, the Netherlands) maintained at 
60°C by a model SpH99 column oven (Spark Holland, Meppel, the Netherlands), a Beam 
Boost photochemical reactor unit supplied with a coil of25 mx0.3 mm J.D. (ICT-ASS-Chem, 
Bad Homburg, Germany), and a Jasco FP-920 fluorescence detector (Jasco, Maarssen, the 
Netherlands) operating at excitation and emission wavelengths of 378 and 420 nm (40 nm 
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band width), respectively. The mobile phases consisted of 1 M aqueous ammonium acetate-
water-acetonitrile (100:725:175, v/v/v), with the pH adjusted to 5.5 with acetic acid. The flow 
rates were set at 1.25 and 0.75 mL/min for the determination of total lurtotecan levels, i.e. 
lurtotecan in and out-side the liposomes, in blood and feces samples, respectively. 
Aliquots (50 f!L) of heparinized whole blood were pretreated with 500 f!L of 5% (w/v) 
aqueous perchloric acid-acetonitrile (5:1, v/v) in 1.5-mL polypropylene tubes (Eppendorf, 
Hamburg, Germany). The samples were vigorously vortex-mixed for 30 minutes on a multi-
tube vortex mixer, followed by centrifugation for 5 minutes at 23,000xg at ambient 
temperature. A volume of 250 ~L of the clear supernatant was transferred to a low volume 
insert of glass, from which 200 f!L were injected into the HPLC system. The calibration 
curves were constructed in saline at concentrations of 0.25, 0.50, 1.00, 5.00, 10.0 and 25.0 
ng/mL, by serial dilutions of a lurtotecan working solution containing 0.10 mg/mL (expressed 
as free base). Three pools of quality-control samples were prepared in heparinized whole 
blood at concentrations of 0.40, 20.0 and 2000 ngimL, by addition of appropriate volumes of 
lurtotecan in saline to whole blood. In addition, to minimize potential differences with clinical 
samples, a lurtotecan recovery-control sample containing 7.50 ng/rnL (as NX 211), was also 
analyzed simultaneously. The sample containing 2000 ng/mL was diluted 100-fold in 
phosphate-buffered saline prior to extraction. 
Aliquots (100 f!L) offeces homogenate were deproteinized and acidified with 1000 f!L of 
5% (w/v) aqueous perchloric acid-acetonitrile (5:1, v/v) containing 6,7-dimethoxy-4-
methylcoumarin at a concentration of I 00 ngimL (Sigma, St. Louis, MO), which was used as 
the internal standard. Subsequently, the samples were vigorously vortex-mixed for 15 minutes 
on a multi-tube vortex mixer, followed by centrifugation at ambient temperature at 23,000xg 
for 5 minutes. A 100-~L volume of supernatant was transferred to a limited volume insert of 
glass, from which 10 ~L were injected onto the analytical column. Spiked homogenized fecal 
samples used as calibration standards in concentrations of 10, 25, 50, 100 and 250 ngimL 
were prepared by addition of 10 ~L of serial dilutions in saline from the lurtotecan working 
solution to 240 ~L of drug-free feces homogenates. Three pools of quality-control samples 
containing lurtotecan at 40, 200 and 2000 ng/mL were prepared by addition of appropriate 
volumes of lurtotecan in saline to blank human feces homogenates. The sample containing 
2000 ng/mL was diluted 10-fold in a mixmre of saline and the extraction solution (1:10, v/v) 
prior to injection. 
Validation of both assays included a set of calibration samples assayed in duplicate, with 
all samples in quintuplicate, and was performed on 4 separate occasions. Within-run and 
between-run precision, calculated by one-way analysis of variance for each concentration 
using the run-day as classification variable, ranged between 2.9-13.2% and 3.9-12.4%, 
respectively, whereas accuracy of both assays was between 94.9-106%. The mean extraction 
recoveries for lurtotecan in feces specimens and whole blood were between 97-103%. 
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Pharmacologic Data Analysis 
Individual plasma and whole blood concentrations of lurtotecan were fit to a model vrith 
multi-exponential functions by the Siphar version 4.0 software package (lnnaPhase Co., 
Philadelphia, PA), using Powell's method. Model discrimination was assessed by a variety of 
considerations, including visual inspection of the predicted curves, dispersion of residuals, 
minimization of the sum of weighted squares residuals, and the Akaike and Schwarz criteria. 
In all cases, concentration-time profiles were best fit to a mono-exponential equation after 
zero-order input with weighting according to Yobs·1. Final values of the iterated parameters of 
the best-fit equation were used to calculate pharmacokinetic parameters using standard 
equations. The disposition half-life was calculated as ln2/k, in which k is the elimination rate 
constant in h-1• The total plasma clearance of lurtotecan was calculated by dividing the dose 
(expressed in mg base equivalents per squared meter of body surface area) by the observed 
area under the plasma concentration versus time curve extrapolated to infinity (AUC). The 
volume of distribution at steady state was calculated using the same program. The fraction of 
the absolute NX 211 dose administered to patients excreted in feces and urine (Fu) as 
unchanged lurtotecan was expressed as a percentage. 
Relationships betv.reen various exposure measures (e.g. plasma AUC) and hematologic 
toxicity were evaluated by sigmoid maximum-effect models using Siphar. Hematological 
pharmacodynamics were evaluated by analysis of the absolute nadir values of blood cell 
counts or the relative hematologic toxicity, i.e., the percent decrease in blood cell count, 
which was defined as: 
%decrease= [(pretherapy value- nadir value) I (pretherapy value)] x 100% 
Within each patient, myelosuppression was described either using continuous variable, 
consisting of the percent decrease in WBC, ANC and platelet count. or as discrete variable in 
case ofNCI-CTC myelotoxicity grade. Data were fitted to a sigmoid maximum-effect model 
based on the modified Hill equation, as follows: 
E =Eo+ Em,, x [(KP'~) I (KP'~ + KPso')] 
In this equation, Eo is the minimum reduction possible, Emu.x is the maximum response (fixed 
to a value of 100), KP is the pharmacokinetic parameter of interest, KPso the value of the 
pharmacokinetic parameter predicted to result in half of the maximum response, and y is the 
Hill constant, which describes the sigmoidicity of the curve. Models were evaluated for 
goodness of fit by minimization of sums of the squared residuals and by reduction of the 
estimated coefficient of variation for fitted parameters. Significance of the relationships was 
assessed by construction of contingency tables with subsequent£· analysis. 
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Statistical Evaluation for the pharmacology data 
Parameters of all pharmacologic analyses are reported as mean value ± SD, unless stated 
othenvise. The relationships bet\.veen peak plasma concentrations of lurtotecan and the 
administered level or corresponding AUC values were analyzed by means of Spearman's or 
Pearson's correlation coefficient, respectively, and linear regression analysis. The difference 
in pharmacokinetic parameters betv.reen patient cohorts was evaluated statistically using the 
Kruskal-Wallis statistic followed by a Dunn's test, if required, to detennine which group 
differed. Interpatient differences in kinetics were assessed by the coefficient of variation 
(CV), expressed as the ratio of the SD and the observed mean. Probability values ofless than 
0.05 were regarded as statistically significant. All statistical calculations were performed 
using the Number Cruncher Statistical System (NCSS) version 5.X software package (Jerry 














































Patients and Treatment 
Twenty-nine eligible patients with advanced carcinomas were recruited into the study. 
Patient demographic data are listed in Table 1. Two patients were not considered assessable 
for the response analysis, leaving 27 patients assessable for response, which included 3 
patients who received only one dose ofNX 211 because of early progressive disease. 
Six dose levels of:NX 211 (0.4, 0.8, 1.6, 3.2, 3.8 and 4.3 mg/m2, respectively) were 
explored during the trial. The 29 patients received a total of 77 courses ofNX 211 (median 2, 
range 1-9). Dose reduction was only required at the highest dose level, where one dose in a 
single patient was reduced from 4.3 to 3.2 mg/m2 because of febrile neutropenia in the 
preceding course. One patient died while on study due to progression of an endometrial 
sarcoma. There were no drug related deaths. In 3 of 29 patients, scheduled doses had to be 
delayed for one week, one because of an intercurrent possible pulmonary embolism and three 
because ofhematological toxicity. 
Table 2. 
Worst Hematologic Toxicity Per Patient (Course 1) 
Dose n No. courses Neutrocytopenia* Thrombocytopenia* 
(mg/m2) 2 3 4 2 3 4 
0.4 3 6 0 0 0 0 0 0 0 0 
0.8 6 14 0 0 0 0 I 0 0 0 
1.6 3 8 0 0 0 0 0 0 0 
3.2 6 15 I I 0 0 1 0 0 
3.8 6 18 0 0 0 0 2 0 0 0 
4.3 5 16** 0 0 0 4 2 0 
* Graded according to NCI-CTC 
Decisions on dose escalation were based on toxicity observed in course 1 only (Table 2). 
At the dose levels (0.4 and 0.8 mg/m2) no relevant toxicity was observed, but for one patient 
in the latter group who developed a seizure. Because of a possible relationship to NX 211 this 
dose level was expanded to six patients. Retrospectively this event however was not 
considered related to the drug but due to brain metastasis progression. At the next t\vo dose 
levels (1.6 and 3.2 mg/m2) hematological toxicity never exceeded grade 2 without remarkable 
non hematological toxicity. The ftrst two patients at the highest dose level ( 4.3 mg/m2), 
developed dose limiting hematologic toxicity. consisting of grade 4 neutropenia and up to 
64 
Phase I NX211 
grade 3 thrombocytopenia. According to the protocol, the previous level (3.2 mg/m2) was 
expanded without remarkable toxicity observed. It therefore was decided to add a new dose 
level of 3.8 mg/m2 in between the latter two. At this dose level 6 patients were included who 
received 18 courses (median 3, range 1-6) ofNX 211, with thrombocytopenia grade I being 
the most severe observed toxicity. Meanwhile we could not find a pharmacodynamic-
pharmacologic relationship nor any other plausible CA1Jlanation for the steep toxicity 
difference in dose levels, and discussion arose whether the observed toxicity in the two 
patients at the highest dose levels could be accidental. It was therefore decided to add futtber 
patients at the 4.3 mg/m2 dose level. One patient treated at this dose level developed grade 4 
neutropenia v.rith fever and grade 3 thrombocytopenia in the first course. In view of these data, 
it was definitely concluded that the 4.3 mg/m2 dose level was the MTD, and the recommended 
dose level for phase II studies 3.8 mg/m2• 
Table3. 
Worst Hematologic Toxicity Per Patient (All Courses) 
Dose n No. courses N eutrocytopenia * Thrombocytopenia* 
(mg/m2) I 2 3 4 I 2 3 4 
0.4 3 6 0 0 0 0 0 0 0 0 
0.8 6 14 0 0 0 0 0 0 0 
1.6 3 8 0 I 0 0 I 0 0 0 
3.2 6 15 0 2 0 0 I 0 0 
3.8 6 18 0 0 0 0 4 0 0 0 
4.3 5 16** 0 0 4 I 3 0 
*Graded according to NCI-CTC 
**in 2 of 16 cycles the patient received a reduced dose of3.2 mg/m2 
Toxicity Profiles 
The main side effects ofNX 211 were hematologic, neutropenia and thrombocytopenia 
being DLT. As can be seen from the data for all courses (Table 3) there was no cumulative 
hematological toxicity. Grade 3 or4 neutropenia was observed in 9 of77 courses, all of them 
at the highest dose level. Febrile neutropenia was observed in only one patient at the highest 
( 4.3 mg/m2) dose level tested. Patients developing severe neutropenia also developed the 
severest thrombocytopenia. Three patients developed grade 3 thrombocytopenia not 
complicated by bleeding, and not requiring platelet infusion. At the recommended dose level 
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for phase II studies (i.e., 3.8 mg/m2), no grade 3 or 4 toxicity was observed, and a I 00% dose 
intensity could be achieved. 
Non-hematologic toxicity in this study was not dose limiting, and although some grade 
three toxicities were observed, no cumulative non-hematological toxicity was found (Table 4). 
Asthenia was the most common side effect observed, while no grade 3 or 4 nausea and 
vomiting was seen. One patient at the first cohort experienced chest tightness and a sensation 
like shortness of breath during the infusion and there were three cases of flushing, symptoms 
commonly associated with a liposomal infusion-related reaction. After discontinuation of the 
infusion, the sensation disappeared spontaneously and quickly. Since no serious symptoms 
persisted, no medication like antihistamines or corticosteroids needed to be administered. At 
rechallange the infusion was started at half speed, after which no recurrence of the reaction 
was noted. Other toxicities, as listed in Table 4, were observed sporadically. Overall, NX 211 
was very well tolerated in this phase I study. 
Table 4, 
Related Non-Hematologic Toxicity by Worst Grade Per Patient on Study (n~29) 
Nnmber (%) of dosed patients with any related adverse event reported in I 0+% of all patients 
Toxicity Grade All Grade 3 or4 
2 3 4 (%) (%) 
asthenia 6 5 2 0 45 7 
fatigue 0 3 0 0 10 0 
malaise 2 I 0 0 10 0 
headache 2 I 0 0 10 0 
nausea 10 5 0 0 52 0 
vomiting 8 3 0 0 38 0 
anorexia 6 3 0 0 31 0 
diarrhea 3 0 0 0 10 0 
abdominal pain 4 0 0 0 14 0 
alopecia 4 0 0 0 14 0 
hypertensitivity reaction 4 0 0 0 10 0 
66 
Phase I NX211 
Antitumor Activity 
Objective responses were not observed, but 9 patients (NSCLC(3), ACUP(2), ovary, 
bladder, biliary and leiomyosarcoma) had stable disease (range 2-9 courses) while on 
treatment with NX 211. There was no apparent relationship bet\Veen the level of pretreatment 
and tbe chance of achieving SD. One patient (ACUP) with stable disease who was treated at 
the 4.3 mg/m2 dose level, experienced a tumor regression of 49% after six courses with l\"X 
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Time (h) 
Representative concentration versus time profiles of lurtotecan in plasma 
(closed circles) and whole blood (open circles) in a single patient after 
administration ofNX 211 at a dose level of3.8 mg/m2. 
Plasma and Blood Disposition 
Complete plasma phannacokinetics were performed in all 29 patients, whereas whole 
blood data were available for 27 patients. The reported lurtotecan concentration after 
treatment with NX 211 are the sum of both encapsulated and non-encapsulated drug [21]. A 
typical example of a plasma concentration-time profile of lurtotecan is shown in Fig. 2. The 
concentration-time profiles could best be fitted by a one-compartmental model. The mean 
percentage of tbe AUC extrapolated was l.O±l.l% (range, 0.04-4.2), justifYing tbe use of 
compartmental methods. After NX 211 administration, peak concentrations were observed at 
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Table 5, 
Pharmacokinetics of Lurtotecan in Plasma as a Function of NX 211 Dose 
Dose II Cnux AUC CL v, T112 
(mg/m2) (ng/mL) (mg.h/L) (L/h/m2) (Lim2) (h) 
- ~ ·~~"'"'-··~----~"""'-·-···--~"------
0.4 3 180±25.6 1.21±1.51 0.85±0.64 2.56±0.51 4.29±4.86 
(165-210) (0.30-2.95) (0, 14-1.36) (1.97-2.88) (1.30-9.91) 
0.8 6 369±159 1.70±1.92 1.14±1.01 3.36±1.81 3.24±2.69 
(163-629) (0.28-5.33) (0.15-2.93) ( 1. 77 -6.29) (1.51-8.48) 
1.6 3 448±131 1.42±0.87 1.46±0.86 5.79±2.26 3.26±0.67 
(306-564) (0.67-2.37) (0.67-2.38) (3.94-8.31) (2.65-3.99) 
3.2 6 1717±441 13.2±10.5 0.41±0.38 2.28±0.85 5.46±3.24 
(1254-2316) (2.77-33.4) (0.1 0-1.15) (1.45-3.63) (2.42-11.2) 
3.8 6 1517±621 12.0±12.1 0.83±0.71 3.95±2.32 6.81±3.43 
(757-2073) (2.21-28.0) (0.14-1.72) (1.84-7.01) (2.54-1 0.8) 
4.3 5 2359±857 31.2±16.9 0.51±0.88 6.23±10.4 13.0±7.45 
(886-3130) (2.08-44.8) (0.10-2.07) (1.42-24.8) (8.58-26.3) 
Overall mean 29 - 0.82±0.78 3.92±4.43 6.24±5.16 
_,,,_ 
NOTE. Data are expressed as mean± SO, \vith observed ranges in parenthesis. 
Abbreviations: n, number of patients studied; Cma_"' peak concentration; AUC, area under the plasma concentration-time curve; CL, total plasma 
clearance; Vd, volume of distribution; Tw, terminal disposition half-life. 
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the end of the 30-minute IV infusion, with an immediate decline following cessation of the 
infusion. The mean estimated pharmacokinetic parameters for lurtotecan in plasma as 
calculated by this model are listed in Table 5. Substantial interpatient variability in kinetic 
parameters was apparent, with a >2-fold variation in peak plasma concentrations and AUC 
values, although mean values were strongly correlated to dose (Cmax, Spearman's rho=.94 at 
P=.002; AUC, rho~.89 at P=.023). Peak plasma concentrations were also significantly 
correlated to corresponding AUC values (adjusted R2~.87 at P=.004). A similar degree in 
variability between patients was evident in total body clearance (CV~95.4%), thereby 
influencing the actual systemic exposure to lurtotecan during NX 211 treatment. There were 
no significant differences in (dose-normalized) phannacokinetic parameters betv.reen the 
various NX 211 dose levels, including the mean total body clearance (P~.42; Kruskal-Wallis 
statistic, corrected for ties). Over the total dose range, the peak concentration and AUC values 
increased from 180±25.6 (mean±SD) to 236±857 ng/mL and from 1.21±1.51 to 31.2±16.9 
mg.bJL, respectively, consistent with a linear and dose-independent kinetic behavior of the 
drug. 
Table 6. 
Pharmacokinetics ofLurtotecan in Whole Blood 
Parameter n Mean±SD Range 
Lurtotecan 
CL (Lih/m2) 27 1.15±0.958 0.173-2.93 
v, (L/m2) 27 5.74±3.68 2.07-15.0 
T11z (h) 27 7.00±4.19 1.76-17.3 
B/P ratio 27 0.647±0.134 0.403-1.10 
NOTE. Data were obtained from patients treated with NX 211 at dose levels ranging from 0.4 to 4.3 
mg/m2• 
Abbreviations: n, number of patients studied; CL total blood clearance; V d· volume of distribution; 
T 112, terminal disposition half-life~ B/P ratio, AUC ratio oflurtotecan in whole blood and plasma. 
Disappearance of lurtotecan from the central plasma compartment was characterized by 
elimination in an apparent mono-exponential fashion, with a very slow total body clearance of 
0.82±0.78 Llh/m2, typical of liposomal-formulated agents [19]. The estimated terminal 
disposition half-life was relatively consistent in all patients, exhibiting a mean value of 
6.24±5.16 hours (CV~82.7%), and was not dependent on the NX 211 dose (P~.42). As a 
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result of the slow clearance, extended persistence of lurtotecan was apparent, with detectable 
levels of the compound even at 4 days after initial treatment in most patients. The volume of 
distribution of lurtotecan was extremely low and averaged 3.92±4.43 L/m2, suggesting 
distribution takes place mainly within the central compartment, with slow distribution to 
extravascular tissues. The concentration-time course of lurtotecan in whole blood followed 
the same general pattern as in plasma, although concentrations were always well below 
corresponding plasma levels (Fig 2). The AUC ratio of lurtotecan in whole blood and plasma 
was 0.647±0.134 (n=27), and is indicative for liposomal encapsulation of lurtotecan in the 
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A) Representative cumulative excretion of unchanged lurtotecan in urine 
(closed circles) and feces (open circles) in a single patient after administration 
ofNX 211 at a dose level of3.8 mg/m::. 
B) Representative excretion of unchanged lurtotecan in urine (closed bars) and 
feces (open bars) in a single patient after administration of NX 211 at a dose 
level of 3.8 mglm::. 
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Urinary and Fecal Recove1}' 
Complete data on urinary excretion were available from 23 of 29 patients, whereas data 
on fecal excretion could be collected in 9 patients. The time course of the cumulative urinary 
and fecal elimination of lurtotecan for a representative patient is depicted in Fig 3. The 
urinary excretion pattern was virtually identical in all patients, with approximately 10% 
(range, 4.90-18.7) of the dose excreted in the first 72 hours and only little after this time. The 
time course of the fecal excretion was more variable, with most of the compound excreted 
from 48 to 72 hours after the NX 211 infusion. Although samples were collected for only 96 
hours following drug administration, the shov.rn data render it unlikely that the cumulative 
excretion in either urine or feces will change significantly after this time period. 
The total cumulative urinary excretion of lurtotecan accounted for 10.1±4.05% 
(mean±SD) of the dose in all patients, and was independent of the NX 211-dose. Surprisingly, 
fecal excretion represented only I 0.2±9.28% (range, 3.28-31.4) of the dose, leading to a total 
recovery of approximately 20% (range, 8.50-46.5) of the dose. This suggests that lurtotecan is 
extensively metabolized into unknown degradation products. Analysis of the HPLC 
chromatograms from fecal extracts revealed 2 major additional peaks in all 9 patients (absent 
in fecal extracts obtained prior to NX 211 treatment), that might represent lurtotecan 
metabolites (data not shown). 
Figure 4. 
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Relationships between lurtotecan dosexFu values of individual patients and the 
percent decrease in (A) "WBC, (B) ANC and (C) platelet count at nadir relative 
to pretreatment values. Data were obtained from 23 patients treated with a 30-
minute IV infusion ofNX 211 at dose levels ranging from 0.4 to 4.3 mg/m2• The 
lines represent the fit of the data to a sigmoid maximum-effect model. 
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Hematological Pharmacodynamics 
Pharmacokinetic-pharmacodynamic relationships between systemic exposure measures 
of lurtotecan and hematologic toxicity, including WBC, ANC and platelets, were evaluated 
using sigmoid maximum-effects models, by plotting kinetic data against the percent decrease 
in blood cell count at nadir relative to the pretreatment value. The AUC values oflurtotecan in 
plasma or whole blood were not significantly related to hematologic toxicity and/or 
misspecifications were noted in the models tested (P>.05) (Fig. 4). Based on the known 
available pharmacokinetic characteristics of lurtotecan, we hypothesized that unbound (i.e., 
non-liposomal) lurtotecan concentrations would be more closely related to side effects than to 
total drug levels, and that an estimate or surrogate measure of exposure to unbound lurtotecan 
could be obtained from the dose excreted in urine ( dosexFu, expressed in mg/m2). Indeed, we 
found that this parameter was significantly correlated to the percent decrease in WBC 
[(dosexFu)50=0.33±0.083 mg/m2 (CV=25.0%); y=l.35±0.350; P<.00001; R2=.86)], ANC 
[(dosexFu)50=0.33±0.087 mg/m2 (CV=26.5%); y=l.49±0.422; P<.00001; R2=.85)] and 
platelets [(dosexFu)so=0.43±0.069 mg/m2 (CV=l6.0%); y=2.75±l.02; ?<.00001; R2=.79)], 
and, overall, patients with a higher values of dosexFu experienced greater hematologic 
toxicity (Fig. 5). Since the dosexFu values obtained over the 96-hour time period were closely 
related to those obtained using the 0-12 hour (R=.77) or 0-24 hour urine-collection interval 
(R=.93), we also evaluated whether hematologic toxicity could be predicted from excretion 
data obtained early after NX 211 administration. Unformnately, these relationships, although 
still significant (P:,;.012), were substantially weaker (R2=.5l to .80; CV=44.2 to 74.6%), 
thereby limiting the general applicability of using urine data to predict NX 211-mediated side 
effects in future clinical trials. 
Discussion 
This study represents the results of a Phase I trial of NX 211 in patients with solid 
twnors. Overall, this study demonstrates that NX 211 given every 3 weeks is well tolerated 
and that no unexpected toxicity was observed. The DLT ofNX 211 given as a single drug 
administration as a 30-minute IV infusion repeated every 3 weeks, consisted of a combination 
of neutropenia and thrombocytopenia. For hematologic toxicity a remarkable contrast was 
noted betvveen the 3.8 mg/m2 and 4.3 mg/m2 dose levels. Overall, the non-hematologic 
toxicity was relatively mild, and consisted mainly of nausea, vomiting and fatigue. These 
findings on toxicity appear to be similar to the results of other schedules investigated with NX 
211 [22], and also largely resemble side effects of other topoisomerase I inhibitors [3]. 
The pharmacokinetic model currently presented accurately describes the plasma 
concentration versus time profile of lurtotecan after NX 211 administration, and emphasizes 
the need to apply appropriate kinetic models with sufficient sampling time points, in this case 
up to 96 hours, coupled with sensitive analytical procedures for the accurate estimation of 
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kinetic parameters. In general for topoisomerase I inhibitors prolonged exposure has been 
associated with an increase in cytotoxicity [3]. Of particular note, the phase I data for free 
(i.e., non-liposomal) lurtotecan suggest that antitumor activity may be enhanced with 
prolonged infusion regimens [9,10]. Therefore, the use of a liposomal formulation of 
lurtotecan may improve efficacy at optimally-defmed doses by increasing exposure to the 
drug. 
In our study, we have shown that lurtotecan after NX 211 dosing delineates a linear and 
dose-independent pharmacokinetic behavior over the dose range studied (0.4-4.3 mg/m2), in 
agreement with other tested schedules of NX 211 administration [22]. The disappearance of 
lurtotecan was characterized by a mono-exponential decline with a terminal disposition half-
life in plasma of approximately 6 hour. This is in contrast to the multiphasic elimination from 
plasma reported for non-liposomallnrtotecan, which displays a terminal half-life estimated as 
9.6±4.8 hour in a cohort of 14 patients [6]. The basis for the longer elimination half-life of 
non-liposomal lurtotecan is most likely due to the slow elimination of the larger fraction of 
drug initially distributed to tissue. With NX 211, a prolonged association of lurtotecan within 
circulating intact liposomes in the plasma compartment would be assumed to release free drug 
over a period of time, quite possibly resulting in the same terminal half-life as lurtotecan, but 
with concentrations below the lower limit of quantitation of our HPLC assay [21]. The 
prolonged association of lurtotecan with liposomes is thus likely to mask the true disposition 
half-life of the free drug, as has been observed previously with other agents, including 
liposomal daunorubicin (DaunoXome) [23]. The total lnrtotecan plasma clearance from NX 
211, on average 0.82 L/h/m2, is approximately 25-fold slower than the clearance of the free 
drug, which was established at 21.0±9.6 Llh/m2 [6]. The observed steady state volume of 
distribution of 3.92±4.43 Lim' and the blood to plasma AUC ratio of 0.647±0.134 are 
indicative for prolonged encapsulation of lurtotecan in the liposomes, which are presumed to 
be localized in the plasma compartment. In this regard, the clinical pharrnacokinetic behavior 
of NX 211 is similar to that observed in previous clinical trials with other liposome-
encapsulated anticancer agents, including anthracyclines (e.g., daunorubicin and doxorubicin) 
and vinca alkaloids (e.g. vincristine) [23-25]. 
The observed variability in the pharmacokinetic behavior of lurtotecan after the 
administration of NX 211 is slightly higher than that reported for the free drug, with an 
interpatient variability in the plasma clearance of 95.4% for NX 211, versus 46% for free 
lurtotecan, while these values for the volume of distribution were 113% and 52%, respectively 
[6]. Interestingly, after correction for the body-surface area of individual patients, the 
interpatient variability in clearance remained in a similar order of magnitude (95.4 versus 
98.8%), suggesting that body-surface area is not a significant predictor oflnrtotecan clearance 
and that flat-dosing regimens might be applied in future studies without compromising overall 
safety profiles. 
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The cumulative urinary excretion of unchanged lurtotecan of approximately 10% is very 
well consistent with data of previous studies in which non-liposomal lurtotecan was 
administered, indicating that renal clearance plays a minor role in drug elimination [5,6]. The 
mean renal clearance oflurtotecan, i.e., the product of the dose-fraction excreted in urine and 
the total body clearance, was estimated to be 0.074±0.075 Lih/m2 (range, 0.008-0.313). This 
value is much lower than the glomerular filtration rate in humans, presumably due to the 
association of the drug with the liposomes and binding of free drug to plasma proteins, and 
suggests that lurtotecan is neither reabsorpted nor actively secreted into the tubular lumen to 
any great extent. It also indicates that as much as 89.9% (range, 81.3-95.1) of the overall 
clearance can be attributed to non-renal processes, including hepatobiliary secretion of 
lurtotecan. Indeed, part of the non-renal elimination was accounted for by fecal excretion of 
unchanged lurtotecan. However, since the total amount of lurtotecan in feces amounted to 
only l 0% of the administered dose, leading to a total recovery of approximately 20%, 
lurtotecan is probably extensively metabolized. 
An important question that remains unanswered is whether monitoring of extra-liposomal 
lurtotecan in the systemic circulation would aid in deriving exposure measures more closely 
linked to NX 211-induced side effects. The rationale for measurement of free-drug 
concentrations is founded on the basic pharmacologic tenet that agents associated with drug-
carrier systems or other macromolecules such as serum proteins are unable to cross cell 
membranes and interact with extravascular (active) sites. The current finding that various 
commonly applied exposure measures (e.g. AUCs in plasma and whole blood) were not 
predictive for hematologic toxicity further substantiates this concept. We have previously 
sho\VTI that the inherent instability of the current NX 211 formulation in aqueous solutions 
under laboratory light renders it extremely difficult to develop analytical methodologies that 
allow separation of free and liposomal lurtotecan [21]. Since knowledge of the extent of 
binding of lurtotecan within the circulation was considered of crucial importance for a proper 
understanding of the clinical pharmacologic behavior of this drug, we set out to define a 
surrogate measure that could be linked to the (dose-limiting) toxicity of NX 211. We 
hypothesized that a dose-corrected urinary-excretion fraction of unchanged drug within a 
certain time span would reflect systemic exposure to non-liposomal lurtotecan in each 
individual patient. The calculated parameter (i.e., dosexFu) was indeed clearly related to 
pharmacodynamic outcome of NX 211 treatment in terms of hematologic toxicity, and a 
sigmoid maximum-effect model was found most appropriate to fit the kinetic data to the 
observed myelosuppression. Considering this pharm.acokinetic-pharm.acodynamic relation, a 
target dosexFu could be defined prospectively according to the grade of toxicity that is 
considered to be acceptable, and applied in future studies to determine optimal dosing with 
NX 211 treatment in this scbedule. Currently, the suitability ofthis relationship will be further 
explored in other dosing schedules with NX 211 [22]. 
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In conclusion, in this phase I study with N administration of liposomal lurtotecan (NX 
211) given once every 3 weeks, the DLT is a combination of neutropenia and 
thrombocytopenia. The recommended dose for phase II studies with NX 211 in this regimen 
is 3.8 mg/m2• Objective responses were not observed, but 9 patients had stable disease while 
one of these patients experienced a tumor regression of 49%. We have fmmd a 
pharmacologic-pharmacodynamic relationship for this liposomal encapsulated drug calculated 
as the dose corrected urinary excretion in relation to hematologic toxicity. Moreover, we have 
shown that administration of this formulation significantly reduces the plasma clearance of 
lurtotecan, which in tum might prove beneficial for phannacodynamic outcome. 
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An additional chromatographic peak was observed in plasma samples of patients 
receiving NX 211, a liposomal formulation of the topoisomerase I inhibitor lurtotecan. We 
have isolated and purified this product by sequential solid-phase extractions, and we report its 
structure and cytotoxicity relative to lurtotecan and related agents. NMR data indicate that 
cleavage of the piperazine moiety occurred at the N-C bond of the B-ring, yielding 7-methyl-
1 0,11-ethylenedioxy-20(5)-camptothecin (MEC). Tests of the growth inhibition potential of 
MEC in 7 human tumor cell lines showed that the compound was approximately 2 to 18-fold 
more cytotoxic than lurtotecan, topotecan and SN-38. Subsequently, we found that MEC was 
the product of rapid photolysis of lurtotecan, with the rate of degradation inversely 
proportional to NX 211 concentrations, and greatly depend on light intensity. Furthermore, 
MEC concentrations were found to significantly increase in plasma samples exposed to 
laboratory light, but not in blood. MEC was not produced from NX 211 in the presence of 
human liver m.icrosomes, suggesting that is not a product of CYP P450 metabolism. Using a 
validated analytical method, trace levels of MEC were quantitated in blood samples of 2 
patients. These observations confirm that the precautions for protection form light currently 
specified for preparation and administration of NX 211 dose solution are critical. Procedures 
to minimize formation of MEC, by the use of amber vials for NX 211 and by preparation of 
dilutions immediately before clinical use in a fashion totally protected from light, are now 
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The currently known analogues of camptothecin, a cytotoxic plant alkaloid from 
Camptotheca acuminata, share a basic pentacyclic structure with a chiral center located at 
C20 in the terminal E-ring (Fig. 1). Extensive studies on the synthesis of these derivatives and 
the development of structure-activity relationships have been carried out over the last several 
years, and some important general relationships have emerged [1]. One of the principal 
chemical features of this class of agents is the presence of a lactone functionality in the E-
ring, which is not only essential for antitumor activity, but it also confers a degree of 
instability to these agents in aqueous solutions [2]. The camptothecins can undergo a pH-
dependent reversible interconversion behveen this lactone form and a ring-opened carboxylate 
(or hydroxy acid) form, of which only the former exerts the characteristic topoisomerase !-
inhibitory activity. In the search for more potent camptothecin analogues, the synthetic 
preparation ofhexacyclic derivatives has been described, and t\Vo representative agents of this 
class, lurtotecan and exatecan mesylate (DX-895lf) are currently undergoing clinical 
evaluation [3,4]. The former is a water-soluble derivative with a dioxalane moiety benveen 
ClO and Cll [5], and has been evaluated clinically in various phase I and phase II trials using 
a 30-min i.v. infusion given daily for 5 days or as a 72-h continuous i.v. infusion [6-8]. 
Alternative strategies of lurtotecan administration are currently being developed, including a 
new liposomal formulation (NX 211) to further stabilize the lactone moiety and induce 
sustained drug levels that may be required to maximize antitumor activity [9,10]. We 
previously reported the presence of an unidentified compound in the plasma of patients 
treated with NX 211 as well as in control samples spiked with the liposomal product [11]. 
Since the native fluorescence intensity of the parent drug (i.e., lurtotecan) was previously 
shown to be sensitive to UV -light exposure (254 nm) and the fact that the peak height of the 
newly generated compound was correlated with the lurtotecan concentration, we suspected 
photodegradation of lurtotecan to produce an additional species. In the current study, we have 
isolated this unknown compound by using HPLC coupled to fluorometric detection followed 
by :NMR analysis ofthe purified fraction. Next, the properties of this compound in terms of 
cell grov.rth inhibition relative to related analogues were examined in addition to the kinetics 
of lurtotecan photolysis in various aqueous and biological solutions. 
Materials and Methods 
Chemicals 
Lurtotecan and NX 211 were supplied by Gilead Sciences (San Dimas, CA). Topotecan 
was a gift from Smith-Kline Beecham Pharmaceuticals (King of Prussia, PA), while SN-38 
was supplied by Aventis (Alfortville, France). RPMI cell culture medium, penicillin, strepto-
mycin and /-glutamine were purchased from Life Technologies (Gaithersburg, :MD) and fetal 
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calf serum was delivered by Hyclone (Logan, UT). ACN and MeOH, both HPLC-grade, were 
obtained from Biosolve (Valkenswaard, The Netherlands) and DMSO from Rathburn 
(Walkerbum, UK). Baker (Deventer, The Netherlands) delivered TCA, HAC (99-100%), PCA 
(70%), and HCI (36-3S%) and annnonium acetate was from Roth (Karlsmhe, Germany). 
Sulforhodamine B and NADPH were obtained from Sigma (St. Louis, MO). PBS was obtained 
from Oxoid and supplied by Boom (Meppel, Netherlands), and consisted of tablets containing 
sodium chloride (8.0 g/1), potassium chloride (0.2 g/1), disodium hydrogenphospate (1.15 g/1) 
and potassium dihydrogenphosphate (0.2 g/1), each dissolved in I 00 mL purified water. All 
water used in the study was filtered and deionized with a Milli-Q-UF system (Millipore, Milford, 
MA). 
Isolation and Purification 
MEC was prepared by exposure of 17 mg of the lactone form ofLRT in a total volume of 
40 mL DMS0-0.1 M annnonium acetate pH~5.5 (1:4, v/v) to UV light of254 mu in a Beam-
Boost photochemical reactor unit (ICT-ASS-Chem, Bad Homburg, Germany) for 5 min. After 
irradiation, the sample was acidified with 400 fi] PCA and applied onto 4 CIS solid-phase 
extraction cartridges (Applied Separations, Allentown, PA). Subsequently, the cartridges were 
washed 3 times with 1 mL 25 mM anunonium acetate pH~3.0, followed by 3 times with 1-
mL volumes of a mixture of 25 mM annnonium acetate pH~3.0-MeOH (6:4, v/v). The 
columns were eluted with three 1-mL volumes of25 mM annnonium acetate pH~3.0-MeOH 
(1:9, v/v), followed by three 1-mL volumes of MeOH. The eluate was dtied at 60°C under 
nitrogen until approximately 1 rnL was left over~ which resulted in a precipitate in the sample. 
In order to resuspend the precipitate, the sample was diluted with 10% PCA-ACN-PBS (2/1/6, 
v/v/v) to 12 mL, and 200-f'L portions of this mixture were injected onto the HPLC-system as 
described previously [1 1 J with the flow rate set at 3. 75 mL. The peaks with a retention time of 
17 min were collected, in a total volume of approximately 1 L, whlch was acidified with 10 
ml PCA and filled with water up to 2 L. Further purification was achieved on CIS solid-phase 
extraction cartridges, which were washed 3 times with 1 mL water, followed by elution v.rith 5 
volumes of I mL MeOH. The eluate fractions were collected and lyophilized using a FDC206 
Freeze drying Chamber (Savant, Farmingdale, NY) to obtain the pure compound for chemical 
and biological characterization. 
Structural Analysis 
The isolated powder was characterized by lH-NMR spectrum, measured on a Broker 
AM-300 (300 MHz, FT) spectrometer. Chemical shift values are reported as o-values in parts 




The human colon carcinoma WiDr, the ovarian adeno-carcinoma IGROV-1, the M-19 
melanoma, the H226 lung cancer, the renal cancer cell A498, and the MCF7 and EVSAT breast 
cancer cell lines were grown and maintained in RPMI medium. Cells were kept in continuous 
logarithmic growth at 3 7'C in a humidified atmosphere in 5% C02 in media supplemented with 
10% (w/v) of heat-inactivated fetal calf serum, 100 U/mL of penicillin, 100 fLg/mL of strepto-
mycin and 2 mM /-glutamine. Exponentially grown cells were trypsinized and plated (200 flL 
with 2000 cells/well) in 96-well culture plates (Costar Corporation, Cambridge, MA), 48 hours 
before drug exposure. The stock solution ofMEC was diluted in a mixture ofDMSO/HCl (98:2, 
v/v), resulting in a concentration of 18 }lM, while lurtotecan, topotecan and SN-38 were 
dissolved separately in DMSO/HCl (98:2, v/v) to obtain concentrations of 180 fLM. Prior to 
addition to the cells, the solutions were diluted 20-fold in culture medium, resulting in 
concentrations of0.90 fLM ofMEC and 9.0 fLM oflurtotecan, topotecan and SN-38. A volume of 
100 fLL of these solutions was added to the cells, followed by 3-fold serial dilutions in the 96-
well plate. Subsequently, the plates were incubated for a period of 5 days. For comparative 
purposes, MEC, lurtotecan, topotecan and SN-38 were evaluated in parallel in all 
experiments. After fixation with 10% (w/v) aqueous TCA, inhibition of cell proliferation was 
assessed using sulforhodarnine B staining as described [12], with minor modifications [13]. Each 
compound was tested in quadruplicate in 3 independent experiments. Cell survival was plotted 
relative to controls incubated in medium in the absence of the drugs. IC50 values were calculated 
after fitting the individual curves to a Hill function using the software package Siphar version 4.0 
(SIMED, Cn\teil, France). 
Analytical Methods 
Totallurtotecan concentrations in human whole blood were determined using a validated 
HPLC method (to be published elsewhere). In brief, aliquots of 50 flL heparinized whole 
blood were pretreated with 500 flL of 5% (w/v) aqueous PCA-ACN (5:1, v/v), followed by 
vigorous vortex-mixing for 30 min. Subsequently, the samples were centrifuged for 5 min at 
23,000 x g. The HPLC system was identical to that described previously for the detennination 
of lurtotecan concentrations in urine [11], with the flow-rate set at 1.25 mL/min. For 
determination of MEC in whole blood samples the HPLC system consisted of a constaMetric 
3200 solvent delivery system (LDC Analytical, Riviera Beach, FL), a Waters 717plus 
autosampler (Milford, MA) from which the sample-tray was protected from light, a Inertsil-
ODS 80A analytical colunm (!50 x 4.6 mm internal diameter; 5 fim particle size; Alltech 
Applied Sciences, Breda, The Netherlands) maintained at 60'C by a model SpH99 column 
oven (Spark Holland, Meppel, The Netherlands), and a Jasco FP-920 fluorescence detector 
(Jasco, Maarssen, The Netherlands) operating at excitation and emission wavelengths of 378 
and 420 nm ( 40 nm band width), respectively. The mobile phases consisted of 1 M 
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ammonium acetate-water-ACN (1:6:3, v/v/v), with the pH adjusted to 55 and the flow rate 
was set at 050 rnL/min. 
MEC was extracted from 50-JlL aliquots of heparinized whole blood using 250 JlL of a 
mixture of MeOH/ACN (1:1, v/v) in 1.5-rnL polypropylene tubes (Eppendorf, Hamburg, 
Germany). The samples were vigorously vortex-mixed for 5 min on a multi-tube vortex 
mixer, followed by centrifugation for 5 min at 23,000 x g at ambient temperature. A volume 
of !50 JlL of the clear supernatant was transferred to a new 1.5-rnL polypropylene tube, 
followed by addition of 250 JlL of 25 mM ammonium acetate pH~3.0. Subsequently, a 
volume of 300 )lL was transferred to a low volume insert of glass, from which 200 f..LL were 
injected into the HPLC system. The calibration curves were constructed in human heparinized 
whole blood in concentrations of 0.1 0, 0.25, 1.00, 250, 5.0 and 10.0 ng/rnL, by serial 
dilutions in PBS of a MEC working solution containing 10 Jlgfml in DMSO. Four pools of 
QC samples containing :MEC were prepared in heparinized whole blood at concentrations of 
0.40, 4.00, 8.00 and 80.0 ng/rnL MEC, by addition of appropriate volumes of dilutions of 
MEC in PBS to whole blood. A fifrh QC sample containing 800 ng/rnL NX 211 was also 
prepared in heparinized whole blood, to minimize potential differences with clinical samples. 
Validation of the assay included a set of calibration samples assayed in duplicate, with 
LLQ and QC samples in quintuplicate, and was performed on 4 separate occasions. Within-
run and betv.reen-run precisions were calculated by one-way analysis of variance for each 
concentration, using the run-day as variable. The extraction recovery for :rvffiC was calculated 
by comparing peak heights obtained from processed samples containing 2.50 ng/mL :rvffiC in 
PBS to those obtained in extracted calibration samples. 
Stability of NX 211 
The increase of MEC in plasma and whole blood containing NX 211 (800 ng/rnL) was 
tested on 3 separate occasions at ambient temperature, by placing 250-J..lL aliquots of the 
samples in the dark and in sodium light (lamp: Philips SON-T-Plus 70 W), laboratory (lamp: 
Philips TLD 36W) and in sunlight. After a 2-h incubation, 50-JlL aliquots were stored in 
duplicate at -80'C until analysis. The plasma and whole blood concentrations of MEC were 
determined using the method described above and were compared to MEC concentrations in 
non-incubated samples. The increase of:MEC in the extracts of the QC sample containing NX 
211 (800 ng/mL) was tested by placing the extracts on 3 separate occasions at ambient 
temperature in laboratory and sodium light. After 1 and 2-h incubation periods, the extracts 
were placed in the autosampler and peak heights were compared to those of extracts stored in 
the dark. The light sensitivity of the clinical formulation of NX 211 was tested by placing 
serial dilutions ofNX 211 in D5W in the dark, and in sodium and laboratory light. After 2 h, 
50-J..lL aliquots were stored in duplicate at -80°C and were analyzed for MEC concentrations 
using the assay described. The concentrations of MEC in the incubated samples were 
compared to non-incubated serial dilutions ofNX 211 in D5W. 
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To rule out a potential metabolic conversion oflurtotecan into MEC, 1-mL aliquots of (l 
mg/mL) pooled human liver microsomes (Gentes!, Woburn, MA) were incubated in the dark 
in a phosphate buffer ofpH~7.4 at 37°C with 2 ).lM of lurtotecan or l\JC 211 in the presence 
of 3 ).lM NADPH. After a 1-h incubation period, 50 ).lL aliquots were analyzed for MEC 
concentrations resulting from metabolic instability, as described for whole blood samples. 
Clinical Samples 
"Whole blood samples for phannacokinetic analysis were dravvn from a vein in the ann 
opposite to that used for drug infusion from 2 male cancer patients (age, 3 9 and 64 years) 
participating in a phase I trial [10], and collected in 4.5-m.L glass tubes containing lithium 
heparin as anticoagulant. Samples were obtained before drug administration and at 0.5 (end of 
infusion), l, 1.5, 2.5, 4, 6, 8, 24, 48, 72, and 96 h after start of infusion and were immediately 
transferred to a polypropylene vial and stored at -80°C. The NX 211 was formulated as a 
sterile liposomal dispersion of lurtotecan in a buffer composed of 10 mM ammonium chloride 
and 9% sucrose and was supplied in 50-mL clear glass vials containing 5 mg of the active 
agent. Each vial contained 80 mg hydrogenated-soy phosphatidylcholine, 19 mg cholesteroL 
0.9 g sucrose, 2 mg citric acid, and 5 mg ammonium chloride to a total volume of 10 mL. 
Dose solutions for administration were prepared in polyvinyl chloride-free infusion syringes 
under aseptic conditions by dilution of the phannaceutical preparation with D5W to a volume 
of 25 mL. The solution was delivered by a 30-min intravenous infusion, protected from light 
by wrapping the syringe in aluminum foil. Small aliquots of the NX 211 solutions were stored 
at -80 oc for analysis of MEC and total lurtotecan [ll] concentrations. The current clinical 
protocol was approved by the Rotterdam Cancer Institute Review Board, and both patients 
signed informed consent before study entry. 
Results 
Structural Identification 
The principal unknovvn peak observed in plasma samples of patients receiving NX 211 
[ll] was prepared and isolated (0.6 to 0.7 mg) after irradiation oflurtotecan, and dried down 
to a pale-yellow powdery residue. The purified compound yielded NMR spectra with the 
aromatic part very similar to that ofLRT (14); [0=0.87, t, 3H, J~ 7.2 Hz, 19-CH,; 8~!.87, m, 
2H. !8-CH2; 8~2.67, s. 3H, B-ring CH3; 8~.43, s, 4H, O-CH2-CH2-0; 5~5.22 and 0=5.42, 
2xs, 2x2H, CH0 s 5 and 17; 8~7.25, s, lH, Ar-H; 8~7.54, s, lH, Ar-H; 8~7.59, s, lH, Ar-H]. 
However, the 8 protons of the piperazine group on the B-ring at C-7 at 8=2.40 ~ 2.65 (m) 
were absent in the isolated product. The signal at 0=2.67 (s, 3H), characteristic of ann-methyl 
substituent suggested that scission of the piperazine group had occurred at the N-C bond of 
the B-ring, and thus could be assigned to NIEC (Fig. 1 ). Electrospray ion-trap mass-
spectrometric analysis also already indicated the loss of the C-7 side chain of the lurtotecan 
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molecule [molecular ion at mlz 409 (parent- C-7 chain)] (II). The chromatographic purity of 
the compound on the reversed-phase system was found to be >99% (data not shown). 
In Vttro Cytotoxicity 
The cytotoxic properties of I\1EC relative to lurtotecan and several clinically important 
analogues were assessed by exposure of each test compound to a panel of 7 cell lines. Under 
the experimental conditions applied, MEC was found to be a highly potent inhibitor of cell 
proliferation in all cell lines. Among the tested topoisomerase I inhibitors lurtotecan, 
topotecan and SN-38, MEC was found to be the most potent inhibitor of cell-growth during a 
5-days continuous exposure (Table 1). On average MEC was 3.4 ± 0.88 fold more potent than 
lurtotecan, 3.5 ± 1.1 fold more potent than SN-38 and 13 ± 3.0 fold more potent than 
topotecan in the 7 tested cell lines. 
Table 1. 
Comparative in vitro cytotoxicity of:rvffiC and structural analogues. 
Cell line MEC Iurtotecan SN-38 topotecan 
IC-50 (nM) IC-50 (nM) F' IC-50 (nM) F IC-50 (nM) F 
W!Dr 2.4 ± 0.035 7.6 ± 1.8 3.1 8.0± 0.87 3.3 27 ± 1.9 11 
IGROV-1 1.6 ± 0.023 5.4 ± 0.67 3.3 3.5 ± 0.92 2.2 19 ± 2.9 12 
Ml9 25 ± 2.1 80 ± 65 3.2 117 ± 96 4.6 271 ± 185 II 
H226 8.1 ± 0.55 15 ± 1.9 1.8 34±40 4.2 103 ±51 13 
A498 3.3 ± 0.17 13±11 4.0 8.5 ± 1.4 2.6 32 ± 7.7 9.7 
MCF-7 1.3 ± 0.022 4.3 ± 1.63 3.5 3.5 ± 0.80 2.8 19 ±4.3 15 
EVSAT 8.1 ± 0.58 38± 30 4.7 41 ± 31 5.0 147 ± 46 18 
'Abbreviation: F, fold less toxic than MEC. 
Stability of NX 211 
To gain insight into the degradation kinetics of lurtotecan, as a potential source of MEC 
formation, experiments were conducted under various conditions and light intensities. In 
plasma as well as in whole blood, MEC was formed out ofNX 211 when incubated for 2-h at 
ambient temperature in suulight, with, respectively, a 99-fold and 4.5-fold increase in MEC 
concentration as compared to samples stored at -80°C (Fig. 2). Plasma samples placed under 
sodium light and laboratory light also showed increased MEC concentrations, while in blood 
no increase was observed under the same conditions (Fig. 2). An increase in the concentration 
of MEC also was found after incubation of blood·extracts at ambient temperature under 
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sodium light and laboratory light (Fig. 2A). Increased concentrations of MEC in the clinical 
formulation of NX 211 were observed after a 2-hr incubation at ambient temperature under 
sodium- and laboratory light. After dilution of this clinical formulation in D5W. the ligbt 
sensitivity ofNX 211 was increased (Fig. 2B). In addition, no increase in MEC concentrations 
were found after a 1-h incubation period of lurtotecan or 1:'\TX 211 in pooled human liver 
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Blood extract Dilution in D5W 
Blood Plasma 
Stability of lurtotecan in human whole blood and plasma spiked with NX 211 
(800 ng/mL), blood extracts (insert A) and aqueous dilutions ofNX 211 in D5W 
(insert B) expressed as fold increase in MEC fonnation relative to a control 
sample (nominal). Data are presented as mean values (bar) .:1: SD (error bar). 
The various bars refer to the various incubation/light intensity conditions: 
black, dark; gra)'', sodium light; hatched. laboratory light; white, sunlight. 
To obtain information on the pharmacological and toxicological relevance of the 
lurtotecan photolysis, we set out to develop an analytical method to allow quantitative 
determination of MEC in samples of patient receiving NX 211 infusions. In view of the 
relative stability of MEC in whole blood samples, we focused our attention on this matrix to 
address the phannacokinetic behavior of the compound. The calibration curves of MEC in 
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human heparinized whole blood were linear over the studied range of 0.10 to 10 ng/mL, with 
Pearson's regression coefficients ranging from 0.9986 to 0.9995 using weighted (1/[MEC]) 
linear least-squares regression analysis. The retention time of MEC was 13 min (overall run 
time, 15 min)) and no endogenous interferences were found in drug-free specimens (Fig. 3). 
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Reversed-phase HPLC tracings of a blank whole blood extract (panel A). a 
whole blood sample spiked with MEC (0.25 nglmL) (panel B). and a whole 
blood sample spiked with the clinical fonnulation ofNX 211 (800 ng/mL) (panel 
C). The peak labeled I indicates ME C. 
The LLQ of the method was established at 0.10 ng/mL (-0.24ru\1) and the within- and 
between-run precisions of the LLQ and quality-control samples were ~7.8%, with the 
accuracy ranging from 98.4 to 104% (Table 2). The within and between-run precisions of the 
QC sample containing 800 ng/mL NX 211 were 9.7 and 17%, respectively. All the QC 
samples were found to be stable during 3 freeze-thaw cycles. The recovery of MEC was 
constant over the entire range and was 104 ± 1!.9% (n=43). Overall, these validation data of 




Validation characteristics ofQC samples for the HPLC assay ofMEC. 
Nominal Observed WRPa BRP ACC 
(ng/ml) (ng/ml) (%) (%) (%) 
O.lOb 0.10 7.1 2.7 104 
0.40 0.40 7.8 c 101 
4.00 4.01 3.4 6.0 100 
8.00 8.23 6.0 c 103 
80.0 78.7 3.9 7.5 98.4 
800NX211 0.92 9.7 17 
a Abbreviations: WRP, within-run precision; BRP, betvveen-run precision; ACC, accuracy. 
b Lower limit of quantitation samples. 
c No additional variation was observed as a result of performing the assay in different runs. 
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In vivo pharmacokinetics of total lurtotecan (circles) and MEC (triangles) in 
whole blood of 2 patients treated with NX 211 [7.3 mg (open symbols) and 7.5 




The 2 studied patients received 7.5 mg and 7.3 mg NX 211 (14.5 and 14.1 ).lmol), 
respectively. The total amount of lurtotecan in the infusion solutions of both patients was 
established at 6.9 mg (13.2 ).liDO!). The total amount of MEC in the sample taken prior to 
infusion of patient I was 30.1 ).lg (73.5 mnol), while at the end of the infusion the total 
amount of MEC was increased to 73.5 ).lg (!80 mnol). Thus, the percentage of NX 211 
administered as MEC, on molecular basis, was 0.56% prior to infusion and 1.4% at the end of 
the infusion. From patient 2 a sample was taken prior to infusion, which contained 75.7 )lg 
MEC (185 mnol), i.e., at least 1.4% of the total amount of drug administered was in the form 
of MEC. The kinetic profiles of totallurtotecan and MEC obtained from the two patients are 
shown in Fig. 4. 
Discussion 
In the present study, we isolated sub-milligram quantities (0.6 to 0.7 mg) of a (highly 
apolar) circulating compound present in the plasma of patients treated with NX 211, a 
liposomal preparation of the topoisomerase I inhibitor lurtotecan. Following serial purification 
steps, the product was eventually obtained as a pale yellow powdery residue, and the use of 
HPLC in combination with fluorescence detection and NMR enabled us to identify its 
chemical structure. NMR characteristics of the aromatic part were shown to be very similar to 
that of lurtotecan, and the isolated product was tentatively identified as MEC. This structural 
assignment is in accordance with our earlier finding of the loss of the C-7 side chain of the 
lurtotecan molecule using electrospray ion-trap mass-spectrometric analysis [11]. 
MEC was found to be a highly potent inhibitor of cell growth in culture following a 5-day 
continuous exposure in a panel of 7 cell lines, with ICso values on average 3.4, 3.5- and 13-
fold lower than those of the parent drug lurtotecan, the irinotecan metabolite SN-38 and 
topotecan, respectively. These data are consistent with earlier findings of the substantially 
higher in vitro cytotoxic activity of 7-methyl-1 0,11-methylenedioxy-camptothecin compared 
to 10,11-methylenedioxy-camptothecin after a 3-day continuous exposure [15]. The former 
compound is chemically similar to MEC, with a methylenedioxy substitution at the CIO,ll-
positions in the core structure instead of an ethylenedioxy moiety for :MEC. The substitution 
of the methyl moiety at the B-ring thus resulted in enhanced cytotmacity, which is in 
agreement 'With known structure-activity relationships of camptothecin analogues indicating 
that alkylated substitutions at C7 tend to increase topoisomerase !-inhibitory activity and 
simultaneously decrease aqueous solubility [16]. Moreover, 7-chloromethyl-10,11-
ethylenedioxy-camptothecin was recently found to be a more potent inhibitor of cell growth 
than lurtotecan and topotecan in several tumor cell lines during a 48-h continuous exposure 
[14]. In addition, this agent which has an additional Cl-substitution at the methyl-moiety at 
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the B-ring relative to MEC, was almost insoluble in water, which is also in agreement with 
the current fmdings. 
MEC is most likely a product of lurtotecan photolysis, as the parent drug was highly 
sensitive to light-induced degradation, and was not significantly converted to MEC by human 
liver microsomes. In aqueous solutions, the rate of lurtotecan degradation appeared to be 
inversely proportional to drug concentration, and was greatly depending on light intensity 
with no noticeable degradation occurring in the dark and progressively increased instability in 
the presence of sodium light<laboratory light<sunlight. The lurtotecan degradation kinetics in 
biological fluids was markedly altered, which is most likely associated with stabilizing effects 
of matrix components, as has been observed previously for anthracycline antineoplastic 
agents [ !7], As outlined, such effects might be either caused by increased drug stability due to 
binding to matrix constituents or by quenching of incident light by intense coloring of the 
sample or the presence of particulate matter (e.g., blood cells). In conttast to the 
photodegradation of lurtotecan, photolysis of irinotecan (CPT-11), one of the most 
extensively studied camptothecin analogues, only occurs at the fragile lactone-ring structure 
(!8,!9). In view of the close chemical similarity of the lactone moiety between 
camptothecins, photodegradation of lurtotecan is also likely to occur at this site of the 
molecule. In general, however, such degradation products are not of major (clinical) interests, 
since the reactivity of an intact lactone-ring structure is required for the generation of 
topoisomerase !-mediated DNA cleavage and antitumor activity of all knmvn camptothecin 
analogues [20]. 
The question arises if the additional chromatographic peak observed in the plasma 
samples of patients were the result of photochemical degradation during the blood sample 
handling and subsequent analytical procedure, or that MEC was co-administered 
simultaneously with the NX 211 infusate. We found that, in vitro, the amount of MEC in 
plasma samples increased 99-fold, 16-fold and 2.2-fold after a 2-h exposure to sunlight, 
laboratory light and sodium light, respectively, while after incubation in the dark no increase 
was observed. In contrast to plasma, MEC concentrations did not increase in whole blood 
under similar conditions with the exception of sunlight exposure, where incubation resulted in 
a 4.5-fold increase in MEC concentration. Although it was beyond the scope of this study to 
assess the chemical basis of this discrepant behavior, the apparent stability of MEC in whole 
blood samples provided the possibility to study its disposition in patients. The HPLC-method 
developed for this purpose was sho\Vll to be sufficiently accurate and precise to monitor 
circulating concentrations in patients treated with NX 211. On average, the total amount of 
MEC in the samples spiked with 800 ng/ml NX 211 (!544 nM LRT) was established at 0.92 
ng/ml (2.25 nM). Hence, a small fraction (-(l.\5%) of the clinical formulation ofNX 2!! is 
thus already present in the form of the photochemical degradant MEC. 
The lower percentages of MEC present in the blood samples of the 2 studied patients, 
ranging from 0.061 to 0.24%, compared to values of 0.56 to 1.4% in the NX 211 infusates, 
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could be indicative for extra-liposomal positioning of MEC. The photostability data presented 
here also suggests that the infusates are far more sensitive to production of MEC than whole 
blood under laboratory conditions. Currently, we are conducting a retrospective analysis of 
whole blood samples in a larger group of cancer patients treated with NX 211 to describe in 
more detail the phannacokinetic behavior of ME C. 
In conclusion, we have shown that lurtotecan in the liposomal formulation (NX 211) is 
sensitive to a rapid degradation if exposed to light resulting in formation of a highly cytotoxic 
compound, that was structurally identified as MEC. The data presented may be of clinical 
importance as dilutions of NX 211 for use in patients are prepared in aqueous solutions, 
usually in advance of administrations as 30-min i.v. infusion. Clearly, the presence of this 
product at high enough concentrations could not only confound in vitro and in vivo 
cytotoxicity and antitumor activity studies but might distress efforts to elucidate the metabolic 
fate oflurtotecan and potentially other (C7-substituted) camptothecin derivatives. Procedures 
to minimize formation of MEC, by the use of amber vials for NX 211 and by preparation of 
dilutions immediately before clinical use in a fashion totally protected from any light, are 
currently being routinely implemented. 
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Abstract 
The active metabolite of irinotecan (CPT -ll ), 7-ethyl-1 0-hydroxycamptothecin (SN-38), 
is either formed through enzymatic cleavage of CPT -11 by carboxyl esterases (CE) or through 
cytochrome P450 3A-mediated oxidation to 7-ethyl-1 0-[ 4-(1-piperidino )-!-amino] 
carbonyloxycamptothecin (NPC) and a subsequent conversion by CE. In the liver, SN-38 is 
glucuronidated (SN-38G) by UGT!Al, which also conjugates bilirubin. Fourteen patients 
were treated with 350 mg/m2 CPT-11, and we performed phannacokinetic analysis during a 
500-h collection period. The half-life and area under the plasma concentration-time curve of 
SN-38 were 47±7.9 hand 2.0±0.79 ,M.h, respectively, both representing a 2-fold increase as 
compared to earlier reported estimates (A. Sparreboom, et a/., Clin. Cancer Res., 4: 2747-
2754, 1998). As an explanation for this phenomenon, we noted substantial formation of SN-
38 from CPT-11 and NPC by plasma CE, consistent with the low circulating levels ofNPC 
observed. In addition, transport studies in Caco-2 monolayers indicated that non-
glucuronidated SN-38 could cross the membrane from apical to basolateral, indicating the 
potential for re-circulation processes that can prolong circulation times. Interestingly, 
individual levels of fecal ~-glucuronidase, which is known to mediate SN-38G hydrolysis, 
were not related to any of the SN-38 kinetic parameters (F0.09; 1>=0.26), suggesting that this 
enzyme does not play a role in SN-38 re-circulation. We have also found, in contrast to earlier 
data, that SN-38G/SN-38 plasma concentration ratios decrease over time from -7 (up to 50 h) 
to -1 (at 500 h). This decrease could be explained by the fact that glucuronidation of SN-38 
and bilirubin is increasingly competitive at lower drug levels. In addition, no evidence was 
found for SN-38G transport through the Caco-2 cells. Our findings indicate that until! now the 
circulation time of SN-3 8 has been underestimated. This is of crucial importance to our 
understanding of the clinical action of CPT -11 and for future pharmacokinetic/pharmaco-
dynarnic relationships. 
Introduction 
CPT-113, a water soluble derivative of camptothecin, is currently registered for use in 
patients with metastatic colorectal cancer refractory to 5-fluorouracil therapy as well as first 
line therapy, and has shown clinical activity against several other types of solid tumors [1,2]. 
CPT -11 itself has weak, if any, phannacologic activity in vitro and is thought to exert its 
antitumor activity in vivo following enzymatic cleavage by a CE that generates the active 
metabolite, SN-38, which is at least 100-fold more cytotoxic than CPT-11 [3]. Peripheral 
converting enzyme activity in animals has been characterized in serum [4], liver [5] and the 
small intestine [6], and prelintinary evidence indicates CE activity within the tumor as well 
[7-9]. SN-38 can be metabolized very efficiently further by UDP glucuronosyltransferase 1Al 
[10] and 1A7 [11] to an inactive ~-glucuronide derivative, SN-38G [12,13]. Another 
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metabolic pathway of CPT -11 consists of a cytochrome P-450 3A4 and 3A5-mediated 
oxidation of the hi-piperidine side-chain attached to the core structnre [14,15]. The main 
metabolites resulting from this pathway have been identified as APC [16] and NPC [17]. 
Although APC has been shown to be a poor substrate of CE in in vitro models [16], NPC can 
be converted into SN~38 by liver CE and, as such, may contribute to the overall production of 
the pharmacologically active species [17]. We previously reported that CPT-II is 
predominantly eliminated in feces following hepatobiliary and intestinal secretion, with 
unchanged drug as the major excretion product followed by smaller amounts of SN-38 and 
APC [18]. Interestingly, SN-38G concentrations in feces were vecy low, presumably as a 
result of hydrolysis of the glucuronic acid moiety by bacterial ~-glucuronidases [18,19]. We 
hypothesized, based also on the long terminal disposition half-life and extensive biliary 
secretion, that CPT -11 and its metabolites can undergo enterohepatic recirculation, and that 
this might play a role in the variability of pharmacokinetic patatneters observed earlier. In the 
present study, we have re-exanrined the plasma disposition of CPT -11 and its metabolites 
using an extended sampling-time period of 500 hours in a group of patients with colorectal 
cancer receiving the drug as single agent at a dose level of 350 mg/m2, and performed various 
in vitro experiments to explain the observed phenomena 
Materials and Methods 
Patients and Treatment 
Patients Mth a histologically or cytologically confinned diagnosis of colorectal cancer 
refractory to standard therapy or for whom other treatment options were not available, were 
eligible for the present study. Additional eligibility criteria included: age between 18 and 70 
years; Eastern Cooperative Oncology Group (ECOG) performance status :>I; no previous 
treatment with antineoplastic agents for at least 4 weeks (or 6 weeks in case ofnitrosoureas or 
mitomycin C); no prior treatment with CPT -II or other topoisomerase I inhibitors; adequate 
hematopoietic (WBC count >3.0x!09/L, absolute neutrophil count >2.0xi09/L, and platelet 
count >100xl09/L), renal (serum creatinine concentration ::;135 ~or creatinine clearance 
<:60 mL/min), and hepatic fimction (total serum bilirubin :01.25 x upper normal limit, and 
aspartate aminotransferase (ASAT) and alanine anrinotransferase (ALAI) concentrations $3.0 
x upper normal limits); and no unresolved bowel obstruction or chronic colic disease. The 
current clinical protocol was approved by the Rotterdam Cancer Institute Review Board, and 
all patients signed informed consent before study entry. 
Vials that contained 40 or 100 mg of CPT-11 (as a hydrochloride trihydrate form) 
formulated as a concentrated sterile solution (active drug concentration, 20 mg/mL) in d-
sorbitol and a lactic acid-sodium hydroxide buffer system of pH 3.5-4.5 were provided by 
Rh6ne-Poulenc Rorer (Antony Cedex, France). The CPT-11 dose of 350 mg/m2 was 
administered as a 90-min i.v. infusion, after dilution of the pbannaceutical preparation in 250 
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rnL of isotonic sodium chloride. In all patients, premedication consisted of ondansetron 8 mg 
i.v. combined with dexamethasone 10 mg i.v., administered 30 min before the start of 
chemotherapy. 
Sample Collection and Handling 
Blood samples for pharmacokinetic analysis were drawn from a vein in the ann opposite 
to that used for drug infusion, and collected in 1 0-mL glass tubes containing lithium heparin 
as anticoagulant. Samples were obtained at the following time points: before drug 
administration; at 0.5, 1, and 1.5 h dnting infusion; and 0.17, 0.33, 0.5, 1, 1.5, 2. 4, 5, 8.5, 24, 
32, 48, 56, 196, 360, and 504 h after the end of infusion. Blood was innnediately processed to 
plasma by centrifugation for 5 min at 2500 rpm (4°C), which was then stored at -80°C until 
the time of analysis (see below). A pretreatment feces sample was collected from all patients 
one day prior to drug administration in a polystyrene container and stored immediately at -
80°C. Following thawing, these samples were homogenized individually on ice (at 0°C) to 
prevent enzyme degradation in one or two volumes of a 0.1-M sodium acetate buffer (pH 7.0), 
depending on the water content of the sample, using an Ultra-Turrax T25 homogenizer (IKA-
Labortechnik, Dottingen, Germany). The homogenates were centrifuged for 5 min at 15,000 
rpm, and the clear supernatants were diluted one-fold with 50% glycerol in water (v/v). The 
dilutions were stored at -80°C until analysis for ~-glucuronidase activity (see below). 
Drug Analysis 
Pure reference standards of CPT-11 hydrochloride trihydrate (batch: K016) and the 
metabolites SN-38G trifluoroacetate (batch: YE0265), NPC trifluoroacetate (batch: 
YE0304), and SN-38 hydrochloride (batch: LIE783) were kindly provided by Rhone-Poulenc 
Rorer and were used as received. Drug concentrations in plasma were deternllned as the total 
oflactone and carboxylate forms by a validated HPLC method with fluorescence detection as 
described previously [20]. This method was further modified, as reported, to allow 
determinations of SN-38 and SN-38G at the low femtomole level [21]. Because of straying 
fluorescence characteristics, an incomplete extraction, and the compound's low relative 
retention on the reversed-phase HPLC column (Hypersil ODS with 5 fJ.IIl particles), the 
unchanged parent drug could not be detected with this latter method [21]. 
Pharmacokinetic Analysis 
Individual plasma concentrations of CPT-11 and its metabolites were fitted to a three-
compartment model using the Siphar version 4.0 software package (SIMED, Creteil, France), 
as described (18). The rate constants of the various disposition phases and the AUC were 
estimated with a weighted-least squares method (weighting factor: 1/y) using the fitted model, 
whereas the total plasma clearance of CPT -11 was calculated by dividing dose (expressed in 
mg base equivalents per squared meter ofbody surface area) and the observed AUC. The Cma." 
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values were determined graphically (as observed values) in a concentration-time scatter plot. 
Metabolic ratios were calculated as defined [22], and included the relative extent of 
conversion (REC) ofCPT-11 to SN-38 (i.e., AUCso;.38/AUCcPT-u), and the relative extent of 
glucuronidation of SN-38 (i.e., AUCsN-3sa/AUCsN-38). The latter was also evaluated as a 
function of time after drug administration. The systemic SN-38 glucuronidation rate in 
individual patients was estimated by calculation of the biliary index values (23), expressed as 
AUCcPT-11 x (AUCsK-3s/ AUCso;.,so). 
Measurement of Fecal (J-Glucuronidase Activity 
The enzyme activity was determined by a miniaturized colorimetric assay using 
phenolphthalein glucuronic acid as an artificial substrate, based on a procedure described for 
~-glucuronidase in bile of mini pigs [24]. Briefly, 20 J..LL-sample aliquots of feces homogenate 
were mixed with 20 fLL 0.1 M sodium acetate buffer (pH 7 .0) containing 0.2% (w/v) bovine 
serum albumin and 10 fLL of the same buffer in the presence of 0.03 M phenolphthalein 
glucuronic acid (Sigma-Aldrich Co., Zwijndrecht, the Netherlands), and incubated for 1 hat 
37°C in a shaking water bath. The enzymatic reaction was terminated by the addition of 200 
fLL 0.1 M sodium phosphate buffer (pH 12.0), and the reaction product phenolphthalein was 
determined by measurement of the absorbance at 550 run against a reagent blank on a Bio-
Rad Model 550 automated microplate reader (Bio-Rad Laboratories, Hercules, CA). A 
calibration standard curve of phenolphthalein was constructed on the day of analysis, and 
concentration versus absorbance data were fitted by linear regression analysis. The mean 
regression equation had slope andy intercept values of 0.292±0.021 and -0.004±0.013 
(n=l5), respectively, with a Pearson's moment correlation coefficient >0.9943. Enzyme 
activity levels in unknown feces samples were calculated in triplicate using interpolation of 
the corresponding regression analysis, and expressed as micrograms of phenolphthalein 
liberated per hour at 37°C per milligrams of feces based on dry-weight measurements 
(fLg/h/mg). A formal method validation was performed as described [25] by replicate analysis 
of quality control samples spiked to contain 3 different concentrations on several occasions in 
the presence of a duplicate 7-point calibration curve and reference samples containing 1.6 
nnits!h oflyophilized type IX -A 0-glucuronidase (EC 3 .2.1.31) from Escherichia coli (Sigma, 
St. Louis, MO) dissolved in 50% glycerol in 0.1 M sodium acetate buffer (v/v). The within-
run and betvveen-run precision, as determined by one-way ANOV A, ranged from 2.18-3.55% 
and 2.84-4.89% (n=22 at each of the concentrations), respectively, with a mean percentage 
deviation from nominal values of less than ±6.14% for phenolphthalein data and ±3.30% for 
the ~-glucuronidase reference standard. 
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In Vitro Metabolism of CPT-11 and NPC 
Biotransformation of CPT-11 and NPC into SN-38 was studied in freshly prepared 
aliquots of human plasma, following a 5-min centrifugation step at 3000 x g of whole blood 
samples obtained from healthy volunteers. Prior to incubation, plasma samples were placed in 
a shaking water bath at 3rC for 5 min. Aliquots of 50 ~L of the lactone forms ofCPT-11 and 
NPC (from stock solutions containing 1.00 and 1.77 mg/mL in dimethyl sulfoxide, diluted in 
a mixture ofmethanol-0.01 Mhydrochloric acid) were then added to 450 ~L plasma to yield 
the desired final concentrations (-0.2 to 200 fL\1), followed by slight agitation by vortex-
mixing. To determine the reaction velocity (i.e., V expressed in nM per hour per liter of 
plasma), sample aliquots were taken at a fixed time interval of24 h, which was determined in 
preliminary experiments to be sufficiently long to achieve steady-state (not shown), and 
analyzed for the presence of total SN-38 as described above for plasma samples. The 
Michaelis-Menten kinetics of the maximum process rate (i.e., V mu.x) and the drug 
concentration associated with 0.5xVmux (i.e., Km) were determined by a nonlinear regression 
analysis implemented on the Number Cruncher Statistical System software package (version 
5.X; Jerry Hintze, East Kaysville, UT, 1992). 
Drug Transport by Caco-2 Cells 
The human colon adenocarcinoma cell line Caco-2 (American Type Culture Collection, 
Rockville, IviD) was grovm as monolayers in Dulbecco's minimum essential medium 
containing 10% heat-inactivated fetal bovine serum, l 00 ~g/mL penicillin and streptomycin, 
and 2 mM freshly added L-glutamine (all from Life Technologies, Inc., Breda, the 
Netherlands) according to procedures recommended by the American Type Culture 
Collection. Cells were grown at 37°C in a humidified atmosphere in 5% C02/95% air as stock 
cultures in 75-cm3 flasks and split at -80% confluency using tcypsin-EDTA. Caco-2 cells 
were then seeded at a density of 2.5xl04 cells per insert in Transwell 12-well plates 
containing l-cm2 permeable polycarbonate inserts with a 0.4-~m pore size (Costar Corp., 
Cambridge, MAJ. The Caco-2 cells were maintained to monolayer growtb by medium change 
every 3 days, untill use in transport experiments at 28 days after seeding. The apical side of 
the cell layer (insert) contained 0.5 mL, whereas the basolateral side (well) contained 1.5 mL. 
Transport studies were initiated with CPT-II, SN-38 and SN-38G [all dissolved in a mi"ture 
of methanol-O.OIM hydrochloric acid (1:1, v/v) and diluted further in medium at final 
concentrations of 1.7 and 17 ~ (CPT-11), 2.5 and 25 ~ (SN-38), and 1.5 ~ (SN-38G), 
respectively], added to either the apical or basolateral side. The final concentration of 
methanol in the dosing medium was always <1 %. At the end of the experiment (1, 2, 6 or 24 
h continuous-exposure times), the entire apical and basolateral side solutions were collected 
separately in 1.5-mL polypropylene tubes (Eppendorf, Hamburg, Germany), and then 
centrifuged for 5 min at 15,000 rpm (4°C) to remove residual particulate matter. The 
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supernatants were transferred to clean tubes and immediately stored at -SO'C until analysis by 
HPLC as described [20]. Mean transport rates were calculated as the fraction of the total drug 
transported after exposure. 
The ~-glucuronidase content in the Caco-2 cells was measured using the phenolphthalein 
assay as described above for feces samples (detection limit, 0.3 J.lg/b/mg of protein), and total 
protein levels with the Coomassie-brilliant blue G-250 assay (26). 
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Plasma concentration-time profiles of SN-38 in 14 patients treated with a 90-
min i.v. infusion ofCPT-11 at a dose level of350 mg/m2• Inset concentration-
time data up to I 0 h after start of drug infusion. 
Patient Characteristics and Toxicity 
A total of 14 patients (4 females and 10 males) with various solid tumors was studied, 
with a median performance status of 0 (range, 0-1 ). The median age was 53 years (range, 37-
71 years), and all patients had normal hematopoietic and liver functions at the time of the 
study; the median clinical chemistry values for all 14 patients included a total bilirubin level 
of 9 j.tM (range, 4-12 j.tM); a serum creatinine level of 103 j.tM (range, 72-132 j.tM); ASAT 
and ALAT levels of 34 units!L (range, 17-185 units!L) and 22 units!L (range, 6-225 units!L), 
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respectively; a total protein concentration of 79 g/dL (range, 69-87); and a serum albumin 
level of 45 g/dL (range, 38-51 g/dL). All 14 patients were assessable for complete 
phannacokinetics of irinotecan and metabolites. Overall~ the treatment was very well 
tolerated, with neutropenia being the main hematological toxicity, although neutropenia 
graded ;:a (on a 4-point scale according to NCI Common Toxicity Criteria Version 2.0) was 
encountered in only 3 patients (20%). Gastrointestinal toxicity was most prominent among 
nonhematological side effects, with diarrhea graded ;::::2 occurring in 8 patients (53%), and 
graded ~3 in only 1 patient. One patient developed severe liver dysfunction immediately 
following CPT-11 administration, with total bilirubin levels rising to levels >250 ).l.M'" within 
200 hand ASAT graded 3. This patient died eventually 9 days after CPT-11 administration 
after experiencing grade 4 leukocytopenia, grade 4 neutropenia, and grade 4 diarrhea. 
Autopsy revealed an obstructed biliary tree by pigment stones. 
Table 1. 
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0.020±0.011 (range, 0.008- 0.045) 
10.4±8.20 (range, 2.10- 28.0) 
2015±!359 (range, 439- 5160) 
nData were obtained from 14 patients treated with a 1.5-h i.v. infusion ofCPT-11 at a dose level of350 
mg/m2• Data are expressed as mean values± SD. 
b CPT-11 could not be detected in plasma samples obtained at 196, 360 and 504 h after the end of 
infusion with the applied HPLC assay [lower limit of quantitation, -3.4 nM] (20). 
Abbrev·iations: Cmu."' peak plasma concentration~ AUC, area under the plasma concentration-time 
curve~ T 112, half-life of the terminal disposition phase; CL, total plasma clearance; V~s, volume of 
distribution at steady-state; MRT, mean residence time, REC relative extent of conversion ofCPT-11 




The plasma concentration-time profiles of SN-38 after CPT -11 treatment were very 
similar for all patients studied (displayed in Fig. 1). In lioe with previous findings [18,22], 
plasma concentrations gradually increased to reach peak levels within 1.5 to 3 h after start of 
the i.v. administration, and slowly began to decline thereafter. SN-38 concentrations still 
remained detectable at 500 h after drug administration (lower limit of quantitation of the 
HPLC assay, -13 pM [21]). As a result, values for AUCo.iof and Tw were significantly higher 
as compared to estimates based on standard sampling time periods (Table 1). SN-38G was the 
principal metabolite of CPT -II (detected in plasma of most patients), with an estimated T 112 
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Concentration ratios of SN-38G and non-glucuronidated SN-38 (SN-38G/SN-
38) as a function of time after CPT-11 infusion. Data were obtained from 14 
patients treated with a 90-min i.v. infUsion ofCPT-11 at a dose level of 350 
mglm1, and are displayed as mean values (~ ::t SD (error bar). Insert, 
concentration ratio-time data up to 30 h after start of infUsion. 
The time profile of the molar concentration ratios of SN-38G and SN-38 was also 
relatively consistent behveen patients (Fig. 2), showing peak values at ~6 h and a gradual 
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decrease toward the end of the sampling time period. Data obtained from the patient with liver 
dysfunction and biliary obstruction showed aberrant pharmacokinetic profiles (Fig. 3), with 
substantially increased plasma concentrations of both SN-38G and SN-38. 
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Plasma concentration time profiles of CPT-II (411). SN-38G (Q!. SN-38 (.4.) 
[all lefty-axis] and total bilirubin (0, dotted line) [right y-axis) in a single 
patient with progressive{v impaired liver function treated with a 90-min i. v. 
infusion ofCPT-11 at a dose level of350 mg/m2• 
Since SN-38G is susceptible to the effects of bacterial ~-glucuronidases following 
hepatobiliary secretion [18,19], pre-therapy values of fecal ~-glucuronidase activity were 
evaluated to gain insight into potential enterohepatic recirculation mechanisms involved in the 
prolonged circulation times ofSN-38. Individual levels of enzyme activity were found to vary 
enormously between patients (range, 0.56-44.6 flglb/mg of feces), and were not related to any 
of the SN-38 kinetic parameters (F0.09; ?=0.26), suggesting that this enzyme does not play a 
(major) role in SN-38 recirculation. 
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The potential of oxidative metabolites of CPT -11 taking part in the overall production of 
SN-38 was evaluated in experiments in freshly prepared human plasma at fixed 
concentratious ofl\'PC and CPT-11 [17]. The formation ofSN-38 from NPC and CPT-11 by 
serum CE is shovvn in Fig. 4. The mean values of Km and V mn..x obtained using the Michaelis-
Menten equation were 74 f1M and 76 pmol!b/mL plasma, respectively, which is within the 
same range as described for this conversion previously in an experimental setting using 
human liver microsomes or purified hepatic CE [17]. We also confirmed the possibility of 
CPT -11 transformation to SN-38 in human plasma with Km and V m~ values of 126 f1M and 
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Kinetics of the biotransformation ofSN-38 (V, velocity) from CPT-11 (II, solid 
line) and NPC (0. dotted line) by human plasma as a function of the substrate 
(S) concentration (A). and the same data in a Michaelis-Menten plot [V=Vm= x 
[S] I ([S] + KmJ] (B). 
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We have also studied the transepithelial flux of CPT-11, SN-38 and SN-38-G using the 
human colonic cell line Caco-2, a well-established model of human intestinal absorption [28-
30], to further define the potential role of enterohepatic circulation in the kinetic profile of 
SN-38. The total transport rate was clearly time-dependent due to increased transport rates of 
the carboxylate forms ofboth compounds. CPT-11 and SN-38 were found to be transported to 
the apical side in a concentration-dependent manner with the 24-h exposure times, with 
transport rate values of 0.404 and 0.405 at low concentrations, and 0.269 and 0.399 at the 
highest concentrations tested, respectively. The flux from the basolateral to the apical side 
was substantially greater (4 to 9-fold) than that from the apical to the basolateral side. 
Interestingly, SN-38G could not be transported to the basolateral side following exposure at 
the apical side at the tested concentration. In addition, SN-38 could not be detected after 
exposure to SN-38G in either compartment, consistent with undetectable levels of J3-
glucuronidase in the Caco-2 cells (not shown). 
Discussion 
By prospectively measuring concentrations of CPT -11 and its metabolites in plasma of 
cancer patients over an extended sampling time-period of 500 h, we demonstrated in the 
present work that the terminal disposition half-life and AUC of the active metabolite SN-38 
are -2-fold increased as compared to estimates reported in earlier studies [18,22]. In addition, 
we found that the SN-38-G/SN-38 plasma concentration ratio decreases in time from -7 (at 
50 h) to -1 (at 500 h). These data not only emphasize the need to apply approptiate kinetic 
models with sufficient sampling time-points for the accurate estimation of complete 
concentration-time profiles, but may also have direct significant clinical relevance in view of 
the fact that relationships between drug exposure and effect (i.e. toxicity and efficacy) are still 
poorly defined. 
Several possible explanations can account for the increase in disposition half-life of SN-
38 and the time-varying SN-38G/SN-38 concentration ratios after i.v. administration ofCPT-
11. Previously, biliary secretion of CPT-11, SN-38 and SN-38G has been desctibed and 
quantitated in a rat model, whereas intestinal reabsorption of biliary secreted radioactivity in 
that same study already suggested recirculation of at least some of the compounds [31]. This, 
in combination with numerous clinical data, has led to the proposed enterohepatic 
recirculation of CPT -11 and its metabolites. It has been suggested in clinical studies that the 
enterohepatic recirculation is so prominent that its effects can be measured in the systemic 
circulation by a short rise of concentration of SN-38 at approximately 8 h after i.v. 
adntinistration of CPT -11 [23]. As described in earlier reports [18,32], and again in this study, 
we could not confirm a consistent rise in the SN-38 plasma concentration shortly after 
systemic drug exposure. Direct prove of a recirculation process of any of the compounds has, 
to our knowledge, not yet been published. For this reason, we investigated the intestinal 
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absorption and transepithelial flux of CPT-ll, SN-38 and SN-38-G in vitro in Caco-2 cell 
mono layers, an established model of human intestinal drug absorption resembling the small 
bowel. In these in vitro experiments, we found a time and concentration-dependent transport 
rate for both CPT-ll and SN-38. Although the transport rates from basolateral to apical were 
higher as compared to that from apical to basolateral, it is still possible that in vivo transport 
from the intestinal lumen to the circulation of CPT-ll and SN-38 is of clinical relevance. 
especially when intraluminal concentration of either one of the compounds is relatively high. 
SN-38G on the other hand could not be transported from the apical to basolateral side, 
consistent with its increased aqueous solubility resulting from the highly polar nature of the 
glucuronic acid group. In addition, the difference in absorption pattern betvveen SN-38 and 
SN-38G is in accordance with the decreasing SN-38G/SN-38 ratio in time. Furthermore, we 
could not detect SN-38 after exposure of SN-38G in any compartment of this model. 
consistent with the undetectable levels of f)-glucuronidase activity in the Caco-2 cells. There 
was also no metabolism of CPT -ll in the Caco-2 cells, in spite of the fact that cytochrome P-
450 3A4, the major isoform in the human intestine [33,34], has been indicated to be present at 
low levels in the Caco-2 cell line [35]. To further examine the potential contribution of 
cytochrome P-450 3A4, if any, to the transport of CPT-II using the Caco-2 cell syste~ 
experiments using cells v.rith increased expression of this isozyme induced with addition of 
la,25-dihydroxyvitarnin D3 [36] to the growth medium are currently under investigation. 
Since we found a concentration-dependent uptake of SN-38 in the above described 
model, high fecal SN-38 concentrations can be of clinical significance, in a sense that a 
potential recycling of SN-38 reduces the effective clearance and may add a distributional 
compartment by way of the enteric circuit. Many glucuronides are susceptible to the effects of 
enterohepatic recirculation following hydrolysis through the action of bacterial and enteric ~­
glucuronidases [37]. Indeed, conversion of SN-38G to SN-38 by bacterial intestinal ~­
glucuronidase has been shown to occur in animal models [38] as well as in humans [18]. In 
addition, high intraluminal concentrations of SN-38 in combination with prolonged retention 
and subsequent structural and functional injuries to the intestinal tract is considered to be one 
of the mechanisms underlying the late-onset form of intestinal toxicity encountered in patients 
treated with CPT -ll [39]. To assess the importance of SN-38G deconjugation with respect to 
potential SN-38 recycling, we therefore also evaluated the levels of ~-glucuronidase activity 
in fecal pre-treatment specimens of individual patients. Inter-patient enzyme activity varied 
up to a 100-fold, and did not correlate with any of the plasma pharmacokinetic parameters of 
SN-38. Overall, this finding suggests that this enzyme does not play a (major) role in SN-38 
recirculation. This is also consistent with our recent observation that modulation of fecal ~­
glucuronidase activity by neomycin co-administration has no significant influence on 
systemic (plasma) concentrations of SN-38 [40]. A potential approach for reducing CPT-ll-
induced intestinal toxicity may therefore be to reduce bacterial ~-glucuronidase-mediated 
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deconjugation of SN-38G to limit local accumulation of SN-38 and subsequent mucosal 
destruction. A clinical trial to evaluate the toxicological consequences of pretreatment vrith 
neomycin before tbe administration of CPT-!! is in progress [4]. The paradox between tbe 
concentration-dependent absorption process of SN-38 in tbe Caco-2 cells and tbe lack of 
relationship of fecal ~-glucuronidase activity witb SN-38 pharmacokinetics is presumably 
caused by the lack of enzyme activity in the luminal contents of the entire small intestine 
where re-absorption of drug is most likely to occur [39]. 
Another possibility that could lead to prolongation of the terminal disposition phase of 
SN~38 is its continuous formation out of the oxidative metabolites ofCPT-11. In an in vitro 
model, conversion of APC to SN-38 by rabbit liver CE has been desctibed [41]. However, 
rabbit liver CE, though very similar to human liver CE with respect to amino acid sequence, is 
-100-fold more efficient in activating APC tben tbe human enzyme in vitro [42]. Indeed, in 
vitro conversion of APC to SN-38 by human CE or human liver rnicrosomes could not be 
demonstrated (16), suggesting that .A.PC is not a prodrug of SN-38 in humans. NPC on the 
other hancL. could be metabolized into SN-38 in vitro by human liver microsomes and human 
liver CE to SN-38 following enzymatic cleavage of the 4-N-(l-piperidino)-!-arnino group at 
ClO [17]. We have recently reported tbat peak plasma concentrations and AUC values of 
l\'PC are very low after CPT-11 administration [32], which could point to rapid and virtually 
complete conversion of this compound to SN-38 in the systemic circulation. To test this 
possibility, we evaluated tbe in vitro production ofSN-38 from NPC and CPT-11 in freshly 
prepared human plasma, and found substantial formation from botb compounds. These data 
appear to indicate that this metabolic pathway is underestimated concerning to what extent it 
adds to tbe total amount of SN-38 formed. Although tbis route could clearly contribute to tbe 
prolonged disposition phase of SN-38 and may be an important determinant oftbe substantial 
interpatient variability in CPT-!! pharmacokinetics observed here and elsewhere [32]. tbe 
overall quantitative aspects of this source ofSN-38 remain unknovvn. 
Another potential contributing factor to the prolonged circulation time of SN-38 may 
come from competitive binding ofSN-38 and bilirubin to UDP glucuronosyltransferases [43]. 
Thus, in the lower concentration regions of SN-38 competitive binding with bilirubin may 
inhibit glucuronidation and prolong circulation times of the active metabolite. Although we do 
not have direct prove for this mechanism in the clinical situation, it is knovvn that even minor 
liver-enzyme disturbances and/or slight hyperbilirubinemia can give significant rise in both 
hematological and intestinal toxicity [44-46]. In patients witb (slightly) elevated bilirubin 
levels, competitive binding will influence the early plasma SN-38 concentration only to a 
minor extent but will give a disproportional prolongation of the terminal disposition phase of 
SN-38 and is tbus likely to affect SN-38G/SN-38 concentration ratios. The importance of this 
competitive interaction bet\veen SN-38 and bilirubin is further underscored by our 
observations made in a single patient who developed very severe toxicity. This patient 
developed liver failure during treatment with CPT-11 accompanied with a dramatic rise in 
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serum bilirubin concentrations. Compared to other patients this patient experienced at least a 
lO~fold increase in the SN-38 plasma concentrations, which is in accordance with this 
hypothesis and consistent with other published data indicating substantial increases in 
systemic exposure to CPT-!! and SN-38 in patients with liver dysfunction [45]. 
In conclusion, we have shown by applying an extended sampling-time period of 500 h 
that until! now the circulation rime of SN-3 8 in cancer patients treated with CPT -11 has been 
greatly underestimated. Because of the poorly defined relationships between pharmacokinetic 
parameters and pharmacodynamic outcome of CPT -1! treatment, the presently observed 
prolonged terminal disposition phase of SN-38 should be taken into consideration in future 
studies attempting to identifY kinetic correlates that would assist in prediction of both 
hematological and intestinal toxicity. Further investigation to reveal the clinical importance of 
our findings is clearly warranted. 
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Abstract 
This study was designed to evaluate irinotecan (CPT-11) disposition and pharmaco-
dynamics in the presence and absence of the broad-spectrwn antibiotic neomycin. Seven 
evaluable cancer patients experiencing diarrhea graded ~ after receiving CPT -11 alone (350 
mg/m2 i.v. once every three weeks) received the same dose combined with oral neomycin at 
1000 mg t.i.d. (days ~2 to 5) in the second course. Neomycin had no effect on the systemic 
exposure of CPT -11 and its major metabolites (1'<:0.22). However, it changed fecal ~­
glucuronidase activity from 7.03±1.76 ~glh/mg (phenolphthalein assay) to undetectable 
levels, and decreased fecal concentrations of the phannacologically active metabolite SN-38. 
Although neomycin had no significant effect on hematological toxicity (P>0.05), diarrhea 
ameliorated in 6 of 7 patients (?=0.033). Our findings indicate that bacterial ~-glucuronidase 
plays a crucial role in CPT -11-induced diarrhea without affecting enterocycling and systemic 
SN-38levels. 
Introduction 
CPT -11 3 is an inhibitor of topoisomerase I, an enzyme responsible for variations in the 
topological form of DNA during replication and transcription. Unlike other clinically-used 
camptothecin analogs, CPT -11 is a prodrug with very little inherent antitumor activity that 
needs to be hydrolyzed by a carboxylesterase to form the active metabolite SN-38 [1] (Fig. 1). 
SN-38 in its turn is efficiently metabolized by UDP glucuronosyltransferase lAl to form the 
inactive SN-38G [2]. 
Myelosuppression and diarrhea are among the most common side effects of CPT -11 [3], 
regardless of the schedule of administration. Delayed-type diarrhea is defined as diarrhea 
occurring >24 h after CPT-11 administration, and contrasts to the early-onset diarrhea which 
is acetylcholine-mediated and can be prevented by atropine [4]. CPT-11-induced delayed-type 
diarrhea has been reported to be severe (NCI-CTC grade 3-4) in approximately 25% of the 
patients [5]. Moreover even less severe diarrhea might influence continuation of therapy. The 
median onset of delayed-type diarrhea is day 5 after start of CPT-11 administration, and the 
median duration is 5 days. Delayed-type diarrhea necessitated hospitalization in 9% of the 
cycles for i.v. rehydration. There is no generally accepted prophylactic treatment for the 
delayed-type diarrhea. However, once diarrhea has occurred, a high dose loperamide regimen 
renders this side effect manageable [6]. 
Many pharmacokinetic analyses in humans have been perfonned in order to predict the 
incidence of delayed-type diarrhea, with conflicting results. Some studies reported a 
correlation bet\veen late-onset diarrhea and biliary secretion of the active metabolite SN-38, 












Schematic representation of CPT-II metabolism and enterohepatic 
recirculation. CE. carboxylesterase; hCEl/2, human carboxylesterase isoforms 
1 and 2: UGTlAl/7. UDP glucuronosyltramferase isoforms IAI and 1A7; 
CYP3A4/5, cytochrome P450 isoforms 3A4 and 3A5; APC, 7-ethyl-10-[4-N-(5-
aminopentanoic acid)-1-piperidino] carbon}·loxycamptothecin; NPC, 7 -ethyl-
10-[4-N-(1-piperidino)-1-aminojcarbonyloxycamptothecin. *indicates the sites 
of drug measurement. 
Recently, it was suggested from animal models that f3-glucuronidases produced by 
micro flora in the large bowel may play a major role in the development of CPT -11-induced 
diarrhea by mediating hydrolysis of SN-38G to form the active SN-38 [8]. Data obtained in 
rats have indicate that penicillin combined with streptomycin inhibited the f3-glucuronidase 
activity from the intestinal microflora, thereby decreasing the luminal SN-38 concentration 
and subsequently reduce cecal damage and ameliorate diarrhea. This antibiotic treatment did 
not alter plasma pharmacokinetics ofCPT-11 or SN-38 in the rat model [9]. 
Theoretically, modulation of CPT -!!-induced delayed-type diarrhea in humans by co-
administration of the poorly-absorbed aminoglycoside antibiotic neomycin [10] could be 
advantageous. In this study we assessed the influence of co-administration of oral neomycin 
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on the metabolic disposition and pharmacodynamics of CPT -11 in a group of cancer patients 
using a cross-over design. 
Patients and Methods 
Patients and Treatment 
Patients with a histologically or cytologically confirmed diagnosis of colorectal cancer 
refractory to therapy with 5-fluorouracil were eligible for the present study. Additional 
eligibility criteria included: age between 18 and 70 years; Eastern Cooperative Oncology 
Group (ECOG) performance status :$1; no previous treatment with antineoplastic agents for at 
least 4 weeks (or 6 weeks in case of nitrosureas or mitomycin C); no prior treatment with 
CPT-II or other topoisomerase I inhibitors; adequate hematopoietic (WBC <:3.0x!09/L, 
absolute neutrophil count <:2.0x!09/L, and platelet count <:!00x!09/L), renal (serum creatinine 
5135 ).lM or creatinine clearance <:60 mL/ntin), and hepatic function (total serum bilirubin 
51.25 x upper normal limit, and ASAT and ALAT levels 53.0 x upper normal limits); and no 
unresolved bowel obstruction or chronic colic diarrhea. The clinical protocol was approved by 
the Rotterdam Cancer Institute Ethics Board, and all patients signed informed consent before 
study entry. 
Vials that contained 40 or 100 mg of CPT-11 (as a hydrochloride trihydrate form) 
formulated as a concentrated sterile solution (active drug concentration, 20 mg/mL) in d-
sorbitol and a lactic acid-sodium hydroxide buffer system of pH 3.5-4.5 were provided by 
Aventis (Hoevelaken, The Netherlands). The CPT-11 dose of 350 mg/m2 was adntinistered 
once every three weeks as a 90-min i.v. infusion, after dilution of the pharmaceutical 
preparation in 250 mL of isotonic sodium chloride. In all patients, premedication consisted of 
ondansetron 8 mg i.v. combined with dexamethasone 10 mg i.v., both administered 30 min 
before the start of CPT-11 infusion. Delayed type diarrhea (in the first course) was treated 
with loperamide 4 mg, followed by 2 mg every 2 h for a 12-h time period after the last stool. 
In case the patient developed diarrhea grade 2 or higher in the first course despite loperamide 
therapy, neomycin (1000 mg daily x 3) was administered orally at days -2 to 5 relative to the 
second CPT -II administration. All toxicities were graded according to the NCI-CTC. 
Sample Collection and Analysis 
Blood samples for pharmacokinetic analysis were dra\Vll during the first course and in case of 
neomycin co-treatment during the second course as well, from a vein in the arm opposite to 
that used for drug infusion and collected in 1 0-mL glass tubes containing lithium heparin as 
anticoagulant. Samples were obtained at the following time points: before drug 
administration; at 0.5, I, and 1.5 h during infusion; and 0.17, 0.33, 0.5, I, 1.5, 2. 4, 5, 8.5, 24, 
32, 48. 56, 196, 360, and 504 h after the end of infusion. Blood was immediately processed to 
plasma by centrifugation for 5 ntin at 2500 rpm (4°C), which was then stored at -80°C until 
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the time of analysis by high-performance liquid chromatography as described [ll, 12]. A 
pretreatment feces sample was collected from all patients one day prior to drug administration 
in a polystyrene container and stored immediately at -80°C. Similarly, stool collections were 
obtained seperately for the duration of hospitalization ( -60 h). After thawing, these samples 
were homogenized individually on ice (at 0°C) to prevent enzyme degradation in 1 or 2 
volumes of a 0.1-M sodium acetate buffer (pH 7.0), depending on the water content of the 
sample, using an Ultra-Turrax T25 homogenizer (IKA.-Labortechnik, Dottingen, Germany). 
The homogenates were centrifuged for 5 min at 15,000 rpm, and the clear supernatants were 
diluted one-fold with 50% glycerol in water (v/v). The dilutions were stored at -80°C until 
analysis for J3-glucuronidase activity by a miniaturized colorimetric assay using 
phenolphthalein glucuronic acid as an artificial substrate [13]. Urine samples were also 
collected from each patient during the second treatment course to evaluate the extent of 
neomycin absorption, as measured by a quantitative cylinder-plate microbial assay (lower 
limit of detection, l.O f!g/ml). 
Feces cultures within 2 days prior to therapy were taken to determine the presence of 
neomycin-resistant microorganism. During the second course, feces cultures were taken daily 
from days -3 to 3 after CPT -ll infusion and analyzed for the presence of neomycin-resistant 
microorganism and/or overgrowth with Staphylococci in addition to microorganism 
(Salmonella, Shigella, Yersinia and Campylobacter species) and toxins (Clostridium species) 
that could provoke diarrhea. 
Pharmacologic Analysis 
Individual plasma concentrations of CPT -11 and its metabolites were fit to a three-
compartment model using the Siphar version 4.0 software package (SIMED, Creteil, France). 
as described [14]. The rate constants of the various disposition phases and the AUC 
(extrapolated to infinity) were estimated with a weighted-least squares method (weighting 
factor: l/y) using the model, whereas the total plasma clearance of CPT -ll was calculated by 
dividing dose (expressed in mg base equivalents per squared meter of body surface area) and 
the observed AUC. The Cmax values were determined graphically (as observed values) in a 
log concentration-time scattered plot. Metabolic ratios were calculated as defined (15), and 
included the relative extent of conversion (REC) of CPT-ll to SN-38 (i.e., AUCSN-
38/AUCCPT-ll), and the relative extent of glucuronidation (REG) of SN-38 (i.e., AUCSN-
38G/AUCSN-38). The latter was also evaluated as a function of time after drug 
administration. The systemic SN-38 glucuronidation rate in individual patients was estimated 
by calculation of the biliary index (BI) values [7], expressed as AUCCPT-ll x (AUCSN-
38/AUCSN-38G). The relative hematological toxicity, i.e. the percentage decrease in WBC, 




All pharmacokinetic parameters are reported as mean values ± SD. Since multiple 
measurements were performed at different times on the same patients, comparisons betvveen 
the sets of observations were based on within subject differences. Therefore, variation 
between subjects, which is usually considerable, does not affect our ability to distinguish 
differences betvveen the sets of observations, which here relate to CPT -11 courses given in the 
absence or presence of neomycin. The effect of neomycin on CPT -11 pharmacokinetic 
parameters was assessed using a paired Student's t test and the 95% confidence limits for the 
mean difference after testing for normality and heteroscedasticity. Similarly, the effect of 
neomycin on CPT~ll-induced diarrhea (scored on a 4-point scale according to NCI-CTC, and 
treated as ordered-categorical data) was evaluated using the Wilcoxon-matched pairs signed 
rank sum test. All calculations were done using the NCSS 5.X Series software package (J.L. 
Hintze, East Kaysville, UT, 1992). Statistical significance was considered to be reached when 
P<0.05, with a two-tailed distribution. 
Results 
Toxicity and Pharmacodynamics 
Twenty patients entered this study, of which 9 (45%) developed grade 2 diarrhea in the 
first treatment course and received neomycin as co-treatment in the second course. Two 
patients in this group were not evaluable for toxicity and pharmacokinetics in the second 
course; one patient went off study after the first course at his own request, and one patient was 
not evaluable due to early death unrelated to treatment. The 7 evaluable patients had a median 
age of 57 years (range, 49-71 years) and an ECOG performance state of 0-1, and all patients 
had normal hematopoietic and liver functions (except ASAT < 2N in two patients) at the time 
of study entry. 
The median clinical chemistry values included a total bilirubin level of 9 ).lM (range. 7-11 
/-(M); a serum creatinine level of 99 ).lM (range, 72-106 /-(M); ASAT levels of 34 units/L 
(range, 17-83 units/L) and ALAT levels of 22 units/L (range, 6-38 units/L); a total protein 
concentration of 79 g/dL (range, 69-87 g/dL); and a serum albumin level of 45 g/dL (range, 
38-51 g/dL). All 7 patients experienced a grade 2 diarrhea with a median duration of 6 days 
(range, 5-8 days) in their first course. Of these 7 (evaluable) patients, 5 (71%, ?~0.0326) did 
not experience any diarrhea in the second treatment course, one experienced diarrhea grade 1 
(3 days) and one experienced diarrhea grade 3 (5 days) in the second course. 
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Table 1. 
Pharmacokinetic variables of350 mg/m2 i.v. CPT-11 for 7 patients in the absence (course 1) 




































course 2 95% C.L. (d) 
7.62±1.72 -1.07. 1.19 
13.4±5.34 -5.99, 4.92 
45.1±20.3 -11.8, 3.52 
14.8±4.42 -1.88. 3.74 
141±48.9 -31.8. 22.5 
10.6±2.76 -2.79, 1.02 
0.161±0.093 -0.081.0.161 
41.9±3.86 -4.92. 14.4 
1.64±1.20 -0.143,0.183 
2.58±2.03 -0.782. 1.70 
0.290±0.072 0.035. 0.211 
36.9±7.69 -10.1, 3.29 
8.66±3.38 -1.39, 1.90 
5.14±2.53 -0.476. 0.884 
3880+0830 -1260,295 

















Abbreviations: 95% C.L. (d), 95% confidence limits for the mean difference; Cm~. peak 
plasma concentration; T Jr.?.(z), apparent half-life of the terminal disposition phase; AUCo-"l.l, 
area under the plasma concentration-time curve extrapolated to infinity; CL, total plasma 
clearance; Vss, volume of distribution at steady-state; MRT, mean residence time, REC, 
relative extent of conversion of CPT -11 into SN-38 (i.e. AUCsN-3si AUCcPT-11); REG, relative 
extent of glucuronidation of SN-38 into SN-38G (i.e. AUC"-3so/AUCsN-3s); BI, biliary index 
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Plasma concentration-time profiles of CPT-I I (A). SN-38 (B) and SN-38G (C) 
inpatients treated with 350 mglm:: Lv. CPT-11 in the absence (0) and presence 
of oral neomycin (S). Data are displayed as mean values of7 patients (0. ~ :1: 
SD (error bar). Note the different scales used for the X-axis andY-axis in the 3 
figures. 
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Figure 3. 
treatment schedule 
Fecal ~glucuronidase activity (A) and fecal SN-38G!SN-38 concentration 
ratios (B) in patients treated with 350 mg/m2 i.v. CPT-11 in the absence and 
presence of oral neomJ'Cin. Data are displayed as mean values of 7 patients 
(bars) .:t SD (error bar). 
The relative hematological toxicity, i.e. the percentage decrease in VIBC, was not 
significantly different between courses with values of 64.4±26.2% and 43.5±34.7% in the 
absence and presence of neomycin, respectively (mean difference, 20.9±5.38%; 95% 
confidence limits for the mean difference, 8.33, 33.5; P=0.058). The occurrence and severity 
of nausea or vomiting during treatment was comparable for both courses (data not shovvn). 
Feces cultures taken during the first and the second course did not reveal neomycin resistant 
microorganisms nor any overgrowth of pathogenic microorganisms. Cultures on infectious 




Plasma pharmacokinetics of CPT -11 and its metabolites were evaluated during both the 
first and second course (with neomycin) in all 7 patients (Table 1 ). The plasma concentration-
time profiles ofSN-38 after CPT-11 trea1ment were very sintilar for all patients studied (Fig. 
1 ). Administration of neomycin did not significantly alter the AUC of CPT -11 and of the 
active compound SN-38, as depicted in Figs. 2A and 2B and Table 1. Only the peak levels of 
SN-38G were significantly lower in the second course (Fig. 2C), but this did not alter the 
overall exposure to this metabolite. Neomycin levels in urine were very low in all patients 
(range, 0.72-7.27 ;tg/ml; interpatient variability, 58± 18%), indicating no relevant ab-sorption 
of the drug. 
Fecal ~-glucuronidase activity in the first course was significantly higher than in the 
neomycin co-treatment course (Fig. 3A), compatible with the elimination of the intestinal 
nticroflora by neomycin. Consequently, the fecal SN-38G/SN-38 ratio was 3-fold higher in 
the second course (Fig. 3B). 
Discussion 
In the current study we obtained both clinical and pharmacokinetic data in humans which 
increase our insight in the pathogenesis and prevention of CPT -11-induced delayed-type 
diarrhea. It has been shown previously that ~-glucuronidase activity derived from the 
intestinal nticroflora is able to hydrolyze biliary secreted SN-38G to the active compound SN-
38 [8, 14]. SN-38 can cause histological damage to the colon with ntinimal damage to the 
small bowel as was observed in a rat model as is believed to be the main course for the 
occurrence ofCPT-11-induced delayed type diarrhea [8]. Our present results indicate that~­
glucuronidase activity can be inhibited by eliminating the microorganisms by administration 
of the (poorly absorbed) antinoglycoside antibiotic neomycin, without any signs of negative 
effects concerning bacterial overgro\Vth, toxins or neomycin resistance. 
Since SN-38 is considered the active compound ofCPT-11 treatment, it is of the utmost 
importance that plasma SN-38 pharmacokinetics are not altered by co-treatment with 
neomycin. Since SN-38 is subject to entero-hepatic recirculation [13], suppressing intestinal 
~-glucuronidase activity could potentially influence plasma pharmacokinetics. In this study 
we have shovm that influencing j3-glucuronidase activity by co-treatment with neomycin in 
patients does not alter the plasma SN-38 pharmacokinetics nor CPT-11 plasma disposition. 
The paradox between the entero-hepatic recirculation of SN-38 and the lack of relationship of 
fecal ~-glucuronidase activity with SN-38 pharmacokinetics is presumably caused by the lack 
of enzyme activity in the luminal contents of the entire small intestine where re-absorption of 
drug is most likely to occur [13]. However we did find a minor but significant decline in the 
peak levels ofSN-38G. Although the total CPT-11 metabolism has still not been completely 
elucidated, this particular alteration might be explained by an upregulation of serum J3-
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glucuronidase activity after repeated exposure to CPT-11, as has been described earlier in a 
rat model [16], rather than by the co-administration of neomycin. The earlier reported 
correlation between systemic glucuronidation and the incidence of diarrhea as expressed in 
the biliary index (7] could not be found in our patient population, nor in a larger previous 
study [17]. In contrast, we found unaltered biliary indices with and without neomycin co-
treatment (Table 1 ), with complete disappearance of diarrhea after neomycin co-
administration in 5/7 patients. This is in keeping with the postulated concept regarding the 
mechanism of CPT -11 induced diarrhea, being a direct local toxic effect of the active 
compound SN-38, and sheds light on an important mechanistic aspect of the role of bacterial 
J3-glucuronidases in its ethiology. 
In contrast to earlier data from phase Ill studies reporting on CPT -11-induced delayed-
type diarrhea [3], only 45% of the patients enrolled in the current study developed diarrhea in 
the first course of chemotherapy, and this diarrhea was never worse than grade 2. This low 
frequency of diarrhea could be either due to patient selection or to the small number of 
patients enrolled in this study. Importantly however, from the 7 patients evaluable for study 
purposes, 5 did not experience any diarrhea after co-administration of neomycin, while 
additionally in one other patient the grade of diarrhea reduced from grade 2 to 1, and this 
diarrhea lasted for only 3 days. Only one patient experienced a more severe diarrhea with co-
administration of neomycin. 
We selected the poorly absorbed aminoglycoside antibiotic neomycin because of its 
broad antimicrobial spectrum as well as its local gastrointestinal disposition. Indeed, 
neomycin concentrations in the urine were very low following its administration, indicating 
that no substantial drug absorption took place. As with many antibiotics, treatment with this 
agent can cause diarrhea and malabsorption, which could have been the case in the one patient 
who experienced grade 3 diarrhea in the second course. This side effect is usually seen only 
with chronic administration in high (?:12 g per day) dosage regimens [18]. Since neomycin 
can induce diarrhea, largely depending on dosage and duration of treatment, with no data 
available on i)-glucuronidase activity compared to lengths of treatment, these are currently 
subject of investigation by us. 
In theory, other antibiotics could also have been used in the treatment of CPT -!!-induced 
delayed-type diarrhea, but clearly a non-resorbable drug is to be preferred. It would be even 
more attractive to use an agent that specifically inhibits the microbial i)-glucuronidase 
activity. Hange-shasin-to (also referred to as TJI4) a herbal medicine that contains the ~­
glucuronidase inhibitor baicalin, has recently been described to be a potent inhibitor of 
delayed-type diarrhea caused by CPT-11 in a rat model [19] as well as in humans [20]. 
Unfortunately there is yet no information on possible changes in plasma i)-glucuronidase 
activity due to this agent. Neither are there data if and how this agent influences plasma CPT-
II and SN-38 disposition, information of vital importance considering antitumor activity. 
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In conclusion co-treatment of CPT -11 with neomycin effectively decreases fecal B-
glucuronidase activity and consequently decreases enteral SN-38 concentrations without 
altering the plasma pharmacokinetics and metabolic profiles of both CPT-II and SN-38. This 
therapy could ultimately lead to decreased CPT -11-induced delayed-type diarrhea. A large 
randomized clinical trial of CPT -11 chemotherapy with or without prophylactic neomycin 
administration to patients is presently being conducted to confirm the present fmdings. 
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Abstract 
A high-performance liquid chromatographic assay with UV detection has been developed 
for the determination ofketoconazole in human plasma. Quantitative extraction was achieved 
by a single solvent extraction involving a mixture of acetonitrile-n-butyl chloride (1 :4 v/v). 
Ketoconazole and the internal standard (clotrimazole) were separated on a column packed 
with lnertsil ODS-80A material and a mobile phase composed of water-acetonitrile-tetra-
hydrofuran-annnonimn hydroxide-triethylamine ( 45:50.2:2.5:0.1:0.1, v/v). The column 
effluent was monitored at a wavelength of 206 nm -with a detector range set at 0.5. The 
calibration graph was linear in the range of 20-2000 ng/ml, with a lower limit of quantitation 
of 20.0 ng/ml. The extraction recoveries for ketoconazole and clotrimazole in human plasma 
were 93±9.7% and 83±10.0%, respectively. The developed method has been successfully 
applied to a clinical study to examine the pharmacokinetics of ketoconazole in a cancer 
patient. 
Introduction 
There is considerable motivation for understanding drug-drug interactions with anticancer 
agents because of their narrow therapeutic index and the numerous concomitant medications 
that are administered routinely or intermittently [1]. These interactions may arise as a result of 
altered pharmacodynamics or pharmacokinetics of the drugs involved. In the latter case, this 
is usually due to modification of tissue distribution and metabolism of the drugs. Most of the 
data currently available to evaluate potential drug interactions with (novel) anticancer agents 
have been addressed by animal experiments or the use of test systems in vitro [1]. It has been 
shown that ketoconazole (Fig. I), a synthetic imidazole-type broad-spectrmn antifungal agent 
is a highly potent inhibitor of CYP3A4 [2,3], and can inhibit anticancer drug metabolism at 
concentrations as low as 1 J.LM [2,4]. Previous investigations have shov.rn that with standard 
clinical doses of ketoconazole (200-400 mg/day p.o.), peak plasma concentrations are in the 
range of 4 to 20 J.LM [5], suggesting that concomitant treatment of ketoconazole is likely to 
substantially alter the disposition of various anticancer agents when administered to patients. 
Although the key rationale for conducting experiments in vitro on metabolism and drug-drug 
interactions is the presumed applicability to the clinical situation, for most anticancer agents 
there are no data yet indicating that the in vitro studies are predictive of results in vivo. 
Although ketoconazole is generally well absorbed after oral administration, there is large 
inter- and intrasubject variation in peak concentrations after the same oral dose [6]. It has 
been proposed, therefore, that determination of ketoconazole concentrations in patients is 
expedient before attempting to draw any correlation betv.reen ketoconazole dose and biologic 
effects. Hence, to enable further investigation of the interaction between ketoconazole and 
anticancer agents, a specific and accurate assay method for the determination ofketoconazole 
128 
HPLC Ketoconazole 
in human plasma was considered obligatory. Several microbiological [7-9], 
spectrofluorimetric [I 0] and electrochemical assays [8], as well as HPLC methods [11-16] 
have been described for the determination of ketoconazole in human plasma (using UV or 
fluorescence detection), but generally, these lack sufficient sensitivity. The reported HPLC 
methods offer greater precision than the microbiological assays, but are no more sensitive and 
involve complicated (solid-phase) extraction procedures. In this report, we describe a novel 
HPLC method with UV detection for the determination of ketoconazole in human plasma, 
with a lower limit of quantitation of 20 ng/ml. The method involves a rapid and highly 
selective one-step solvent extraction, which avoids the use of expensive and time consuming 
solid-phase extraction teclmiques for sample clean up. The method has been extensively 
validated, and a pilot pharmacokinetic study in a cancer patient receiving ketoconazole was 
included to investigate the suitability of the method. 
Cl 
Figure 1. Chemical structure of ketoconazole. 
Experimental 
Chemicals 
Ketoconazole (lot 79H4087) and the internal standard clotrimazole (lot 118H1359) were 
obtained from Sigma (St. Louis, MO, USA). Acetonitrile was obtained from Biosolve B.V. 
(Valkenswaard, The Netherlands). Tetrahydrofuran was obtained from Rathburn 
(Walkerburn, UK) and triethylamine and annnonium hydroxide from Baker (Deventer, The 
Netherlands). All chemicals and solvents were of analytical grade or better. Water was 
purified and deionized by the Milli-Q-UF system (Millipore, Milford, MA). Human plasma 
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was obtained from healthy volunteers via the Blood Bank of the University Hospital 
Rotterdam (Rotterdam, The Netherlands). 
Preparation of Stock Solutions 
Stock solutions ofketoconazole (1.0 mg!ml) and clotrimazole (1.0 mg!ml) were prepared 
by dissolving the appropriate amount of drug in acetonitrile and were then stored in glass at-
80'C. An internal standard working solution of 10,000 ng/ml was prepared by dilution with a 
mixture of acetonitrile-water (1: 1 ~ v/v), and was stored for later use at 4°C. 
Sample Pretreatment 
A volume of 100 J.Ll of methanol-0.05 M sodium hydroxide (40:60, v/v), 100 J.Ll of 
internal standard solution (10 J.Lg/ml) and 5 ml ofacetonitrile-n-butyl chloride (1:4, v/v) were 
added to 0.5 ml of human plasma in a 12-ml glass tube and closed with a PTFE-faced screw 
cap. The tube was mixed for 5 min on a multi-tube vortex mixer and centrifuged for 5 min at 
4000 g. After centrifugation, the organic layer was transferred to a clean glass tube with a 
Pasteur pipette, and evaporated to dryness under a constant stream of nitrogen at 60°C. A 
volume of 125 J.Ll of acetonitrile-water (1:1, v/v) was added to the residue, which was 
reconstituted by ultrasonication for 2 min. After additional centrifugation for 2 min at 4000 g, 
the contents of the tube was transferred to a low-volume glass insert and a 1 00-J.Ll aliquot was 
subjected to chromatography. 
HPLC Analysis 
The chromatographic system consisted of a ConstaMetric 3200 pump (LDC Analytical, 
Riviera Beach, FL, USA), a Waters 717plus autosarnpler operating at 4'C (Milford, MA, 
USA), a model SpH99 colunm oven (Spark Holland, Meppel, The Netherlands) and a Spectra 
Physics UV-2000 detector (San Jose, CA, USA). The stationary phase was composed of 
lnertsil ODS-80A material (5-J.Lm particles) packed in a 150x4.6 mm I.D. stainless-steel 
colunm (GL Science, Tokyo, Japan), protected by a Lichrospher 100 RP-18 guard colunm 
(4.0x4.0 mm; 5 J.Lm particles). The mobile phase consisted of water-acetonitrile-
tetrahydrofuran-arumonium hydroxide-triethylamine (45:50.2:2.5:0.1:0.1, v/v), with the pH 
adjusted to 6.0 (formic acid). The flow rate of the mobile phase was set at 1.00 rnVmin, and 
the column effluent was monitored at an absorption wavelength of 206 run, and a detector 
range of 0.5. The colunm temperature was maintained 30'C. Acquisition and integration of 
data was performed with the ChromCard data analysis system connected to an ICW 
chromatographic work station (Fisons, Milan, Italy) running on an IBM-compatible computer 
under Microsoft Windows v95. Calibration graphs were calculated by weighted (l/x2) least-
squares linear regression analysis of the peak area ratio of ketoconazole and the internal 




Precision and Accuracy 
Method validation was performed according to procedures described in detail by Shah et 
al. [17]. With each chromatographic validation run, duplicate calibration standards were 
prepared in blank human plasma by serial dilution at ketoconazole concentrations of 20.0, 
50.0, 100, 500, 1000 and 2000 ng/ml. Sets of quality control (QC) samples were prepared in 
batch in the same manner at 75.0, 750, 1500 and 15,000 ng/ml and were analyzed in 
quintuplicate. The QC sample containing the highest concentration was used to investigate the 
effect of sample dilution and/or limited sample-volume injection. The complete validation 
procedure was performed on four separate days. The precision of the assay was assessed by 
the betvveen-run and within-run precision. Estimates of the betv.reen-run precision were 
obtained by one-way analysis of variance (ANOV A) using the run day as classification 
variable. The between-groups mean square (MSbet), the within-groups mean square (MSwit), 
and the grand mean (GM) of the observed concentrations across run days were calculated 
using the NCSS package (Version 5.X, Dr. Jerry L. Hintze, East Kaysville, UT; 1992). The 
between-run precision (BRP) was defined as: 
BRP ~ ([(MSb"- MS,~,)/n]05) * 100% (eq. 1) 
where n represents the number of replicates within each validation run. The within-run 
precision (WRP) was calculated as: 
WRP ~ [(MSw,)05/GM] * 100% (eq. 2) 
Lower Limit of Quantitation 
For determination of the lowest standard concentration in the analytical run (LLQ) with 
acceptable accuracy and precision, five plasma samples from five individuals were spiked at a 
ketoconazole concentration of 20.0 ng/ml and analyzed in quadruplicate. For the 
concentration to be acceptable, the percentage deviation from the nominal value of at least 
80% of the samples assayed should be :QO%, with a resulting WRP of ~20%. 
Extraction Recovery 
The extraction recovery of ketoconazole was established at concentrations of 20.0, 50.0, 
100, 500, 1000 and 2000 ng/ml, by comparing peak heights of samples prepared in human 
plasma with those prepared in a mixture of acetonitrile-water (1: 1 v/v). The recovery was 
determined in four independent analytical runs, and expressed as a percentage. 
Specificity and Selectivity 
Five different human plasma samples were used to investigate the potential interference 
of endogenous components. In addition, the following commonly used drugs in clinical 
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oncology were used for potential interference with the analytical method: acetaminophen, 
alizapride, atropine sulfate, codeine, dexamethasone, leucovorin, loperamide, lactulose 
(Legendal), lorazepam, metoclopramide, morphine hydrochloride, omeprazole, paroxetine, 
ranitid.ine, and temazepam. 
Stability 
The stability of ketoconazole in human plasma was investigated by analysis after storage 
of the various QC samples at 37°C for 30 hand after three consecutive freeze-thawing cycles. 
After the indicated duration and storage conditions, the samples were analyzed immediately 
as outlined above. 
Pharmacokinetic Analysis 
The patient studied was a 53-year old male with a histologically confinned diagnosis of 
advanced colorectal carcinoma refractory to therapy with 5-fluorouracil. The patient received 
chemotherapeutic treatment with irinotecan (CPT-ll), and during one of the treatment 
courses, ketoconazole was administered orally at a dose of 200 mg (Nizoral tablets, provided 
by Janssen-Cilag, Tilburg, The Netherlands), and was given every 24 hours for a period of 3 
days. The current experiment was approved by the Rotterdam Cancer Institute Review Board, 
and the patient signed informed consent before study entry_ 
A total of !6 blood samples (5 ml each) were obtained and collected in 10-ml glass tubes 
containing 143 units of lithium heparin as anticoagulant. The samples for ketoconazole and 
analysis were taken immediately before intake and !, !.15, 1.3, 1.5, 2, 3, 3.5, 4.5, 6.5, 7.5, 10, 
26, 34, 50 and 68 h after dosing. Blood was immediately processed to plasma by 
centrifugation for 5 min at 3000 g, and was kept at -20°C until storage at -80 oc_ Individual 
plasma concentration-time data ofketoconazole were analyzed by non-compartmental models 
using the Siphar version 4.0 software (SIMED, Creteil, France), as described [24]. 
Results aud Discussion 
Chromatography 
Fig. 2 displays chromatograms of an extract of a blank buman plasma sample (A), an 
extract of a plasma sample spiked with ketoconazole at a concentration of 2000 ng/ml (B), 
and an extract of a plasma sample taken 6.5 hours after ketoconazole intake and i.v. infusion 
of CPT-!! (! 00 mg/m2) (C). Ketoconazole (tJF5.9 min) and the internal standard clotrimazole 
(tr22.0 min) were well separated, and the overall chromatographic run time was established 
at 30 min. Several different drugs were tested for potential interference with ketoconazole and 
the internal standard (see: Experimental), and none of these drugs was found to give an 
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Figure 2. 
Time (min) 
Chromatograms from reversed-phase HPLC analysis of a blank human plasma 
sample (A), a human plasma sample spiked with ketocona::ole at a 
concentration of 2000 ng/ml (B), and a plasma sample obtained from a male 
patient with colorectal cancer at 6.5 h after oral administration of ketoconazole 
(200 mg) (C). The labeled chromatographic peak indicte ketoconazole (!) and 
the internal standard clotrimazole (II), respectively. 
Validation Characteristics 
The assay for ketoconazole analysis in plasma was found to be linear over the range of20 
to 2000 ng/ml, applying the peak height in combination with a weighting factor of l/x2, as 
indicated by the mean linear-regression correlation coefficient of 0.9975 (n=4). In order to 
increase the sensitivity of the method, the range of the detector was set at 0.5 in stead of 1.0. 
In blank human plasma spiked with ketoconazole at 20 ng/ml, three out of 1:\venty samples 
were outside the acceptable ±20% deviation limits, while the remaining samples were within 
18%, with a mean percentage deviation from the nominal concentration and a within-run 
variability of 1. 7 and 6.6%, respectively. Based on these results, the LLQ was established at 
20 ng/ml, which is about three to four times more sensitive than earlier described methods 




Accuracy, within-run and betvveen-run precision for the analysis of ketoconazole in spiked 
human plasma samples. 
Nominal GMa ACC WRP BRP 
(ng/ml) (ng/ml) (%) (%) (%) n 
20.0 20.3 1.7 6.6 7.1 5 
75.0 71.2 -5.1 10.4 0.44 5 
750 739 -1.5 6.3 2.0 5 
!500 1534 2.3 3.9 3.3 5 
!5000 16653 11.0 2.6 2.9 5 
n Abbreviations: GM. grand mean~ ACC. accuracy (percent deviation from nominal value): \VRP, within-run 
precision: BRP. between-run precision: n, number of replicate observations vvithin each validation run. 
Validation data of the analytical method in terms of accuracy (percent deviation) and 
precision are shovm in Table 1. At the upper limit of quantitation, i.e., 2000 ng/ml, the mean 
percentage deviation and the within-run variability were also less than 20%. The method was 
shown to be accurate, with an average accuracy at the four tested concentrations betv.reen -5.1 
and 11.0%, and precise with a within-run and between-run precision always within 15%. In 
addition, sample dilution and/or limited sample-volume injection had no effect on the 
validation characteristics (Table 1 ). The mean overall extraction recoveries, determined in 
four separate analytical runs, were 93±9.7% for ketoconazole (n=45) and 83±10.0% for the 
internal standard (n~45), and were independent of the spiked concentration. Repeated freeze-
thawing cycles had no influence on the stability. In addition, plasma samples spiked with 
ketoconazole stored for 30 hat 37"C were also stable (not shown). 
Clinical Pharmacokinetics 
The described analytical method was applied to a phannacokinetic pilot study of 
ketoconazole given orally to a cancer patient. The observed concentration-time profile of 
ketoconazole is shovro in Fig 3. The peak concentration ofketoconazole was 4.63 ~g/ml (i.e., 
8.71 )lM), and the area under the concentration-time curve amounted to 12.9 )lg.h!ml, which 
is similar to a mean (±S.D.) value of 12.3±7.7 ~g.hlml previously obtained in nine adults with 
hematological malignancies who were also given a dose of 200 mg [18]. The concentration-
time data indicated that the ketoconazole concentration required to completely inhibit 
CYP3A4-mediated in vitro metabolism of, for example, CPT -II (i.e., I ,uM), was achieved 
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Plasma concentration-time profile ketocona=ole (---) after oral administration 
of a dose of200 mg to a male cancer patient with colorectal cancer. 
In conclusion, the method presented for the determination of ketoconazole in human 
plasma is specific, accurate and precise, and is selective and sensitive enough to be used in 
clinical trials. The method permits the analysis of patient samples with low concentrations of 
ketoconazole, and is currently being used to investigate whether concomitant treatment of 
CPT -11 with ketoconazole could reduce CYP3A4-mediated drug inactivation in colorectal 
cancer patients. 
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Background Irinotecan (CPT-ll) is a prodrug of SN-38 and has been registered for the 
treatment of advanced colorectal cancer. It is converted by the cytochrome P450 3A4 isozyme 
(CYP3A4) into several inactive metabolites, including APC. To investigate the role of 
CYP3A4 in CPT-11 phannacology, we evaluated the consequences of simultaneous treatment 
of CPT -11 with a potent enzyme inhibitor, ketoconazole, in a group of cancer patients. 
Methods: A total of 7 evaluable patients was treated in a randomized cross-over design with 
CPT-11 (350 mg/m2 i.v. over 90 min) given alone, followed 3 weeks later by CPT-I I (100 
mg/m2) in combination with ketoconazole (200 mg orally b.i.d. for 2 days), or vice versa. 
Serial plasma, urine and feces samples were obtained up to 500 h after dosing and analyzed 
for CPT-11, metabolites [SN-38, SN-38 glucuronide (SN-38G), APC], and ketoconazole by 
HPLC. 
Results With ketoconazole co-administration, the formation of APC was reduced by 87% 
(P=0.002), while the relative exposure to the carboxylesterase-mediated SN-38 was increased 
by llO% (P=0.004). These metabolic alterations occurred without substantial changes in 
CPT-ll clearance (P=0.60) and formation of SN-38G (P=0.93). In spite of the reduced dose 
in the combination course, no significant differences in toxicity profiles were noted. Parallel 
in vitro studies indicated that ketoconazole had no influence on circulating carboxylesterase 
activity (P=0.89). or on CYP3A4-mediated SN-38 metabolism in human liver microsomes. A 
very minor effect was observed on the transport rate of SN-38 by Caco-2 cells, presumably 
mediated by inhibition ofP-glycoprotein (but not BCRP) activity. 
Conclusions Inhibition of CYP3A4 in cancer patients leads to significantly increased 
formation ofSN-38 following CPT-11 administration. Simultaneous administration of various 
commonly prescribed drugs (either substrate or inhibitor of CYP3A4) can potentially result in 
fatal outcomes, and up to 4-fold reductions in CPT -11 dose are indicated. 
Introduction 
There is considerable motivation for understanding adverse drug interactions v.rith 
anticancer agents because of their narrow therapeutic index and the numerous concomitant 
medications that are administered routinely or intermittently [1]. Indeed, drug interactions 
including those with anticancer agents are a major cause of morbidity and mortality in modern 
meilical practice [2], causing over 100,000 deaths per year in the USA, and making it between 
the fourth and sixth leading cause of death in 1994 [1]. Usually, such interactions arise as a 
result of altered pharmacodynamics or pharmacokinetics of the drugs involved [3]. In the 
latter case, this is usually due to changes in metabolic routes, and several mechanisms 
contributing to clinically important interactions have been identified, including expression of 
cytochrome P450 (CYP) isozymes. This class of enzymes, particularly the CYP3A4 isozyme, 
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is responsible for the oxidation of over 50% of all drugs currently administered to humans [ 4], 
resulting in more polar and usually pharmacologically inactive metabolites, which can be 
excreted efficiently by the kidneys and the liver. It is evident that anticancer substrate drugs 
given in combination with drugs that are efficiently metabolized by CYP3A4, is likely to 
result in serious toxicity. However, most of the data currently available to evaluate possible 
drug interactions vrith anticancer agents have been addressed by animal experiments or the 
use of test systems in vitro [4]. 
In this study, we investigated the effect of CYP3A4 inhibition, using the model inhibitor 
ketoconazole [5], on the pharmacokinetics and toxicity profile ofirinotecan (CPT-11), which 
is a very important drug used in the treatment of colorectal cancer [6], and a partial substrate 
of the CYP3A4 isozyme [7]. 
Materials and Methods 
Patients and Treatment 
Patients were eligible if they had a histologically confirmed diagnosis of metastatic 
colorectal cancer and proven progressive disease after first line chemotherapy (with 5-
fluorouracil) or a malignancy for which there was no effective standard regimen. Additional 
eligibility criteria were identical as documented elsewhere [8,9]. The protocol was approved 
by the Ethics Board of the Rotterdam Cancer Institute, and all patients signed informed 
consent before study entry. 
Patients screened and meeting study entry criteria were randomly assigned to receive 
either CPT-11 alone (as a 90-min i.v. infusion) at a dose of 350 mg/m2, followed 3 weeks 
later by CPT -11 at a dose of 100 mg/m2 given in combination with ketoconazole (200 mg) 
given orally 1 h before and 23 h after the infusion of CPT -11, or both treatment cycles were 
given vice versa. The 3.5-fold dose reduction of CPT-11 in combination with ketoconazole 
was chosen based on pharmacokinetic knowledge from earlier in vitro studies in combination 
with the proposed drug interaction. A restricted randomization was performed to avoid bias 
in cycle sequence and to keep the number of patients close for both arms. Prior to drug 
administration, the clinical CPT -11 formulation (A ventis Pharma, Hoevelaken, The 
Netherlands) was diluted in 250 ml of isotonic sodiutn chloride. 
Patients received a standard regimen of ondansetron and dexamethasone therapy, both 
given 30 min prior to chemotherapy. Atropine 0.25 mg was administered subcutaneously as a 
prophylaxis for CPT-11-induced acute cholinergic syndrome in case the patient experienced 
this side effect in the previous cycle. Physical examination and toxicity assessment were 
performed on a weekly basis, as were clinical chemistry tests in both treatment cycles. 
Pharmacologic Analysis 
CPT-11, SN-38, SN-38-glucuronide (SN-38G), and APC pharmacokinetics were 
performed during both cycles. Blood samples ( -5 ml) were collected inunediately prior to 
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CPT -II infusion, at 30 min after the start of the infusion, at the end of infusion, and at I 0, 20 
and 30 min, and I, 1.5, 2, 4, 5, 8.5, 24, 32, 48, 56, 196 (day 8), 360 (day 15) and 500 (day 21) 
h post infusion. Complete urine and stool was collected in 24-h intervals for 3 days after the 
start of treatment in both cycles. All biologic matrices were handled as outlined [I 0], and 
CPT-II and metabolite (SN-38, SN-38G, and APC) concentrations were determined by 
HPLC as described [11,12]. 
Pertinent pharmacokinetic parameters, including peak concentration, area under the 
plasma concentration-time curve (AUC), total plasma clearance (CL, defined as the ratio of 
dose administered in mg/m2 and AU C), the rate constant of the terminal disposition phase (k), 
and the half-life of the terminal disposition phase (defined as ln21k), were calculated using a 
linear 3-compartment model running on Siphar v4.0 (lnnaPhase, Philadelphia, PA) [13]. 
Metabolic ratios were calculated from plasma AUCs as well as urinary and fecal excretion 
data, as described previously [14]. Plasma concentrations ofketocona?...ole were measured by 
HPLC with UV detection [15]. 
Pharmacodynamic evaluation involved analysis of pretherapy and nadir values of white 
blood cell counts and absolute neutrophil counts as a function of treatment course, expressed 
in absolute values (in 1 09/liter) and in percent decrease relative to pretherapy values (e.g., 
[(pretherapy value - nadir value )/pretherapy value] x I 00% ). 
Enzyme Activity in Plasma 
Carboxylesterase activity in plasma samples was determined by a spectrophotometric 
assay using o-nitrophenyl acetate as a substrate [16], using purified carboxylesterase 
(EC3.1.1.1; Sigma, St. Louis, MO) as a reference. Briefly, extracts prepared by sonication in 
50 Illi\1 HEPES (pH 7.4) were incubated in 3 mM of o-nitrophenyl acetate, and the 
absorbance at A420 was measured at 1-minute intervals for 10 minutes. Protein 
concentrations in extracts were determined using a Coomassie brilliant blue G250 dye-
binding assay [17], using bovine serum albumin as a reference standard. Carboxylesterase 
activity is reported as micromoles of o-nitrophenyl acetate converted per minute per mg of 
protein (~mol/minlmg). 
Hepatic Metabolism In Vitro 
Pooled human liver microsomes (Gentest Corp., Woburn, MA) containing l mg of 
protein per ml were incubated with CPT-II or SN-38 (both at a final concentration of I ~M) 
in the presence and absence of ketoconazole (I ~M) as described [18]. Reactions were 
incubated for 60 min at 37°C in the presence or absence of an NADPH-regenerating system. 
The decrease in drug concentration was measured at serial time points by HPLC as described 
[19]. 
140 
Irinotecan and Ketocona:;ole 
Drug Transport Assays 
Caco-2 cells were cultured and treated as described earlier [20]. Transport studies of 
CPT-11 and SN-38 across complete monolayers in 12-well Transwell clusters (Costar, 
Cambridge, MA) with !-cm2 polycarbonate membrane filters (0.4-flm pore size) were 
conducted in a controlled enviromuent at a temperature of 37°C. The integrity of the cell 
monolayers was evaluated by measuring transepithelial transport of [14C]marmitol as 
described elsewhere [21]. Transport inhibition experiments were performed under identical 
conditions in the presence of ketoconazole or the P-glycoprotein!breast cancer-resistance 
protein (BCRP) inhibitor GF!20918 (Glaxo Wellcome, Research Triangle Park, NC) added to 
the apical or basolateral side of the monolayer [22]. For each experiment, the mean transport 
rate was calculated from the linear part of the plot of the total amount of drug transported 
versus time. The apparent permeability coefficient (Papp ), expressed in centimeters per 
second were calculated as D.Q/D.t x 1/60 x 1/A x !/CO, where D.Q/D.t is the permeability rate 
(in f!g/min), A is the snrface area of the membrane (in cm2), and CO is the initial 
concentration in the donor chamber (in f!g/ml) [21]. 
Statistical Considerations 
All data are presented as mean values ± standard deviation, unless stated othenvise. The 
statistical significance of differences in pharmacokinetic, pharmacodynamic, or in vitro data 
between treatments was evaluated using t\Vo-tailed, paired, Student's t tests, with a 
significance level of P<0.05, after testing for normality. All calculations were performed on 
the NCSS version 5.X software (J.L. Hintze, East Kaysville, UT). 
Table 1. 
Sununary of hematological pharmacodynamics 
Parameter CPT-11 CPT -11/keto P Diff (±SE)* 95%C.L. 
Leukocytes 
%decrease 'NBC 67.1±27.2 55.4+09.8 o.s3 Il.7±18.o -29.8 I 53.2 
(29.9-98.0) (17.0-91.7) 
Nadir (x!09/L) 2.33±1.70 3.29±1.61 o.38 -o.97±l.o5 -3.38 I 1.44 
(0.55-4.70 (0.97-4.90) 
N eutrophils 
%decrease ANC 74.5±22.5 56.9+03.3 0.26 17.6±14.5 -15.8 50.9 
(42.4-99.6) ( 46.0-96.5) 
Nadir (xl09/L) 1.11±0.87 1.93±1.19 0.25 -0.82±0.66 -2.33 0.70 
(0.1 0-2.30) (0.34-3.40) 
Abbreviations: WBC, white blood cells; ANC, absolute neutrophil count 




Patients and Toxicity Profiles 
To detennine the influence of CYP3A4 inhibition by ketoconazole on CPT-11 
pharmacokinetics and toxicity, a total of 9 patients was accrued to the study. In 2 of 9 
patients, ketoconazole was inadvertently only administered on day 1 in the combined 
schedule, and therefore these patients were considered not evaluable. Of the 7 remaining 
patients, 3 were male and 4 were female with a median age of 54 years (range, 42-71) and a 
median performance score of 1 (range, 0-2). All patients completed the study within the 
scheduled time without delay. The predominant disease type was colorectal cancer (n~5), and 
the principal toxicity consisted of neutropenia. Paired analysis of hematological 
pharmacodynamic parameters indicated that the degree of myelosuppression, including the 
percent decrease in absolute neutrophil count (P=0.26), was not significantly different 
between the courses, in spite of a 3.5-fold reduced CPT-11 dose when given in combination 
with ketoconazole (Table 1). The severity and incidence of nonhematological toxicities, 
including gastrointestinal side effects (nausea, vomiting and diarrhea) were also not dissimilar 
in the tvvo regimens (data not shown). 
CPT-11 Disposition and Effects ofKetocona:ole 
Since ketoconazole is a known potent inhibitor of CYP3A4, and given the prominent role 
of this enzyme in CPT -11 metabolism, we assessed the influence of ketoconazole on 
disposition profiles (Table 2). The peak concentration of ketoconazole was 4.72±2.53 ~glml, 
and the AUC amounted to 15.4±9.80 ~g.h!ml, which is similar to previous findings [5). This 
suggests that ketoconazole concentrations required to completely inhibit CYP3A4-mediated 
CPT-!! metabolism in vitro (i.e., 1 ~M) were achieved for at least 7 h in all patients [18]. 
Indeed, in the presence of ketoconazole, the formation of the CYP3A4-mediated metabolite 
APC was reduced by 87% (P~0.002), while the relative exposure to the pharmacologically 
active metabolite SN-38 increased by 1!0% (P~0.004). The opposing effects of these 
metabolic routes on drug elimination left the systemic clearance of CPT -11 almost unaffected 
(P~0.60). Similarly, ketoconazole had no effect on circulating levels of SN-38G (P~0.93), 
suggesting no effect on ~-glucuronidation pathways. The cumulative exposure to the total of 
all metabolites, on a molar basis and normalized to a 350 mg/m2 dose~ was also not dependent 
on the presence of ketoconazole (13.7±5.00 vs 11.5±4.50 ~M.h; P~0.65). In addition, the 
cumulative fecal excretion of CPT-11, expressed as the percentage of the absolute dose 
excreted in feces within the first 56 h after drug administration, was not different in the 
presence or absence of ketoconazole (13.8±!5.9 vs 19.5±13.9%; P~0.48). However, the 
recovery of SN-38 was increased by 207% and the formation of APC was reduced by 78.0%. 
The similarity of the terminal disposition phases in plasma of these metabolites (Fig. 1) 
betvveen treatment courses indicate that the altered fecal excretion of the metabolites in the 
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presence of ketoconazole is related to altered formation rather than diminished biliary 
secretion. 
Table 2. 
Summary ofCPT-11 pharmacokinetics (normalized to a CPT-II dose of350 mg/m2) 
Parameter CPT-II CPT -lliketo Difference (%) p' 
Irinotecan dose (mg) ~¥ 650 180 
(600-875) (175-230) 
Infusion duration (h)" !.50 !.50 
(1.45-1.60) (1.30-1.50) 
CPT-ll 
Cmu.x. (~M) 7.65±1.53 7.45±1.53 
AUC (~M.h) 46.9±16.0 42.3±9.55 
CL (L/b!m2) 14.9±4.51 14.7±3.16 8.94±16.5 0.60 
SN-38 
Cm, (~M) 0.164±0.063 0.309±0.152 
AUC(~M.h) !.!1±0.476 2.09±0.859 
REC 0.033±0.023 0.055±0.0 19"' 109±36.6 0.004 
SN-38G 
Cm,, (~M) 0.312±0.083 0.484±0.042 
AUC (~M.h) 4.53±1.64 8.56±3.64 
REG 4.18±0.372 4.14±!.!7 -1.56±22.6 0.93 
APC 
Cm•x (~M) 0.627±0.283 0.139±0.049 
AUC(~M.h) 8.03±3.80 0.843±0.0.436 
REM 0.177±0.092 0.020±0.012 -86.9±7.14 0.002 
Abbreviations: Cmu. ..... , peak plasma concentration; AUC, area under the plasma concentration 
versus time curve; CL, apparent plasma clearance; REC, relative extent of conversion (AUC 
ratio of SN-38 to CPT-ll); REG, relative extent of glucuronidation (AUC ratio of SN-38G to 
SN-38); REM, relative extent of metabolism (AUC ratio of APC to CPT-ll). 
*Wilcoxon test for matched pairs; **Median with range; ***The coefficient sofvariation of 
the REC values are 7!.!% and 35.1%, respectively, for treatment courses with CPT-II alone 
and the combination with ketoconazole. 
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Figure 1. Plasma concentration-time curves ofCPT-11 (A), SN-38 (B) and APC (C) in the 
presence (solid line, tl) and absence (dashed line, 0) of ketoconazole. Data 
from the CPT-11/ketoconazole combination were nonnalized to a CPT-11 dose 
of 350 mglm=. Results are presented as all individual data time points. fitted 
simultaneously to a linear 3-compartment model. 
Ex Vivo Analysis of Carboxy/esterase Activity in Patient Plasma 
In order to gain insight into the observed altered pharmacokinetic behavior of CPT -11 in 
the presence of ketoconazole, various in vitro experiments were performed. We and others 
have shown recently that determination of plasma carboxylesterase activity by measuring 
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hydrolysis of an artificial substrate (such as o-nitrophenyl acetate) has utility in predicting 
SN-38 pharmacokinetics (8,23). The carboxylesterase activity in patient plasma, measured 
over 50 h after CPT -11 administration was relatively consistent, and independent of sampling 
time points, with mean values of 20.7±1.58 and 20.9±2.40 f!moVntinlmg in the absence and 
presence of ketoconazole, respectively (P=0.89). This suggest that ketoconazole does not 
influence or induce circulating CPT -11-hydrolyzing esterases. 
Effect of Ketoconazole on SN-38 Metabolism by Human Liver Microsomes 
To assess a possible role of effect of ketoconazole on metabolism of SN-38 by human 
liver microsomes, we incubated microsomal preparations with CPT -11 and SN-38 for 60 min 
at 3TC. In line with previous findings [18], we found that CPT-11 was extensively 
metabolized to various polar compounds, including APC, but not in the presence of 
ketoconazole (99-100% inhibition). In contrast to previous data published in abstract form 
[24], no metabolic degradation by liver nticrosomes was observed for SN-38, and no 
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Transepithelial (apical to basolateral direction) transport of CPT-II (A) and 
SN-38 (B) across Caco-2 cell mono/ayers in the absence (#J, 0) and presence of 
ketoconazole (.., <>), the P-glycoprotein!BCRP inhibitor GFI209I8 (A.Ll), or 
ketoconazole plus GFI209I8 ('9';" r:). Results are presented as mean values 
(s;.-mbol) .:t standard deviation (error bar) of 3 independent observations at 
initial CPT-II and SN-38 concentrations of I 0 p.M 
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Polarized Transport of SN-38 in Human Intestinal Cells 
We next studied the transepithelial flux of CPT -11 and SN-38 in Caco-2 cell mono layers, 
a well-established model of human intestinal absorption [25], to further define the potential 
role of active transport mechanisms in SN-38 pharmacokinetics and the influence on these 
processes by ketoconazole. Previously, we showed that Caco-2 cells demonstrate significant 
expression of P-glycoprotein, multidrug-resistance associated protein (MR.P-1), and the 
canalicular multispecific organic anion transporter (cMOAT or MRP-2) [20]. We also 
recently observed pronounced staining using immunoprecipitation at the apical side of Caco-2 
cells with an antibody to BCRP (manuscript in preparation, A. Sparreboom and M. 
Maliepaard), a recently identified member of the ATP-binding cassette transporter family for 
which SN-38 is one of the best known substrates [26]. 
The flux of CPT -11 and SN-38 across Caco-2 cell mono layers, when drug was loaded on 
the apical side of the cells was essentially linear for up to 3 h (Fig. 2). In the presence of the 
P-glycoprotein!BCRP inhibitor GF120918, the Papp for the apical to basolateral transport 
increased more than 2-fold from 3.6x!0-6 to 7.0xl0-6 crn!sec and from 3.6xl0-6 to 9.7xl0-6 
em/sec for CPT-11 and SN-38, respectively, consistent with the known prominent role ofP-
glycoprotein and BCRP activity in SN-38 transport [27]. With ketoconazole, the flux of CPT-
II and SN-38 was increased by 47.2% (Papp~5.3xl0-6 crn!sec) and 55.6% (PapF5.6xl0-6 
em/sec), respectively, whereas addition of ketoconazole to GF!209!8 had essentially no 
additional effect as compared to GF120918 alone (CPT-11, Papp~6.2xl0-6 em/sec; SN-38, 
Papp~8.0x!0-6 em/sec). Since Caco-2 cells fail to express significant CYP3A4 activity under 
the culture conditions employed [25], the most likely explanation for the observed effect on 
drug transport is inhibition ofP-glycoprotein activity, a known property ofketoconazole [28]. 
Discussion 
This study shows that inhibition of CYP3A4 by the potent enzyme inhibitor, 
ketoconazole, results in a substantial pharmacokinetic interaction with CPT -11. The overall 
results indicate a significantly reduced formation of the principal oxidative metabolite APC 
by 87%, as well as highly increased (approximately 110%) circulating concentrations of the 
pharmacologically active metabolite, SN-38. The importance of CYP3A4 activity in CPT -11 
pharmacology is further substantiated by the finding that the interindividual variability in 
ielative exposure to SN-38 was reduced from 71.1% with CPT-11 administered alone to 
35.1% in the presence of ketoconazole. These data not only emphasize the need to consider 
the plausibility of kinetic interactions in the development of anticancer drugs, but also have a 
direct significant clinical relevance for treatment Vlith CPT -11. 
Clinically, the most important pathway of CPT -11 elintination consists of an esterase-
mediated hydrolysis of the bipiperidine moiety, leading to SN-38 (considered essential for 
antitumor activity) [7]. Subsequently, UDP glucuronosyltransferase (UGT) !AI mediates a~-
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glucuronic-acid conjugation, forming SN-38G [7], a metabolite that may play a principal role 
in the occurrence of CPT -11-induced diarrhea [29]. The previous recognition that CPT -11 is a 
substrate of CYP3A4 is a salient finding, since it makes the agent potentially subject to a host 
of enzyme-mediated drug interactions, even with commonly prescribed mediation [18]. For 
example, the prototypical CYP3A4 inhibitor troleandromycine inhibits the conversion of 
CPT-11 into APC in vitro almost completely [18], which is consistent with our current in vivo 
findings (see http://W\VVI.georgetown.edu/departments/pharmacology/davetab. html for an up 
to date CYP drug interaction table). In addition. both loperamide and racecadotril inhibit APC 
formation by more than 50%, whereas ondansetron causes inhibition by >25% [18], 
suggesting that some degree of interaction is to be expected with simultaneous administration 
of these agents with CPT-11. 
The CYP3A4-mediated metabolism of CPT-!! has until now received little more than 
cursory interest from both pharmacologists and oncologists, most likely because the 
contribution of this pathway to overall elimination of CPT -ll is rather low [1 0]. and in view 
of the fact that oxidative metabolism of CPT -11 is generally considered an efficient 
detoxification route [!8]. The current observation that inhibition of CYP3A4-mediated 
metabolism of CPT -11 leads to an induced carboxylesterase-mediated hydrolysis to form SN-
38 was rather unexpected, and in order to discriminate between increased formation and 
reduced elimination of SN-38 as the principal mechanism underlying this phenomenon, 
several additional in vitro experiments were performed. By measuring carboxylesterase 
activity in plasma of patients, ketoconazole was found to have no inducing effect on 
circulating enzyme levels that might explain the increase in relative exposure to SN-38. 
Similarly, ketoconazole had no effect on SN-38 biotransformation in human liver 
microsomes, in contrast to a previous observation suggesting prominent CYP3A4-mediated 
oxidation of SN-38 to a polar. currently unidentified compound [24]. Our in vitro data 
obtained in the Caco-2 cell monolayers suggest that ketoconazole might interfere with active 
drug transport mediated by P-glycoprotein, which is consistent with previous observations 
that ketoconazole is a (poor) inhibitor of P-glycoprotein [28]. In our patients. we observed 
that co-administration with ketoconazole had a marked effect on the fecal elimination of both 
APC and SN-38. However, the similarity of the terminal disposition phases in plasma of both 
metabolites between treatment courses indicates that the increased fecal excretion ofSN-38 in 
the combination courses is unlikely related to diminished (P-glycoprotein-mediated) biliary 
secretion. Collectively, these findings suggest that the pharmacokinetic interference described 
here appears to be the result of inhibition of one of two competing enzymes involved in 
(hepatic) CPT-!! metabolism, which results in shunting of parent drug to SN-38. 
As mentioned previously, various classes of enzymes are involved in CPT-11 
metabolism, and variability in the expression of each of these will contribute to variability in 
drug handling between patients. In addition, this variability is further influenced by the 
recognition that polymorphic drug-metabolizing enzymes (e.g., UGTlAl [30]) exist that can 
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alter drug disposition. Recent studies have sho'Nn that determination of individual UGTIAl 
genotypes for CPT -11 treatment alone is clearly insufficient in predicting clinical effects [31 ]. 
In view of our current observation that CYP3A4-mediated metabolism of CPT-II might be 
more important than held previously, we have recently initiated a prospective trial to 
corroborate the usefulness of gene diagnosis of UGTlAl in combination with CYP3A4 
polymorphism prior to CPT -11 chemotherapy. In addition, because CYP3A5 represents at 
least 50% of the total hepatic CYP3A content in people polymorphically expressing CYP3A5, 
this isozyme may be the most important genetic contributor to interindividual and interracial 
differences in CYP3A-dependent drug clearance and in responses to many agents [32]. In this 
context, it is of particular importance, however, that recent data indicate that the metabolism 
of CPT -11 by CYP3A5 was markedly different because, in contrast to CYP3A4, no APC was 
formed, whereas a new metabolite was formed by de-ethylation of the camptothecin moiety 
[33]. 
Clinically we found no statistically significant difference in hematologic toxicity and 
non-hematologic toxicity between the treatment courses, in spite of the reduced CPT-11 dose 
in the presence of ketoconazole, which might be explained by the increased exposure to SN-
38. Previously, the idea of intentionally adding ketoconazole to systemic treatment with 
CYP3A4 substrate drugs (e.g. cyclosporin A) for the purpose of decreasing toxicity and costs 
through a reduction in dosage regimens has been put forward [34]. However, before taking 
advantage of the metabolic interaction bernreen ketoconazole and CPT -11 described here to 
supply the two drugs as a unique preparation for clinical use, a number of important questions 
need to be solved. Most importantly, it is not yet kno\Vll whether systemic circulating 
concentrations of SN-38 have any predictive ability toward antitumor activity. In fact, recent 
data from a study of CPT -11 administered in combination with cyclosporin A (a competitive 
inhibitor of CYP3A4) and phenobarbital (an inducer of UGT!Al) suggest responses to 
treatment in patients with metastatic colorectal and esophageal cancer without any significant 
diarrhea, despite a very low exposure to SN-38 [35]. This finding supports the hypothesis that 
intratumoral hydrolysis ofCPT-11 by carboxylesterases may be more important than plasma 
concentrations ofSN-38 [36,37]. This suggests that the concept of using intentional CYP3A4-
mediated interactions with CPT -11 therapy may substantially deteriorate overall antitumor 
activity. 
In conclusion, ketoconazole considerably increased the plasma concentrations of the 
pharmacologically active CPT-II metabolite (SN-38), as a result of inhibition of CYP3A4-
mediated biotransformation. Concomitant use of CPT -11 with ketoconazole or other potent 
substrates or inhibitors of CYP3A4 can potentially result in fatal outcomes, and up to 4-fold 
reductions in CPT -11 dose are indicated. 
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Purpose: To investigate the feasibility and the phannacokinetics of CPT -II administered 
iv once every three weeks with the orally administered farnesyltransferase inhibitor Rll5777 
bid in different schedules. 
Patients and methods: At the frrst dose level Rll5777 was administered continuously, 
but starting at day 3 in the first cycle, enabling pharmacokinetic interaction assessment. In the 
second part of the study intermittent administration of Rl!5777 was assessed. The dose of 
both drugs was escalated, for CPT-11 up to the recommended single agent dose, 350 mg/m2 
once every three weeks, and for Rll5777 up to dose limiting toxicity. Phannacokinetics were 
performed during the first t\vo cycles. 
Results: Twenty-nine patients with a median age of 52 years (range 34-75), median 
ECOG-PS I (range, 0-1 ), received I 04 cycles. The combination was tolerated reasonably well 
up to the level of CPT-II 350 mg/m2 with continuous R!l5777 200 mg bid. The toxicities 
most frequently observed were leucopenia and neutropenia. The frequency and severity of 
nausea, vomiting and diarrhea seemed to parallel those of single agent CPT -11. At the 
continuous Rll5777 schedule, the area under the curve (AUC) of SN-38 in the second cycle 
was significantly higher than in the first cycle (p~0.0211), as was the AUC of CPT-11 
(p~0.0335). Because of clinical and phannacokinetic findings, the administration ofR1!5777 
was changed from continuous to intermittent dosing in the second part of the study. In 
contrast to the continuous Rl15777 dosing, the AUC of SN-38 and CPT-11 did not alter with 
intermittent Rll5777 dosing (p~0.0758). Fatigue was more pronounced in the patients treated 
in the continuous schedule than with the intermittent schedule. Currently, the combination 
with escalating doses of intennittent Rll5777 bid is under investigation. 
Conclusions: Although the MTD has not yet been reached, the combination therapy of 
CPT-11 at its full single agent dose with either continuous Rll5777 200 mg bid or 
intermittent Rll5777 300 mg bid is feasible. Continuous dosing of R115777 does influence 
the disposition of CPT-11, although the clinical relevance of this observation has not been 
resolved. 
Introduction 
Improved understanding of the signal transduction pathways has resulted in identification 
of various potential therapeutic targets [1-3]. Among these are the Ras-proteins that are 
synthesized as cytosolic precursors that attach to the membrane to transmit signals. This 
attachment depends on the addition of a 15-carbon famesyl group to Ras, which reaction is 
catalyzed by the enzyme farnesyltransferase [4,5]. Farnesyltransferase inhibitors (FTI), such 
as the nonpeptidomimetic competitive agent Rl15777, were specifically developed to 
decrease Ras processing and subsequently downregulate transduction of proliferative signals 
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[6-8]. Other studies have suggested that FTI's might also involve other famesylated 
polypeptides including RhoB [9,10], Lamin B, and centromere-associated protein pathways. 
Regardless of the mechanism of action ofFTl's, it is clear that R115777 has shown evidence 
of anti-tumor activity in vitro and in vivo [11]. Anti-tumor effect has also been observed in 
clinical studies with different schedules of oral R115777 [12-14]. 
CPT-11, a water soluble derivative of camptothecin, is currently registered for use in 
patients with metastatic colorectal cancer refractory to 5-fluorouracil therapy as well as first 
line therapy, and has shovvn clinical activity against several other types of solid tumors 
[15,16]. CPT-11 itself has weak, if any, pharmacologic activity in vitro and is thought to exert 
its antitumor activity in vivo following enzymatic cleavage by a carboxylesterase (CE) that 
generates the active metabolite, SN-38, which is at least 100-fold more cytotoxic than CPT-II 
[17]. Peripheral converting enzyme activity in animals has been characterized in serum [17], 
liver [18] and the small intestine [19], and preliminary evidence indicates CE activity within 
the tumor as well [20-22]. SN-38 can be metabolized very efficiently further by UDP 
glucuronosyltransferase !AI [23] and IA7 [24] to an inactive ~-glucuronide derivative, SN-
38G [25,26]. Another metabolic pathway of CPT -II consists of a cytochrome P-450 3A4 and 
3A5-mediated oxidation of the hi-piperidine side-chain attached to the core structure [27-29]. 
The main metabolites resulting from this pathway have been identified as APC [30] and NPC 
[31] and are inactive. 
Given the distinctly different mode of action of Rl15777 and CPT -11, and the need for 
more efficacious treatment of ( colorectal) cancer, a strong rationale exists for investigating a 
CPT-11 based regimen in combination with R115777. In this report we present data on 
tolerance and pharmacokinetics of Rll5777, CPT-I! and its metabolites, in patients who 
were treated in a phase I dose finding study with oral Rll5777 bid, in combination with 
intravenous CPT -11, given once every three weeks. 
Patients and Methods 
Eligibility Criteria 
Patients with a histologically or cytologically confirmed diagnosis of cancer refractory to 
standard therapy or for whom other treatment options were not available, were eligible for the 
present study. Additional eligibility criteria included: age at least 18 years; Eastern 
Cooperative Oncology Group (ECOG) performance status :51 and adequate unassisted oral 
intake; no previous treatment with antineoplastic agents for at least 4 weeks (or 6 weeks in 
case of nitrosoureas or mitomycin C) and no more than one prior chemotherapy regimen of 
treatment for advanced disease; no prior treatment with CPT -11 or other topoisomerase I 
inhibitors; no known diagnosis of Gilberts syndrome; no prior extensive radiotherapy defined 
as > 25 % of the total bone marrow; adequate hematopoietic (WBC count > 3.5 xI 09 /L, and 
platelet count> 100x109/L), renal (serum creatinine concentration :51.5 x upper normal limit), 
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and hepatic function (total serum bilirubin :>1.5 x upper normal limit, and aspartate 
aminotransferase [ASAT] and alanine aminotransferase [ALAT] concentrations :>2.5 x upper 
normal limits, s;,5 x upper normal limits in case of liver metastases. The clinical protocol was 
approved by the Rotterdam Cancer Institute Ethics Board, and all patients signed informed 
consent before study entry. 
On-Study and Follow-up Investigations 
Patients underwent a complete physical examination at enrollment and prior to every new 
CPT -11 administration. At these visits, ECOG performance status and weight were recorded. 
Determination of hematologic parameters (i.e., full blood count with white blood cell 
differential) and clinical chentistry analyses (i.e., electrolytes, creatinine, calcium, random 
glucose, albumin, phosphate, urea, uric acid, total protein, triglycerides, total cholesterol, 
bilirubin, alkaline phosphatase, ALAT, ASAT and lactate dehydrogenase) were performed 
weekly. ECG was performed before study entry and during treatment only if clinically 
indicated. Ophthalmological examination was performed before study entry and after each 
even-numbered cycle. Tumors were assessed radiologically before patients were enrolled on 
the study, and after every even-numbered cycle. 
Pharmaceutical Preparation and Drug Administration 
Vials that contained 40 or 100 mg of CPT-11 (as a hydrochloride trihydrate form) 
formulated as a concentrated sterile solution (active drug concentration, 20 mg/rnL) in d-
sorbitol and a lactic acid-sodium hydroxide buffer system of pH 3.5-4.5 were obtained from 
Aventis (Hoevelaken, the Netherlands). The CPT-11 dose was administered as a 90-ntin i.v. 
infusion, after dilution of the pharmaceutical preparation in 250 rnL of isotonic sodiwn 
chloride. In all patients, premedication consisted of ondansetron 8 mg i.v. combined with 
dexamethasone 10 mg iv, both administered 30 min before the start of chemotherapy. 
Rll5777 was provided by Janssen Research Foundation (Beerse, Belgium) as 100 mg 
capsules, that were stored at a dry place between 15-25 °C. The drug intakes were seperated 
by intervals of 12 hours, immediately after a meal. 
Study Design 
This is a phase I dose finding study of Rll5777 in combination with CPT -11 in patients 
with cancer. The dose escalation schemes for Rll5777 and CPT-11 were defmed before start 
of the study. R!l5777 was started at 300 mg bid which is the recommended single agent dose, 
with an escalating scheme for CPT -11. CPT -11 was administered once every three weeks and 
was started at 200 mg/m2 and escalated in steps of 50 mg/m2 to the maximum tolarable dose 
as a single agent, 350 mg/m2 In case the latter dose of CPT -11 would be reached further 
escalation ofR115777 would take place in steps of 100 mg bid. 
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At the first cycle the patients started with CPT-!1 at day I and with Rll5777 at day 
three, to enable pharmacokinetic interaction assessment. R115777 was administered 
continuously there after. Dose escalation was performed based on toxicity and 
pharmacokinetics. For safety, the next dose level was not opened until at least 3 patients were 
assessable for the first cycle in the preceding cohort. In case only one patient developed dose-
limiting toxicity (DLT), the dose level was expanded with another 3 patients to a total of 6. In 
case less than 2 of 6 patients experienced DLT, or no DLT was observed, the dose level for 
the next patient cohort was established based on both clinical toxicity and pharmacokinetic 
data observed at the previous dose level. 
Because of unacceptable toxicity observed in the very first patient, the dose ofR115777 
was lowered according to the protocol to 200 mg bid, administered continuously. As 
described in the results paragraph the schedule ofR115777 was changed by an amendment to 
intermittent administration, consisting of bid administration for 14 out of21 consecutive days, 
starting in the first cycle at day 3. In the second and following cycles Rll5777 was started at 
day I, concomitant with CPT-II. 
Toxicity Evaluation 
Toxicity was assessed by the NCIC Expanded Toxicity Criteria. Dose Limiting Toxicity 
(DLT) was defined as: I) grade 4 hematologic toxicity, provided neutropenia lasted more than 
7 days and/or was associated vvi.th fever. 2) Non-hematological grade 3 with the exception of 
untreated nausea and vomiting. 3) a treatment interruption of more than three weeks due to 
toxicity. Only events which occured during the frrst cycle of protocol treatment were taken 
into consideration in defining DLT. 
In case DLT was reached in ~ 2 of 3 or~ 2 of 6 patients, dose escalation was ceased, and 
the dose level defined as maximum tolerable dose (MTD). Once the MTD had been 
detennined, intermediate dose levels could be studied. The recommended dose was defined as 
one dose level below the MTD. 
Response Evaluation 
Tumor response definitions were based on the WHO criteria (\VHO handbook for 
reporting results of cancer treatment, WHO, Geneva, 1979). 
Sample Collection and Handling. 
Blood samples for pharmacokinetic analysis were drawn from a vein in the arm opposite 
to that used for drug infusion, and collected in 10-mL glass tubes containing lithium heparin 
as anticoagulant during the first and second cycle. Samples on day one were obtained at the 
follovvi.ng time points: before drug administration; at 1, and 1.5 h (during infusion); and 2, 2.5, 
3, 4, 7, II, 24, and 48 hours after the start of the drug administration. On day 8 blood samples 
for pharmacokinetic analysis were collected in 5-ml glass tubes containing also lithium 
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heparin as anticoagulant. Samples on day 8 were obtained at the following time points: prior 
to oral drug administration, and at 1, 2, 3, 5, 8, and 12 hours (before the next oral drug 
administration). Blood was immediately processed to plasma by centrifugation for 5 min at 
2500 rpm (4°C), which was then stored at -80°C until the time of analysis (see below). 
Analytical methods 
Plasma samples were assayed for total drug forms (i.e., lactone plus carboxylate) ofCPT-
11 and SN-38 according to a validated reversed~phase high-performance liquid 
chromatographic (HPLC) method reported previously [32]. Briefly, 250-fll aliquots of plasma 
were acidified with 500 fll of a mixture of methanol-5% (w/v) aquesous perchloric acid, to 
enable simultaneous measurements of total drug. The samples were rocked on a multi tube 
vortex-mixer for 5 min, followed by centrifugation at 24,000 x g for 5 min (4°C). The clear 
supernatant from the extracts was diluted with methanol-0.1 M ammonium acetate containing 
10 mM tetrabutylanunonium sulphate (3:7, v/v), adjusted to pH 5.3 with hydrochloric acid. 
The diluted extracts were transferred to limited-volume inserts, and 1 00-).tl aliquots were 
injected into the HPLC system. Fluorescence detection was performed at excitation and 
emission wavelengths of 355 and 515 nm, respectively. The determination of each compound 
was based on chromatographic retention times and peak area measurements in comparison 
with injected standards, typically over a range of 0.5 to 200 ng/rnl. Calibration cuurves were 
prepared in drug-free human plasma and fitted by a least-squares regression function with 
proportional weighting using an Excel macro. The percentage deviation from nominal values, 
and the inter- and intra-assay precision for each compound were always less than 12%. 
Plasma samples were also analyzed for the presence of unchanged Rll5777 using a 
reversed-phase HPLC method, as described elsewhere 12. Prior to analysis, plasma samples 
were alkalinized using 0.1 M sodium hydroxide, and extracted with a mixnrre of heptane-
isoamyl alcohol (9:1, v/v). The chromatographic peak of Rll5777 and the internal standard 
Rl21550 were detected using UV absoprion measurements at 240 nm. 
Pharmacologic Data Analysis 
Concentration-time data of CPT -II were analyzed using the software package Siphar 
v4.0 (lnnaPhase, Philadelphia, PA), by determination of slopes and intercepts of the plotted 
curves with a tri-exponential function, as described [33]. The area under the plasma 
concentration versus time curve (AUC) was estimated from time zero to infinity based on the 
best fit curve, and was used to calculate clearance (CL) and steady-state volume of 
distribution (Vss) using standard equations. The terminal disposition half-life (Tuo) was also 
calculated on the basis of the best fitted curve using the same program. Pharmacokinetic data 
of SN-38 were determined using model-independent analysis based on the trapezoidal rule. 
The relative extent of conversion (REC) of CPT-II to SN-38 was calculated for each 
pharmacokinetic curve using the formula AUCs~.Js/AUCcPT-11 x 100%. 
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Plasma concentration-time profiles of Rll5777 were analyzed by standard 
noncompartmental methods using the sofuvare package Wiru"'Jonlin (Pharsight, Mountain 
View, CA). The following pharmacokinetic parameters were calculated: mmcimum plasma 
concentration (Cmu.x), time to maximum plasma concentration (tmax), trough plasma 
concentration (Coh), and area under the plasma concentration versus time curve over a 12-hour 
dosing interval calculated by trapezoidal summation (AUC12h). Because the pharmacokinetic 
profile ofRll5777 is biphasic, initial (T112 dominant) and terminal half-lives (T112 terminal) 
were estimated by linear regression of the log-transformed concentration versus time data. 
The accumulation ratio was calculated by dividing the AUClZh determined on day 8 by that of 
day l. 
Statistical considerations 
Phannacokinetic parameters for all compounds are reported as mean values ± standard 
deviation. Variability in parameters between the various CPT-11 and Rll5777 dose levels 
was evaluated by one-way analysis of variance to determine potential group differences. 
Interpatient difference in kinetics were assessed by the coefficient of variation, expressed as 
the ratio of the standard deviation and the observed mean value. Potential differences in 
phannacokinetic data from each patient between the two evaluable courses were assessed 
using a paired two-tailed Student's t-test. In addition, patients were also ranked in two cohorts 
with Rl15777 given either on an intermittent or continuous schedule, and analyzed for 
differences in kinetic parameters by an unpaired Student's !-test. Probability values (two-
sided) of less than 0.05 were regarded as statistically significant. All statistical calculations 
were performed using NCSS v5.X (J.L. Hintze, East Kayesville, UT; 1992). 
Results 
Patients and Treatment 
A total of 29 patients were eligible and entered the study. The patients in the CPT -11 350 
mg/m2 and Rll5777 400 mg bid cohort are still under treatment and the pharmacokinetics are 
still being processed, and therefor not considered in the results. 
The median age of the patients was 52 years (range, 34-75), and there were 16 male and 
13 female patients. All patients had a ECOG-PS 0-l. The predominant tumor type was colon 
cancer (15) while 8 patients had other gastrointestinal tumors (esophagus, pancreas, 
duodenum) and 6 had Adeno Carcinoma of Unknown Primary (ACUP). Four patients 
received one cycle of the combination regimen only. Therefore their pharmacokinetic results 
are not evaluable. The number of patients at each dose level are listed in Table I. 
The first patient at the first dose level of CPT-11 200 mg/m2 and R115777 300 mg bid 
developed grade 3 fatigue with severe weight loss, and was admitted to the hospital for 
intravenous rehydration. It was decided, also in view of the toxicity profile of Rll5777 in 
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other ongoing studies, to decrease the starting dose of Rll5777 to 200 mg bid according to 
the protocol. Four dose levels of CPT-11 were explored (200, 250, 300, 350 mg/m2) 
combined with fixed Rll5777 200 mg bid continuously administered (Table 1). 
Table 1. 
Dose levels 
Level CPT 11 R115777 No. patients No. Cycles 
mg/m2 mg bid Cll* (range) 
A 200 200C 4 (lx NE) 12 (2-6) 
B 250 200 c 4 (lx NE) 7 (1-4) 
c 300 200 c 3 16 (2-10) 
D 350 200 c 6 25 (1-6) 
E 350 200 I 6 22 (2-1 0) 
F 350 300 I 6 22 (2-5) 
G 350 400 I ongoing Ongoing 
* C - continuous 
I = intermittent 
During the study the administration schedule ofR115777 was amended to an intermittent 
schedule, based on pharmacokinetic data which revealed a pharmacokinetic interaction 
between Rll5777 and CPT-11 (to be discussed below). To investigate the impact on the 
pharmacokinetics of the change in the schedule, it was decided that at the dose of Rl I 5777 
200 mg bid and CPT-11 350 mg/m2, both the continuous and the intermittent administration 
were to be explored, although no formal DLT was observed in the continuous dosing 
schedule. However, continuous dosing in subsequent cycles seemed impossible with this 
schedule, since in three patients treated with continuous Rll5777 at this level, subsequent 
doses of CPT -11 had to be reduced because of delayed recovery from hematological toxicity. 
Further escalation ofRI 15777 was pursued in the intermittent schedule only, with 300 mg bid 
and 400 mg bid. 
Toxicity profiles 
A total of 104 treatment cycles were given, with a median of 4 cycles (range 1-1 0) per 
patient. The main hematological toxicities observed were leucopenia and neutropenia (Table 
2). CPT -I I could be escalated up to 300 mg/m2 without occurence of DLT in the first cycle. 
One patient treated at the dose level of CPT- I I 300 mg/m2 and Rll5777 200 mg bid 
developed grade 4 leuco- and neutropenia complicated by fever in the second cycle, and was 
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At the CPT-11 350 mglm' with Rll5777 200 mg bid continuous dose level, one patient 
developed a grade 4 leuco-, neutro- and thrombocytopenia in the first cycle, qualifying for 
DLT. Remarkably a 4.5-fold higber AUC ofR115777 compared to previously treated patients 
at this dose level was found in this patient, which could have been explained by an overdose 
ofR115777. The patient however denied having taken all the Rll5777 at once, but (althougb 
he stopped early in the cycle) could not return the remaining tablets to us. The question 
remained unresolved. Having observed DLT, the dose level was expanded with three patients 
and no further DLT was observed. However continued dosing in subsequent cycles seemed 
impossible with this schedule, since in three patients treated with continuous Rll5777 at this 
level, subsequent doses of CPT -11 had to be reduced because of delayed recovery from 
hematological toxicity. 
The next dose level to be studied was CPT-11 350 mg/m2 with Rll5777 200 mg bid 
intermittently administered. One patient experienced DLT by grade 4 leuco-neutropenia in the 
first cycle, complicated by an E. Coli sepsis. The patient continued on single agent CPT-I I. 
Three additional patients were treated at this dose level without the occurrence ofDLT. 
At the dose level studying CPT -11 350 mg/m2 in combination with Rll5777 300 mg bid 
intermittent, hematological toxicity never exceeded grade 3 in the first cycle in the first three 
patients. Given the fact that CPT-11 was administered at its full single agent dosel5 in 
combination with what seemed to be the recommended single agent dose of Rll5777 if 
administered continuously, it was decided to expand this cohort to six patients. Only one out 
of six patient developed a grade 4 neutropenia in the second cycle, whereas all the other 
cycles in this cohort (22 cycles) but two could be administered at full dose intensity. Since no 
MTD was established further escalation of Rll5777 was performed according the protocol, 
and is currently ongoing. 
Table3. 
Non hematologic toxicity, worst per patient, all cycles 
Level Nausea Vomiting Diarrhea Fatigue 
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 
A 2 1 1 1 1 1 
B 1 2 1 2 1 2 1 1 1 
c 2 1 1 1 1 1 1 
D 1 2 1 1 2 1 1 2 1 2 
E 2 2 1 2 1 1 2 1 1 2 
F 3 3 1 3 2 2 2 1 I 1 
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Overall, leuco- and neutropenia was observed more frequent in the second cycle 
compared to the first cycle. Thmmbocytopenia exceeding gtade 2 was only observed 
coinciding with neutropenic fever (Table 2). No platelet transfusions were necessary. 
The main non hematological toxicity (Table 3) observed was fatigne. Especially in the 
continuous Rll5777 schedules cumulative fatigue was observed in 7 out of 17 patients. One 
patient was taken off study because of grade 3 fatigue in the second cycle, and returned the 
normal activity in approximately three weeks after stopping R115777, after which CPT-11 
mono-therapy was restarted. This patient did not develop the severe fatigue while on single 
agent therapy, and experienced a partial response. In another patient who developed grade 3 
fatigue R115777 was also interrupted, and after cessation of this toxicity single agent CPT-11 
was started. However, this patient developed the same fatigue with single agent CPT -11 as 
with combination therapy. Both patients did not show deviant pharmacokinetics. It is of 
particular interest that in patients receiving R115777 in the intermittent schedule, fatigue 
never exceeded grade 2. 
Other types of non-hematological side effects (nausea, vomiting, diarrhea and alopecia) 
were not severe (Table 3) and in line with what can be expected of single agent CPT -1116. 
The administration of R115777 did not influence the incidence or severity of these side 
effects. In all the combination therapy was tolerated remarkably well. 
Antitumor activity 
Two confirmed partial responses were observed (papilla Vateri carcinoma 27 weeks, 
AClJP 12 weeks), and another seven patients experienced a prolonged stabilization of their 
disease (range !2-30 weeks). 
Plasma disposition 
The plasma concentration-time profiles of each compound (CPT-II, SN-38 and 
Rll5777) were similar for all patients studied, with representative examples shown in Fignre 
!. The pharmacokinetics of unchanged CPT -I! could be best described with a three-
compartment model. The kinetic parameters obtained by means of this model are presented in 
Table 4. Over the various dose ranges studied, the AUC and the peak plasma concentrations 
of CPT -11 increased in proportion with dose, indicating a linear and dose-independent kinetic 
behavior. In addition, substantial interpatient variability in parameters was observed (>2-
fold), consistent with previous findings, although mean values were strongly correlated to 
dose, and no significant differences in dose-normalized parameters were observed between 
the CPT-11 dose levels (p~0.4268). Similarly, Rll5777 dose had no effect on CPT-11 
clearance during the first (p~0.2938) or second cycle (p=0.9658). 
In the absence ofR115777 (in the first cycle), CPT-I! and SN-38 pharmacokinetics were 
very similar to previously reported single agent data, with a mean clearance of the parent drug 
!6! 
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of 18.5±4.59 Llh/m2 and a moderate degree of interpatient variability of 24.8%, and a mean 
REC value of 1.73±0.796% [34]. 
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Plasma concentration versus time profiles of CPT-11 and SN-38 from 2 
representative patients treated with CPT-11 at an i.v. dose of 350 mglm:2 as a 
90-min infUsion either given alone (cycle 1) or in combination with a 300-mg 
bid oral dose ofRIJ5777 (cycle 2) given on a continuous (A) or intermittent (B) 
dosing regimen. CPT-11 (circles) and SN-38 (squares): data from course 1 are 
indicated by closed symbols and data from course 2 by open symbols. 
In the group of patients treated with the combination with Rl15777 administered on a 
continuous schedule, CPT~ 11 clearance in the second cycle was slightly reduced as compared 
to the control (p=0.0335). The REC value was unchanged in this group (p=0.1155), whereas 
the AUC ratio of SN-38 was increased by ahnost 40% (p=0.0211), suggesting that the 
increased exposure to SN-38 in the presence of continuous dosing ofR115777 was related to 
an alteration of CPT-11 disposition and not on SN-38 formation or elimination rate. After 
changing RI!5777 administration to an intermittent schedule, this kinetic alteration was no 
longer observed, and both CPT-II clearance (p=0.0976) as well as the AUC ratio of SN-38 
(p=0.0758) were not significantly different between treatment cycles (Table 4). 
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Table 4. 
Summary of CPT-II pharmacokinetics (mean±S.D.) 
Parameter Day I Day21 difference* 
continuous (n~J4) 
CL (L'h/m2) 17.6±4.42 15.4±3.73 2.14±0.901 
MRT(h) 8.59±1.91 10.4±3.91 -L82±L18 
Vss (L/m2) 149±42.9 158±67.9 -9.64±15.6 
Tw (h) 16.7±13.7 16.3±10.5 0.396±2.24 
AUCcPT-11 ratio L14±0.200 
AUCsN-3S ratio !.39±0.4!2 
REC(%) 1.92±0.975 2.19±1.04 0.268±0.159 
intermittent (n= 12) 
CL (Lih/m2) 19.7±4.70 !7.8±4.25 1.83±1.01 
MRT(h) 8.78±2.37 8.79±!.71 -0.018±0.64 
Vss (L/m2) 175±8!.7 !55±42.1 20.5±16.55 
T112 (h) 15.4±7.85 12.7±2.22 2.77±2.06 
AUCcPT-tl ratio L12±0.221 
AUCsN-38 ratio 1.22±0.345 
REC(%) 1.51±0.468 1.69±0.743 -0.178±0.!38 


























Abbreviations: CL, total plasma clearance; :MRT. mean residence time; Vss, volume of 
distribution at steady-state; Tuz, terminal disposition half-life; AUC, area under the plasma 
concentration versus time curve; REC, relative extent of conversion; 95%C.L., 95% confidence 
limits for the mean difference; p, probability value from a paired two -tailed Student's t-test 
* mean difference with standard error. 
The phannacokinetic behavior of Rll5777 was also very similar to previously reported 
single agent data [12] (Table 5). In all patients with two phannacokinetically evaluable 
treatment courses (n=lS), the mean peak plasma concentration and AUC ratios betv.reen the 
courses were 1.05±0.73 (p~0.4977) and 1.02±0.58 (p~0.9960), respectively. This suggests 
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Abbreviations: Co, trough concentration; T max, time to peak concentration; C=."' peak plasma 
concen-tration; AUC, area under the plasma concentration versus time curve; NA, not available 
due to missing data in 6 patients due to HPLC assay sensitivity limitations (<1.0 ngfml). *ratio is 
d8 I dl; ** combined data from patients treated with either the continuous or intermittant 
schedule. 
Discussion 
This phase I study was performed to assess the safety and toxicity profile, and to 
determine the MTD of a combination of the farnesyltransferase inhibitor R115777 and CPT-
I L In addition potential pharmacokinetic interaction between the two compounds was 
investigated. In this interim analysis DLT has not yet been reached, and consequently MTD 
has not yet been defined. 
This study started at continuous dosing of300 mg R115777 bid with 200 mg/m2 CPT-11. 
Based on toxicity from the first patient only it was decided to taper the dose of R115777 to 
200 mg bid. Subsequently escalation of CPT -11 in steps of 50 mg/m2 was performed 
according to the protocol, and toxicity was only mild. Even at CPT -11 recommended single 
agent dose, 350 mg/m2, the schedule was tolerated quite well. We did however observe that 7 
out of 17 patients developed cumulative fatigue in this group of patients that were treated with 
continuous dos:ing of R115777. Fatigue was also reported in other studies with single agent 
R115777 [12-14], but is also observed in patients being treated with single agent CPT-11 
[15]. Of interest in this is the observation made in the two patients that developed fatigue and 
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discontinued Rll5777. After cessation of fatigue, both were treated with single agent CPT-
11, and while one again experienced the same fatigue the other experienced none. In a 
simultaneous combination study with continuous dosing of R115777 however, cumulative 
fatigue was also observed [35]. This, in combination with the pharmacokinetic observation 
discussed later, prompted us to change the dosing schedule of Rll5777 from continuous to 
intermittent~ consisting ofR115777 dosing in 14 out of21 consecutive days. 
Formally the change from continuous to intennittent Rll5777 dosing was a reduction of 
the total amount of administered medication, and consequently the dose of Rll5777 ought to 
be escalated according to the protocol. However, by protocol amendment, first three patients 
were treated at this CPT-II 350 mg/m2 with Rll5777 200 mg bid, but now intermittent, 
which also gave the opportunity to compare pharmacokinetics between both the continuous 
and intermittent group of patients at the same dose of both drugs. One of these patients 
developed DLT, and the dose level was expanded to six patients. Of interest is that no 
cmnulative toxicity was observed at this dose level of the intermittent dosed group, and no 
cycle needed to be postponed. This in contrast to the patients that were treated with 
continuous Rll5777 with the same daily dose, in which three cycles had to be postponed and 
reduced. This could in theory be explained by the altered metabolism of CPT -11 as discussed 
later. Moreover, fatigue never exceeded grade 2 in the whole group of intermittent dosed 
Rll5777, in contrast to the grade 3 and 4 fatigue observed in the continuous dosed group. 
It is of importance to the interpretation of the pharmacokinetics, to consider the dosage 
schedules. All the patients received CPT -11 on day one in every cycle. All the patients started 
with Rll5777 at day three in the first cycle, but at day one in the second and following 
cycles. In the intermittent dosed group of patients however, Rll5777 was discontinued for 
one week before start of a new cycle, in contrast to the continuously dosed patients. 
Pharmacokinetics were performed during the first two cycles, and therefore the influence 
from R115777 on the metabolism of CPT-11 could be investigated, and vice versa the 
influence from CPT-11 on the kinetics ofR115777. The metabolism of CPT-II, expressed as 
the ratio of the AUC ofCPT-11 in the cycle combined with R115777 (second cycle) divided 
by the AUC ofCPT-11 in the cycle without Rll5777 (first cycle), was unaltered in both the 
continuous and intermittent dosing group (Table 4). The active metabolite SN-38 on the other 
hand was significantly increased in the continuous Rll5777 dosing group. Rll5777, inhibits 
CYP3A4 in vitro [36]. Unlike for the continuous dosing group, administration of CPT -11 in 
the intermittent dosing group is preceded in the second cycle by a 1 week wash-out from 
Rll5777. Therefore, it is possible that prolonged exposure to Rll5777 is needed to evoke a 
significant pharmacokinetic interaction. CYP3A4 inhibitors influence the metabolism of CPT-
11 by shifting the routes of metabolism to the carboxyl-esterase pathway, which ultimately 
leads to a decrease in the inactive metabolites APC and NPC in the plasma, and a increase of 
plasma SN-38 [37] (Table 3). Although in a rodent model chronic dosing of high 
concentrations of R115777 did not inhibit diagnostic enzymatic activities [38], it is well 
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knovm that animal models are not always representative for human metabolism. For instance, 
in an in vitro model, conversion of APC to SN-38 by rabbit liver CE has been described [39]. 
However, rabbit liver CE, though very similar to human liver CE with respect to amino acid 
sequence, is -100-fold more efficient in activating APC than the human enzyme in vitro [40]. 
Indeed, in vitro conversion of APC to SN-38 by human CE or human liver microsomes could 
not be demonstrated [30]. This could explain the difference in human and animal model 
phannacoldnetics, and the phannacokinetic interaction found in this study. Although some 
authors consider the plasma SN-38 as important considering anti-tumor activity, others stress 
that only intratumoral carboxyl esterase activity is of importance to the clinical efficacy 
[21,23,41]. This would consequently mean that only the plasma concentration ofCPT-11 is of 
importance, which in unaltered by the administration ofRII5777. 
We did however observe a significant change in AUC SN-38 between the first and the 
second cycle in the continuous treated patients, while at intermittent dosing with the same 
dosage of both drugs, the AUC SN-38 did not change. If we compare continuous to 
intermittent at the dose level of CPT -II 350 mg/m2 combined with Rll5777 200 mg bid, we 
observed enhanced clinical toxicity at the continuous dose level. Given the small number of 
patients the clinical relevance of this observation remains uncertain. Still. since the 
pharmacokinetic alterations match with the clinical observation, we recommend to combine 
these drugs in an intermittent schedule. Moreover, Rl15777 in combination therapy is 
frequently administered intermittently, although pharmacokinetic interaction has not been 
described before [35,42-45]. 
At the RII5777 300mg bid intermittent dose level, six patients were treated without 
DLT. In two patients cycles needed to be delayed. One of these patient showed early PD, 
while the other patient after one delayed cycle received another three cycles without further 
delay. Overall this schedule was well tolerated. Compared to both studies with single agent 
CPT-II and single agent Rll5777, toxicity of this combination therapy seemed not enhanced. 
Given the fact that this report is an interim analysis, definite conclusions can not be stated. It 
can be concluded from these data though, that CPT-II at its full single agent dose, 350 
mg/m2, in combination with either continuous RII5777 200 mg bid or intermittent RII5777 
300 mg bid is feasible. Given the clinical cumulative toxicity and the pharmacokinetic 
interaction observed between CPT-11 and continuously administered Rl15777, in 
combination with the ongoing discussion on the relevance of plasma SN-38 to antitumor 
activity, we clearly recommend to prescribe CPT-II and RII5777 intermittently in the 14 out 
of21 consecutive days schedule. Since CPT-II and Rll5777 have prominent different modes 
of action, and are clinically active, it is worth studying this combination regimen in phase 
11/lll studies once we have defined MTD. 
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Summary, conclusions and future perspectives 
This thesis includes phase I and pharmacological studies on topoisomerase I inhibitors 
and/or in combination with a famesyl transferase inhibitor, aminoglycoside antibiotic and 
CYP3A4 inhibitor. 
Topoisomerase I inhibitors are an important relatively new class of anti cancer drugs, 
-with a unique mode of action. Topoisomerase I is a nuclear enzyme involved in the 
replication of DNA, by forming a covalent binding -with DNA, the cleavable complex. 
Topoisomerase I inhibitors bind to the cleavable complex, resulting in a single strand DNA 
break, which ultimately leads to cell death. 
In Chapter 1 an overview of the current topoisomerase I inhibitors and possible ways to 
modulate these, are summarized. The topoisomerase I inhibitors reviewed in this paper are all 
semisynthetic analogues of camptothecin. We present preclinical and clinical data on 
camptothecin analogues that are already being used in clinical practice [i.e., topotecan and 
irinotecan (CPT-11)] or are currently in clinical development (e.g., 9-aminocarnptothecin, 9-
nitrocarnptotecin, lurtotecan, DX 895lf and BN 80915), as well as drugs that are still only 
developed in a preclinical setting (Silatecans, polymer-bound derivates) . A variety of 
different strategies is being used to modulate the systemic delivery of this class of agents, 
frequently in order to increase antitumor activity and/or reduce experienced side effects. 
Three principal approaches are being discussed, including (i) pharmaceutical modulation of 
formulation vehicles, structural alterations and the search for more water soluble prodrugs, (ii) 
modulation of routes of administration and considerations on infusion duration, and (iii) both 
pharmacodynamic and pharmacokinetic biomodulation. 
In Chapter 2 a method to determine liposomallurtotecan (1\'X211) in human plasma and 
urine is described. In the context of the following study, we developed sensitive RP-HPLC 
methods -with fluorescence detection using a sample clean-up procedure that disrupts the 
liposomes, thus enabling determination of total drug levels in plasma and urine samples 
following NX 211 administration. The methods have been validated in terms of sensitivity, 
accuracy and precision, and have been used in a pharmacokinetic experiment in a patient to 
investigate their applicability in vivo. 
Chapter 3 reports on the phase I open-label, dose-escalating ttial that was initiated to 
determine the maximum-tolerated and recommended dose, toxicity profile and 
pharmacokinetics of the liposomal topoisomerase I inhibitor, lurtotecan (NX 211) 
administered as a 30-minute IV infusion once every 3 weeks in cancer patients. Dose 
escalation decisions were based upon all toxicities during the first cycle as well as 
phannacokinetic parameters. Serial plasma, whole blood, and urine samples were collected 
for up to 96 hours follo'Wing the end of infusion and drug levels were determined by high-
performance liquid chromatography as described in the earlier chapter. 
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Twenty-nine patients received 77 courses ofNX 211 at six different dose levels ranging from 
0.4 to 4.3 mg/m2 Neutropenia and thrombocytopenia were the dose-limiting toxicities, and 
were not cumulative. Other toxicities, including nausea, vomiting and fatigue, were mild to 
moderate. Nine patients had stable disease while on treatment, whereas one of these with an 
adenocarcinoma ofunknovro origin (ACUP) had a significant regression just not reaching the 
criteria of partial response (PR). The systemic clearance of lurtotecan in plasma and whole 
blood was 0.82±0.78 and 1.15±0.96 Lih/m2, respectively. Urinary recovery (Fu) oflurtotecan 
was 10.1±4.05% (range, 4.9 to 18.9). In contrast to systemic exposure measures, the dose 
excreted in urine was significantly related to the percent decrease in neutrophil and platelet 
count at nadir (P<.OOOOl). The recommended dose for phase II studies is 3.8 mg/m2 once 
every three weeks. Pharmacologic data suggest a relationship betvveen exposure to lurtotecan 
and NX 211-induced clinical effects. 
In Chapter 4 the additional chromatographic peak observed in plasma samples of 
patients receiving NX 211 is described. We have isolated and purified this product by 
sequential solid-phase extractions, and report its structure and cytotoxiciiy relative to 
lurtotecan and related agents. NMR data indicate that cleavage of the piperazine moiety 
occurred at the N-C bond of the B-ring, yielding 7-methyl-10.11-ethylenedioxy-20(5)-
camptothecin (MEC). Tests of the growth inhibition potential ofMEC in 7 human tumor cell 
lines showed that the compound was approximately 2 to 18-fold more cytotoxic than 
lurtotecan, topotecan and SN-38. Subsequently, we found that MEC was the product of rapid 
photolysis of lurtotecan, with the rate of degradation inversely proportional to NX 211 
concentrations, and greatly depend on light intensity. Furthermore, rvffiC concentrations were 
found to significantly increase in plasma samples exposed to laboratory light, but not in 
blood. MEC was not produced from NX 211 in the presence of human liver microsomes, 
suggesting that is not a product of CYP P450 metabolism. Using a validated analytical 
method, trace levels of MEC were quantitated in blood samples of 2 patients. These 
observations confirm that the precautions for protection from light currently specified for 
preparation and administration of NX 211 dose solution are critical. Procedures to minimize 
formation of MEC, by the use of amber vials for NX 211 and by preparation of dilutions 
immediately before clinical use in a fashion totally protected from light, are now being 
routinely implemented. 
The high specificity in the mechanism of action of topoisomerase I inhibitors for the S-
phase in the cell cycle has led to the recognition that the compounds may require prolonged 
exposure to maximize the fractional cell kill. In this light we investigated extended 
metabolism of CPT-11 in Chapter 5. The active metabolite of CPT-11, SN-38, is either 
formed through enzymatic cleavage of CPT -11 by carboxyl esterases (CE) or through 
cytochrome P450 3A-mediated oxidation to NPC, and a subsequent conversion by CE. In the 
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liver, SN-38 is glucuronidated (SN-38G) by UGT!Al, which also conjugates bilirubin. 
Fourteen patients that were treated with 350 mg/m2 CPT-11 are described, and 
pharmacokinetic analysis was performed during a 500-h collection period. The half-life and 
area under the plasma concentration-time curve of SN-38 were found to be a 2-fold higher as 
compared to earlier reported estimates. As an explanation for this phenomenon, we noted 
substantial formation of SN-38 from CPT-11 and J'.'PC by plasma CE, consistent with the low 
circulating levels of NPC observed. In addition~ transport studies in Caco-2 monolayers 
indicated that non-glucuronidated SN-38 could cross the membrane from apical to basolateral, 
indicating the potential for re-circulation processes that can prolong circulation times. 
Interestingly, individual levels of fecal ~-glucuronidase, which is known to mediate SN-38G 
hydrolysis, were not related to any of the SN-38 kinetic parameters, suggesting that this 
enzyme does not play a role in SN-38 re-circulation. We have also found, in contrast to earlier 
data, that SN-38G/SN-38 plasma concentration ratios decrease over time from -7 (up to 50 h) 
to -1 (at 500 h). This decrease could be explained by the fact that glucuronidation ofSN-38 
and bilirubin is increasingly competitive at lower drug levels. In addition, no evidence was 
found for SN-38G transport through the Caco-2 cells. These findings indicate that until now 
the circulation time of SN-38 has been underestimated. This is of crucial importance to our 
understanding of the clinical action of CPT -11 and for future pharmacokinetic/pharmaco-
dynarnic relationships. 
lrinotecan (CPT-11) induced diarrhea is a frequent and often dose limiting toxicity in the 
treatment of colon cancer. Recently, it was suggested from animal models that ~­
glucuronidases produced by microflora in the large bowel may play a major role in the 
development of CPT -11-induced diarrhea by mediating hydrolysis of SN-38G to form the 
active SN-38. By eliminating the B-glucuronidases producing bacteria with an antibiotic, this 
hydrolysis could be blocked. The study described in Chapter 6 was designed to evaluate 
CPT -11 disposition and pharmacodynamics in the presence and absence of the broad-
spectrum antibiotic neomycin. Seven evaluable cancer patients experiencing diarrhea grade 
~ after receiving CPT-11 alone, received the same dose combined with oral neomycin at 
1000 mg t.i.d. (days -2 to 5) in the second course. Neomycin had no effect on the systemic 
exposure of CPT-11 and its major metabolites. However, it changed fecal ~-glucuronidase 
activity to undetectable levels, and decreased fecal concentrations of the pharmacologically 
active metabolite SN-38. Although neomycin had no significant effect on hematological 
toxicity, diarrhea ameliorated in 6 of 7 patients. Our findings indicate that bacterial ~­
glucuronidase plays a crucial role in CPT -11-induced diarrhea without affecting enterocycling 
and systemic SN-3 8 levels. 
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Chapter 7 describes a high-performance liquid chromatographic assay with UV 
detection that has been developed for the determination of ketoconazole in human plasma. 
Quantitative extraction was achieved by a single solvent extraction involving a mixture of 
acetonitrile-n-butyl chloride. Ketoconazole and the internal standard (clotrimazole) were 
separated on a column packed with lnertsil ODS-80A material and a mobile phase composed 
of water-acetonitrile-tetra-hydrofuran-anunonimn hydroxide-triethylamine. The column 
effluent was monitored at a wavelength of 206 nm Vlith a detector range set at 0.5. The 
calibration graph was linear in the range of 20-2000 ng/ml, with a lower limit of quantitation 
of 20.0 ng/ml. The extraction recoveries for ketoconazole and clotrimazole in human plasma 
were 93±9.7% and 83±10.0%, respectively. The developed method has been successfully 
applied to a clinical study to examine the pharmacokinetics of ketoconazole in a cancer 
patient. 
There is considerable motivation for understanding adverse drug interactions with 
anticancer agents because of their narrow therapeutic index and the numerous concomitant 
medications that are administered routinely or intermittently. Indeed, drug interactions Vlith 
anticancer agents are a major cause of morbidity and mortality in modem medical practice. 
The consequences of simultaneous treatment of CPT-11 Vlith a potent enzyme inhibitor, 
ketoconazole, in a group of cancer patients is described in Chapter 8. A total of 7 evaluable 
patients was treated in a randomized cross-over design with CPT -11 (350 mg/m2) given alone, 
followed 3 weeks later by CPT-!! (100 mg/m2) in combination with ketoconazole, or vice 
versa. Serial plasma, urine and feces samples were obtained and analyzed for CPT-!! and the 
metabolites SN-38, SN-38-G, NPC and APC. With ketoconazole co-administration, the 
formation of APC was reduced by 87%, while the relative exposure to the CE-mediated SN-
38 was increased by 110%. These metabolic alterations occurred Vlithout substantial changes 
in CPT-!! clearance and formation of SN-38G. In spite of the reduced dose in the 
combination course, no significant differences in toxicity profiles were noted. Parallel in vitro 
studies indicated that ketoconazole had no influence on circulating CE activity, or on 
CYP3A4-mediated SN-38 metabolism in hmnan liver microsomes. Overall, inhibition of 
CYP3A4 in cancer patients leads to significantly increased formation of SN-38 following 
CPT -11 administration. Simultaneous administration of various commonly prescribed drugs 
(either substrate or inhibitor of CYP3A4) can potentially result in fatal outcomes, and up to 4-
fold reductions in CPT-!! dose are indicated. 
Given the distinctly different mode of action of Rll5777 and CPT-!!, and the need for 
more efficacious treatment of ( colorectal) cancer, a strong rationale exists for investigating a 
CPT-!! based regimen in combination with Rll5777. In Chapter 9 we present a preliminary 
analysis of the clinical observations and pharmacokinetics of Rll5777, CPT-!! and its 
metabolites, in patients who were treated in a phase I dose finding study with oral Rll5777 
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bid, in combination with intravenous CPT -11, given once every three weeks. At the first dose 
level Rll5777 was administered continuously, but starting at day 3 in the first cycle, enabling 
phannacokinetic interaction assessment. In the second part of the study intermittent 
administration ofR115777 was assessed. The dose of both drugs was escalated, for CPT-11 
up to the recommended single agent dose, 350 mg/m2 once every three weeks, and for 
Rll5777 up to dose limiting toxicity. Pharmacokinetics were performed during the first two 
cycles. Twenty-nine patients with a median age of 52 years (range 34-75), median ECOG-PS 
1 (range, 0-1 ), received 104 cycles. The combination was tolerated reasonably well up to the 
level of CPT-11 350 mg/m2 with continuous R115777 200 mg bid. The toxicities most 
frequently observed were leucopenia and neutropenia. The frequency and severity of nausea, 
vomiting and diarrhea seemed to parallel those of single agent CPT-11. At the continuous 
Rll5777 schedule, the area under the curve (AUC) of SN-38 in the second cycle was 
significantly higher than in the first cycle (F0.0211), as was the AUC ofCPT-11 (p=0.0335). 
Because of clinical and pharmacokinetic fmdings, the administration of Rll5777 was 
changed from continuous to intermittent dosing in the second part of the study. In contrast to 
the continuous Rll5777 dosing, the AUC of SN-38 and CPT-11 did not alter with 
intermittent Rll5777 dosing (p=0.0758). Fatigue was more pronounced in the patients treated 
in the continuous schedule than with the intermittent schedule. Currently, the combination 
with escalating doses of intermittent Rl15777 bid is under investigation. Although the MTD 
has not yet been reached, the combination therapy of CPT -11 at its full single agent dose with 
either continuous Rll5777 200 mg bid or intermittent Rll5777 300 mg bid is feasible. 
Continuous dosing of R115777 does influence the disposition of CPT-11, although the 
clinical relevance of this observation has not been resolved. 
Topoisomerase I inhibitors are among the most promising new anticancer drugs that have 
been developed in recent years. Topotecan and CPT -11 are now registered for the treatment of 
ovarian and colon cancer, respectively. The unique mechanism of action on topoisomerase I 
and activity against a broad spectrum of other malignancies are an ongoing stimulus for 
further clinical development. With the growing knowledge on pharmacodynamics and 
phannacokinetics of the different topoisomerase I inhibitors, the poor water solubility and pH-
dependent reversible interconvention between the active lactone and inactive carboxylate 
form, as well as increase in activity or stability by substitutions to specific sites on the 
molecule, much effort has and will be done to increase antitumor activity of this group of 
drugs. Meanwhile pharmacological modulation, particularly of CPT -11, can be of interest to 
reduce toxicity and to influence metabolic pathways. In this light we currently investigate the 
clinical applicability of profYlactic treatment of irinotecan induced diarrhea by co-treatment 
with neomycin, in a double blind randomized multi-center study. 
Although much effort is being put into development of new analogues, the question to 
answer remains if drugs under development will ultimately lead to the theoretically expected 
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higher activity and/or reduced toxicity. Last but not least optimization of schedules. routes of 
administration and combination therapies will lead to numerous new studies in different 
twnor types. It is to be expected tbat in tbe future many new formulations and/or 
combinations will be developed. In contrast to other previously registered anticancer drugs, 
the pharmacological knowledge on how topoisomerase I inhibitors behave in humans will 
lead to a more logic and efficient development of these agents. 
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Samenvatting en conclusies 
Dit proefschrift bevat studies met topoisomerase I renuners, een relatief nieuwe groep 
antikanker middelen ( cytostatica) met een uniek werkingsmechanisme. 
Tumoren groeien per defmitie snel. Dit komt doordat de cellen waaruit de tumor is 
opgebouwd een hoge delingssnelheid hebben. Bij elke celdeling verdubbelt bet DNA zich 
ook. Het enzym topoisomerase I speelt een centrale rol bij de DNA replicatie. Door dit 
enzymatische proces te renunen, met een zogenaamde topoisomerase I renuner, wordt de 
DNA replicatie geblokkeerd. Hierdoor treedt er een DNA breuk op in de zich delende 
tumorcel, waardoor deze uiteindelijk te gronde gaat. Inmiddels hebben twee verschillende 
soorten topoisomerase I renuners een vaste plaats in de behandeling van kanker gekregen. 
Een hiervan is irinotecan (CPT-II, zie ook hoofdstukken 5, 6, 8 en 9) dat gebruikt word! voor 
de behandeling van dikke darm kanker 
Aile cytostatica, en dus ook topoisomerase I renuners, hebben naast het gewenste effect 
op tumorcellen ook ongewenste bijwerkingen op andere lichaamscellen, en wel het meest op 
snel delende cellen. Een bekend voorbeeld hiervan is kaalheid door haaruitval. Een ander 
voorbeeld zijn witte bloedcellen in bet been.merg die te gronde gaan, zodat er een tekort aan 
deze cellen ontstaat. Dit heeft tot gevolg dat de afweer van de patient tegen bacterHSle 
infecties, gedurende korte tijd, sterk afneemt. 
In hoofdstuk 1 wordt een overzicht gegeven van de op dit moment bekende 
topoisomerase I renuners die in klinische ontv.rikkeling en/of gebruik zijn. Wij beschrijven de 
farmaceutische modulatie van topoisomerase I renuners, waarbij door veranderingen aan de 
structuurformule stoffen als CPT -11 en lurtotecan zijn gevormd. Onder farmaceutische 
modulatie vallen ook de verschillende verpakkingsvormen, zoals bijvoorbeeld lurtotecan dat 
in een liposoom verpakt is, zoals beschreven in de hoofdstukken 2 tot 4. Vervolgens worden 
verschillende toedienings routes beschreven zoals een pil, zalf, infuusvloeistof alsmede 
verschillende toedienings schema's. Als laatste komt farmaco-kinetische en -dynamische 
biomodulatie aan de orde, ofvvel bet ingrijpen op de biologische omzetting van topoisomerase 
I renuners zoals die plaatsvindt in bet lichaam, waarvan de hoofdstukken 6 en 8 voorbeelden 
zijn. 
Hoofdstuk 2 beschrijft de methode waarmee het farmaceutisch gemoduleerde liposomaal 
lurtotecan (NX211) in bloed en urine door ons gemeten wordt. Ret is bekend dat langdurige 
blootstelling aan topoisomerase I renuners de anti-tumor activiteit doet toenemen. De 
genoemde topoisomerase I renuner zit verpakt in een liposoom, een soort vetdruppeltje, dat 
per infuus wordt toegediend. Het langzaam uit dit vetdruppeltje wegsiepelende medicijn zou 
de anti-tumor activiteit gunstig kunnen be"invloeden 
In hoofdstuk 3 word! de fase I studie met NX211 beschreven, ter bepaling van de 
maximaal aan patienten toedienbare dosering met dit medicijn. Naast de klinische 
haalbaarheid en anti-tumor activiteit, beschrijven wij ook de farmacokinetiek. Hierbij wordt 
een unieke correlatie tussen een farmacokinetische bevinding en klinisch relevante toxiciteit 
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gevonden. Ret blijkt dat de hoeveelheid in de urine uitgescheiden lurtotecan een relatie heeft 
met de daling van het aantal witte bloedcellen. Wij veronderstellen dat de hoeveelheid in de 
urine uitgescheiden lurtotecan een afspiegeling is van de in de bloedbaan aanwezige 
hoeveelheid vrij lurtotecan, dat wil zeggen biologisch actief lurtotecan, wat zich buiten de 
liposomen bevindt en ten dele in de urine wordt uitgescheiden. 
Bij de bepalingen van NX211 uit het b1oed vonden wij een onbekend stofje. In hoofdstuk 
4 beschrijven wij hoe wij dit stofje hebben geisoleerd, gepurificeerd en de structuurformule 
hebben gedefinieerd. Middels proeven met deze niet eerder beschreven stof, 11EC, op 
ge:l\Veekte tumorcellen, tonen wij aan dat deze stof uiterst giftig is, een tiental maal giftiger 
dan lurtotecan. MEC blijkt een fotodegradatie product van lurtotecan te zijn, hetgeen betekent 
dat MEC ontstaat door NX2ll aan (zon)licht bloot te stellen. Ter voorkoming van 
fotodegradatie bij de toediening van NX211 wordt deze nu onder strikte lichtprotectie 
gegeven. 
Ret is bekend dat langdurige b1ootstelling aan topoisomerase I rernmers de anti tumor 
activiteit verbetert. De topoisomerase I renuner CPT -11 wordt eenmaa1 per drie weken 
middels een infuus toegediend. CPT -11 zelf is een niet werk7...ame stof. maar wordt onder 
andere in het lichaam door een reactie met carboxy1esterase (CE) omgezet tot SN-38, dat een 
zeer sterke antikanker werking heeft. De omzetting (metabolisme) van CPT -11 is zeer 
gecompliceerd (zie kaft van dit proefschrift). Om beter inzicht in het metabolisme te lcrijgen 
hebben wij bij patienten die behande1d worden met CPT -11 b1oedmetingen verricht tot 500 
uur na de toediening hiervan. In hoofdstuk 5 wordt deze farmacologische studie beschreven, 
waarbij als meest opvallende bevinding blijkt dat de geschatte hoeveelheid van de 
circulerende actieve metaboliet SN-38, in realiteit tweemaal meer blijkt te zijn dan voorheen 
werd gedacht. In dit hoofdstuk ga ik in op een mogelijke verklaring voor deze observatie. 
Een ernstige en frequente bijwerking van CPT -11 is de laat ontstane diarree, die bij 
ongeveer vijftig procent van de patii!nten optreedt. Alhoewel er redelijke therapie bestaat om 
deze diarree weer onder controle te lcrijgen bij het leeuwendeel van de patienten, zou een 
therapie ter voorkoming van de diarree te prefereren zijn. In hoofdstuk 6 beschrijven wij hoe 
een, in de ontlasting voorkomende inactieve metaboliet SN-38-G (die in de lever gevormd is 
uit het actieve SN-38), weer teruggevormd kan worden naar de actieve metaboliet SN-38. 
Deze reactivatie geschiedt door ~-glucuronidase dat in de darmbacterie zit. Door nu deze 
bacterie met een antibioticum uit te roeien voorkomje vorming van de actieve metaboliet SN-
3 8 in de ont1asting. Hoge concentraties van SN -3 8 in de darm h..'Ullllen locaal schade geven aan 
de dannwand, met als uiteindelijk gevolg laat optredende diarree. Dit proces zou door 
antibiotische therapie voorkomen kunnen worden. In deze pilotstudy hebben wij aangetoond 
dat toediening van het antibioticum geen invloed heeft op het metabolisme van CPT -11 in het 
bloed, waaruit blijh..1: dat je dit middel ongestraft gelijktijdig met CPT-11 kan voorschrijven 
aan een patient. Tegelijkertijd tonen wij aan dat de ~-glucuronidase activiteit in de ontlasting 
bijna geheel verdwijnt en er nauwelijks nog SN-38 in de outlasting aantoonbaar is. Bij 7 
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patienten die tijdens de eerste kuur met CPT-11 diarree hadden ontwikkeld gaven wij 
voorafgaand aan de tv.reede kuur antibiotica. 6 van de 7 patienten hadden geen diarree meer 
tijdens de tweede kuur. 
In boofdstnk 7 beschrijven wij een methode die wij ontwikkeld hebben om ketoconazol 
concentraties in het bleed te meten. Ketoconazol, dat bebalve een frequent aan patienten 
voorgeschreven anti-scbimmel middel is, is tevens een potente remmer van het CYP3A4 (zie 
kaft van dit proefschrift). Onder invloed van CYP3A4 wordt CPT -II omgezet in de niet 
werkzame metabolieten NPC en APC. De primaire vraag die aan de orde is gesteld is welke 
invloed ketoconazol op bet metabolisme van CPT -II heeft en hoe belangrijk deze is. In 
hoofdstuk 8 beschrijven wij de interactie tussen deze tv.ree middelen, door patienten 
acbtereenvolgens eerst met CPT-11 aileen te behandelen, en vervolgens met (een 3.5x 
gereduceerde dosis) CPT-11 en ketoconazol. Om tot een vergelijk te komen werd bij beide 
kuren op vaste tijdstippen metingen uit het bloed gedaan. Het blijkt dat door remming van bet 
CYP3A4 de hoeveelheid NPC/ APC met een factor twee a:fneemt, terwijl de reactie via CE 
(zie hoofdstuk 5) met een factor tv.ree toeneemt. Ergo er ontstaat een dubbele dosis van het 
actieve, maar ook giftige SN-38 in bet bloed. Wij concluderen dat gelijktijdige toediening van 
een volle dosis CPT -11 en een CYP3A4 remmer, kan leiden tot ernstige en zelfs lethale 
toxiciteit. 
In hoofdstnk 9 beschrijven wij een fase I studie met CPT -11 en de farnesyltransferase 
remmer R115777. Deze beide tegen kanker effectieve middelen hebben volstrekt andere 
werkingsmechanismen. Daarmee bestaat er een duidelijke rationale om deze combinatie 
therapie te onderzoeken. Naast de klinische haalbaarheid en anti-tumor activiteit, beschrijven 
wij ook de farmacokinetiek. Het blijkt dat continue dosering van het oraal toegediende 
Rll5777, bet metabolisme van CPT -II bei"nvloedt. Dit heeft, in combinatie met de klinische 
observatie van cumulatieve vergiftigingsverschijnselen, geleid tot bet besluit de Rll5777 
voor te schrijven in een intermitterend schema. Omdat wij in deze studie de maximaal 
tolereerbare dosering nog niet hebben bereikt, is deze studie nog steeds gaande. 
Topoisomerase I remmers behoren tot de meest veelbelovende anti kanker middelen die 
zijn ont\Vikkeld in de afgelopen jaren. Het unieke werkingsmecbanisme in combinatie met de 
activiteit tegen een breed spectrum van tumoren zijn een continue stimulans voor verdere 
klinische ontv.rik.keling. Door een groeiende kennis over de farmacokinetiek en 
farmacodyamiek van deze groep van cytostatica, is en zal er veel onderzoek worden verricht 
teneinde de antitumor effectiviteit verder te verhogen. Tevens is farmacologiscbe modulatie, 
in het bijzonder van CPT-11, van interesse teneinde toxiciteit te verminderen dan wei te 
belnvloeden. In dit licht voeren wij momenteel een dubbelblind gerandomiseerd onderzoek uit 
om de klinische werkzaamheid van profylactische antibiotica tegen CPT -11 gerelateerde 
diarree te bewijzen. 
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Samenvatting en conclusies 
Ondanks aile energie die er in de ontwikkeling van de topoisomerase I remmers wordt 
gestopt is het niet zeker of dit uiteindelijk zalleiden tot theoretisch verwachte effectievere en 
minder toxische middelen. Daamaast zullen er nog veel studies verricht worden om de 
optimale dosering, schema's en/of combinatie-therapieen te onderzoeken. In tegenstelling tot 
de ontwikkeling van eerder geregistreerde cytostatica, zal de farmacologische kennis over hoe 
topoisomerase I remmers zich in mensen gedragen, leiden tot een logischer en efficiCntere 
ontwikkeling van deze middelen. 
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